

Mortality Results from a Randomized Prostate-Cancer

New England Journal of Medicine

360, 1310-1319

DOI: [10.1056/nejmoa0810696](https://doi.org/10.1056/nejmoa0810696)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Collective statistical illiteracy in health. , 0, , 39-58.		0
2	ecancermedalscience. Ecancermedalscience, 2014, 8, 423.	0.6	9
3	ecancermedalscience. Ecancermedalscience, 2014, 8, 435.	0.6	10
4	ecancermedalscience. Ecancermedalscience, 2014, 8, 458.	0.6	6
5	Screening for prostate cancer. , 2006, , CD004720.		74
6	Impact of Australian celebrity diagnoses on prostate cancer screening. Medical Journal of Australia, 2009, 191, 574-575.	0.8	5
7	Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 2009, 191, 226-229.	0.8	12
8	Evidenceâ€based uncertainty: recent trial results on prostateâ€specific antigen testing and prostate cancer mortality. Medical Journal of Australia, 2009, 191, 199-200.	0.8	3
9	Screening for Prostate Cancer: Controversy? What Controversy?. Current Oncology, 2009, 16, 1-2.	0.9	11
10	Reproductive Cancer Screening: Do the New Studies Add Anything to the Debate?. American Journal of Nursing, 2009, 109, 20.	0.2	0
11	Prostatic specific antigen for prostate cancer detection. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 521-531.	0.7	37
12	Update on the management of prostate cancer with goserelin acetate: patient perspectives. Cancer Management and Research, 2009, Volume 1, 99-105.	0.9	0
13	Minireview: Epigenetic Alterations in Human Prostate Cancers. Endocrine Reviews, 2009, 30, 538-538.	8.9	0
14	Is Disease Management Right for Oncology?. Population Health Management, 2009, 12, 337-343.	0.8	4
15	First Trimester Procedural Abortion in Family Medicine. Journal of the American Board of Family Medicine, 2009, 22, 169-174.	0.8	10
16	Age at Diagnosis and Age at Death in Familial Prostate Cancer. Oncologist, 2009, 14, 1209-1217.	1.9	23
17	The Search for New Prostate Cancer Biomarkers Continues. Clinical Chemistry, 2009, 55, 1277-1279.	1.5	18
18	Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screeningâ€A Report From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2009, 27, 6052-6069.	0.8	112

#	ARTICLE	IF	CITATIONS
19	XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16351-16356.	3.3	255
20	Androgen deprivation therapy and bone loss. Nature Reviews Urology, 2009, 6, 642-644.	1.9	3
21	Prostate cancer risk stratification by genotype and PSA. Nature Reviews Urology, 2009, 6, 641-642.	1.9	1
22	Prostate Gland. , 2009, , 559-598.		0
23	Modalities for Imaging of Prostate Cancer. Advances in Urology, 2009, 2009, 1-12.	0.6	21
24	Comparative Effectiveness Research and Cancer Screening in the United States and Europe. Medical Decision Making, 2009, 29, NP12-NP13.	1.2	0
25	Antioxidant Supplementation and Cancer Preventionâ€”Reply. JAMA - Journal of the American Medical Association, 2009, 301, 1877.	3.8	0
26	Prostate Cancer Screening; Is This a Teachable Moment?. Journal of the National Cancer Institute, 2009, 101, 1295-1297.	3.0	18
27	A 64-Year-Old Man With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2141.	3.8	18
28	Shared Decision Making for Prostate Cancer Screening. Archives of Internal Medicine, 2009, 169, 1557.	4.3	8
29	Weighing the Benefits and Downsides of Prostate-Specific Antigen Screening. Archives of Internal Medicine, 2009, 169, 1554.	4.3	6
30	Prostate Cancer Screening and Surveillance. JAMA - Journal of the American Medical Association, 2009, 302, 1529.	3.8	1
31	Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 1685.	3.8	464
32	Stage Shift in Psa-detected Prostate Cancers â€” Effect Modification by Gleason Score. Journal of Medical Screening, 2009, 16, 98-101.	1.1	19
33	Hiking through the Minefield of Prostate Cancer. Oncology Times, 2009, 31, 4-6.	0.1	0
34	Comprehensive Outpatient Health Assessment. Medicine (United States), 2009, 88, 268-278.	0.4	2
35	Many colorectal cancers are â€œflatâ€”clonal expansions. Cell Cycle, 2009, 8, 2187-2193.	1.3	29
36	Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics, 2009, 10, 1077-1081.	0.6	46

#	ARTICLE	IF	CITATIONS
37	Should 5 α -reductase inhibitors be used for prostate disease?. <i>Nature Reviews Urology</i> , 2009, 6, 358-359.	1.9	1
38	Prostate specific antigen for early detection of prostate cancer: longitudinal study. <i>BMJ: British Medical Journal</i> , 2009, 339, b3537-b3537.	2.4	102
39	Prostate-Cancer Screening. <i>New England Journal of Medicine</i> , 2009, 361, 202-206.	13.9	15
40	The Index Lesion and the Origin of Prostate Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 1704-1706.	13.9	323
41	The Capsule and Colorectal-Cancer Screening – The Crux of the Matter. <i>New England Journal of Medicine</i> , 2009, 361, 300-301.	13.9	11
42	To screen or not to screen?. <i>Nature Reviews Urology</i> , 2009, 6, 299-301.	1.9	4
43	Prostate Cancer Screening Decisions. <i>Archives of Internal Medicine</i> , 2009, 169, 1611-8.	4.3	122
45	A Model of Prostate-Specific Antigen Screening Outcomes for Low- to High-Risk Men. <i>Archives of Internal Medicine</i> , 2009, 169, 1603-10.	4.3	37
46	Prostate-specific antigen-based screening for prostate cancer in the third millennium: Useful or hype?. <i>Annals of Medicine</i> , 2009, 41, 480-489.	1.5	24
48	Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening?. <i>Future Oncology</i> , 2009, 5, 923-926.	1.1	4
49	Is serum calcium a biomarker of fatal prostate cancer?. <i>Future Oncology</i> , 2009, 5, 577-580.	1.1	17
50	Direct to consumer genetic testing: Avoiding a culture war. <i>Genetics in Medicine</i> , 2009, 11, 568-569.	1.1	63
51	Response: Re: Prostate-Specific Antigen Testing among the Elderly in Community-Based Family Medicine Practices. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 708-708.	0.8	0
52	Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study. <i>PLoS Medicine</i> , 2009, 6, e1000197.	3.9	103
53	Numbers Needed to Decide. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1163-1165.	3.0	24
54	Estimating the benefits of PSA screening. <i>Nature Reviews Urology</i> , 2009, 6, 301-303.	1.9	17
55	Re: First Trimester Procedural Abortion in Family Medicine. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 707-707.	0.8	2
56	Early detection of cancer: immunoassays for plasma tumor markers. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 597-605.	1.6	54

#	ARTICLE	IF	CITATIONS
57	Minireview: Epigenetic Alterations in Human Prostate Cancers. <i>Endocrinology</i> , 2009, 150, 3991-4002.	1.4	135
58	A 72-Year-Old Man With Localized Prostate Cancer 14 Years Later. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1105.	3.8	0
59	Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 6932-6940.	0.4	279
60	Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1325-1329.	3.0	508
61	Evidence-Based Medicine, Conscience-Based Medicine, and the Management of Low-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4935-4936.	0.8	10
62	Health-Related Quality of Life in Cancer Patients—More Answers but Many Questions Remain. <i>Journal of the National Cancer Institute</i> , 2009, 101, 838-839.	3.0	3
63	Screening for Prostate Cancer — The Controversy That Refuses to Die. <i>New England Journal of Medicine</i> , 2009, 360, 1351-1354.	13.9	320
64	Re: Prostate-Specific Antigen Testing among the Elderly in Community-Based Family Medicine Practices. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 707-708.	0.8	3
65	Small Integrin-Binding Proteins as Serum Markers for Prostate Cancer Detection. <i>Clinical Cancer Research</i> , 2009, 15, 5199-5207.	3.2	32
66	Keeping Our Eye on the Ball: The American Society of Preventive Oncology in 2009. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2796-2802.	1.1	1
67	What Now on Screening for Prostate Cancer?. <i>Journal of Medical Screening</i> , 2009, 16, 109-111.	1.1	5
68	Reply to P.C. Walsh. <i>Journal of Clinical Oncology</i> , 2009, 27, e23-e23.	0.8	1
69	Sociocultural considerations in aging men's health: implications and recommendations for the clinician. <i>Journal of Men's Health</i> , 2009, 6, 196-207.	0.1	2
70	Are U.S. cancer screening test patterns consistent with guideline recommendations with respect to the age of screening initiation?. <i>BMC Health Services Research</i> , 2009, 9, 185.	0.9	6
71	Prostate Cancer: Current Evidence Weighs Against Population Screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 220-224.	157.7	47
72	Screening for Prostate Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 264-273.	157.7	90
73	Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the Literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 379-390.	157.7	126
74	Prospective Evaluation of Prostate Cancer Risk in Candidates for Inguinal Hernia Repair. <i>Journal of the American College of Surgeons</i> , 2009, 209, 371-376.	0.2	3

#	ARTICLE	IF	CITATIONS
75	Commentary. Journal of the American College of Surgeons, 2009, 209, 376-377.	0.2	0
76	Prostate Cancer Screening: The Need For Problem-Solving that Puts Men's Interests First. European Urology, 2009, 56, 34-37.	0.9	7
77	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. European Urology, 2009, 56, 275-286.	0.9	332
78	European Association of Urology Position Statement on Screening for Prostate Cancer. European Urology, 2009, 56, 270-271.	0.9	20
79	Lies, Damn Lies, and Cancer Statistics. European Urology, 2009, 56, 592-593.	0.9	1
80	Re: Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. European Urology, 2009, 56, 1089-1090.	0.9	1
81	Conundrums in screening for cancer. International Journal of Cancer, 2010, 126, 1039-1046.	2.3	25
82	Many unknowns in low-risk prostate cancer treatment. Cancer, 2009, 115, 4645-4646.	2.0	2
83	Clinical Chemistry: Challenges for Analytical Chemistry and the Nanosciences from Medicine. Angewandte Chemie - International Edition, 2010, 49, 1026-1051.	7.2	79
86	Prostate cancer in senior adults: over- or undertreated?. Wiener Medizinische Wochenschrift, 2009, 159, 521-528.	0.5	3
88	Prostaatankerscreening? Nog even niet!. Huisarts En Wetenschap, 2009, 52, 350-351.	0.0	5
89	Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes and Control, 2009, 20, 1799-1810.	0.8	100
90	Prostate cancer screening with PSA: new data, old debate. Oncology Reviews, 2009, 3, 133-135.	0.8	0
91	Translating biological parameters into clinically useful diagnostic tests. Current Psychiatry Reports, 2009, 11, 320-323.	2.1	13
92	Advances and future directions in management of prostate cancer. Indian Journal of Surgery, 2009, 71, 337-341.	0.2	0
98	Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate, 2010, 70, 710-717.	1.2	38
99	A patient recall program to enhance decisions about prostate cancer screening: A feasibility study. BMC Family Practice, 2009, 10, 75.	2.9	1
100	Trends in cancer incidence and mortality in Osaka, Japan: Evaluation of cancer control activities. Cancer Science, 2009, 100, 2390-2395.	1.7	21

#	ARTICLE	IF	CITATIONS
101	Biomarker validation by targeted mass spectrometry. <i>Nature Biotechnology</i> , 2009, 27, 622-623.	9.4	31
102	Markers of dispute. <i>Nature Medicine</i> , 2009, 15, 1339-1342.	15.2	13
104	The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic. <i>International Journal of Clinical Practice</i> , 2009, 63, 1734-1738.	0.8	11
106	Update on prostate-specific antigen (PSA)-based screening. <i>International Journal of Urology</i> , 2009, 16, 711-712.	0.5	3
108	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009, 104, 1592-1598.	1.3	69
109	SCREENING FOR PROSTATE CANCER APPEARS TO WORK, BUT AT WHAT COST?. <i>BJU International</i> , 2009, 104, 290-292.	1.3	5
110	THE ROLE OF MAGNETIC RESONANCE IMAGING IN TARGETING PROSTATE CANCER IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS. <i>BJU International</i> , 2009, 104, 269-270.	1.3	9
111	THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: "DO NOT THROW THE BABY OUT WITH THE BATH WATER". <i>BJU International</i> , 2009, 104, 1553-1554.	1.3	4
112	Biomarkers in Oncology. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 111-118.	1.8	6
113	A structured implicit abstraction method to evaluate whether content of counseling before prostate cancer screening is consistent with recommendations by experts. <i>Patient Education and Counseling</i> , 2009, 77, 322-327.	1.0	6
114	In Reply to Dr. Azria et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1275-1276.	0.4	0
115	In Reply to Dr. Lawrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1276-1277.	0.4	0
116	In Reply to Dr. Lee: Are Prostate Cancers Created Equal?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1276.	0.4	0
117	Prostate-specific antigen screening of workers under the age of 40 in Japan. <i>Cancer Epidemiology</i> , 2009, 33, 309-310.	0.8	4
119	Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1216-1220.	3.0	239
120	Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. <i>European Journal of Cancer</i> , 2009, 45, 2804-2809.	1.3	2
121	Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later. <i>Urology</i> , 2009, 73, S11-S20.	0.5	44
122	Focal Therapy for Prostate Cancer Is a Reasonable Treatment Option in Properly Selected Patients: Oppose. <i>Urology</i> , 2009, 74, 731-734.	0.5	1

#	ARTICLE	IF	CITATIONS
123	Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 583-584.	0.8	3
125	Towards the definition of prostate cancer-related microRNAs: where are we now?. Trends in Molecular Medicine, 2009, 15, 381-390.	3.5	54
126	Serum tumour markers: how to order and interpret them. BMJ, The, 2009, 339, b3527-b3527.	3.0	85
127	Androgen regulated TRPM8 expression: A potential mRNA marker for metastatic prostate cancer detection in body fluids. International Journal of Oncology, 2009, 36, .	1.4	18
128	Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nature Reviews Urology, 2009, 6, 384-391.	1.9	40
129	Screening and Prostate-Cancer Mortality in a Randomized European Study. Yearbook of Urology, 2009, 2009, 154-155.	0.1	0
130	What Would You Do, Doctor?. Journal of Urology, 2009, 182, 421-422.	0.2	8
132	Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk. Journal of Urology, 2009, 182, 2212-2218.	0.2	9
133	Nomograms as a Tool in Predicting Prostate Cancer Prognosis. European Urology Supplements, 2009, 8, 721-724.	0.1	7
135	Uptake in cancer screening programmes. Lancet Oncology, The, 2009, 10, 693-699.	5.1	80
136	PSA screening "a review of recent studies. European Journal of Cancer, 2009, 45, 402-404.	1.3	25
137	Screening for prostate cancer remains controversial. Lancet, The, 2009, 374, 1482-1483.	6.3	22
138	Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras. Journal of Urology, 2009, 182, 2242-2249.	0.2	93
140	Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. Journal of Urology, 2009, 182, 2653-2658.	0.2	52
143	Prostate Specific Antigen Best Practice Statement: 2009 Update. Journal of Urology, 2009, 182, 2232-2241.	0.2	362
145	Risk Factors, Prevention and Early Detection of Prostate Cancer. Primary Care - Clinics in Office Practice, 2009, 36, 603-621.	0.7	6
146	Mortality Results from a Randomized Prostate-Cancer Screening Trial. Yearbook of Urology, 2009, 2009, 145-147.	0.1	1
147	Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18437-18442.	3.3	378

#	ARTICLE	IF	CITATIONS
148	Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 312-318.	1.0	24
149	Screening and Prostate-Cancer Mortality in a Randomized European Study. <i>Yearbook of Medicine</i> , 2009, 2009, 173-174.	0.1	0
150	PROSTATE CANCER SCREENING: Benefits and harms of widespread PSA test use still unclear. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2009, 22, 50-51.	0.1	0
151	Prostate-specific antigen screening and prostate cancer mortality: implications of a randomized European study. <i>Aging Health</i> , 2009, 5, 281-286.	0.3	1
155	PSA testing in Austria: induced morbidity and saved mortality. <i>European Journal of Cancer Prevention</i> , 2009, 18, 377-380.	0.6	7
156	Mortality Results from a Randomized Prostate-Cancer Screening Trial. <i>Yearbook of Medicine</i> , 2009, 2009, 174-176.	0.1	0
157	Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database. <i>European Journal of Cancer Prevention</i> , 2010, 19, 413-416.	0.6	21
158	Big Brother Is Watching You. <i>Circulation</i> , 2010, 122, 319-321.	1.6	19
159	Prostate Cancer Screening 2010: Updated Recommendations From the American Cancer Society. <i>Journal of the National Medical Association</i> , 2010, 102, 423-429.	0.6	32
160	Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2373.	3.8	232
161	Assessing prostate cancer growth with mRNA of spermine metabolic enzymes. <i>Cancer Biology and Therapy</i> , 2010, 9, 736-742.	1.5	10
162	Randomized trial results did not resolve controversies surrounding prostate cancer screening. <i>Current Opinion in Urology</i> , 2010, 20, 189-193.	0.9	11
163	Prostate-specific antigen screening: pro. <i>Current Opinion in Urology</i> , 2010, 20, 185-188.	0.9	19
164	Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 265-270.	2.3	19
165	Cancer diagnosis in primary care. <i>British Journal of General Practice</i> , 2010, 60, 121-128.	0.7	147
166	Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 162-200.	2.3	671
167	Prostate Cancer Early Detection. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 240-262.	2.3	132
168	Patient-Centered Discussions About Prostate Cancer Screening: A Real-World Approach. <i>Annals of Internal Medicine</i> , 2010, 153, 661.	2.0	18

#	ARTICLE	IF	CITATIONS
169	Radical prostatectomy versus watchful waiting for prostate cancer. The Cochrane Library, 2010, , CD006590.	1.5	28
170	Near Infrared Spectroscopy (NIRS) Should Not Be Standard of Care for Postoperative Management. Pediatric Cardiac Surgery Annual, 2010, 13, 51-54.	0.5	58
171	Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. European Radiology, 2010, 20, 2781-2790.	2.3	45
173	Profiling the Cancer Genome. Annual Review of Genomics and Human Genetics, 2010, 11, 133-159.	2.5	43
174	Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomarkers, 2010, 7, 101-108.	0.8	15
178	A comprehensive resequence analysis of the KLK15â€“KLK3â€“KLK2 locus on chromosome 19q13.33. Human Genetics, 2010, 127, 91-99.	1.8	29
179	The disease burden of colorectal cancer in Hungary. European Journal of Health Economics, 2010, 10, 35-40.	1.4	18
180	Du dÃ©pistage au diagnostic des cancers en 2010. Oncologie, 2010, 12, 125-129.	0.2	0
182	Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Irish Journal of Medical Science, 2010, 179, 43-49.	0.8	26
183	Contemporary Management of High-risk Localized Prostate Cancer. Current Urology Reports, 2010, 11, 159-164.	1.0	11
184	Prostate Cancer Screening: What We Have Learned from the PLCO and ERSPC Trials. Current Urology Reports, 2010, 11, 198-201.	1.0	14
185	What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans. Journal of General Internal Medicine, 2010, 25, 1205-1210.	1.3	17
186	Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes and Control, 2010, 21, 1071-1080.	0.8	63
187	Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes and Control, 2010, 21, 1523-1531.	0.8	20
188	Digitization and Its Discontents: Future Shock in Predictive Oncology. Seminars in Oncology, 2010, 37, 60-64.	0.8	5
190	Association between family history of cancers and risk of prostate cancer. Journal of Men's Health, 2010, 7, 45-54.	0.1	4
191	Managing benign prostatic hyperplasia and prostate cancer â€“ the challenges today. Journal of Men's Health, 2010, 7, 113-124.	0.1	2
192	Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening. Ca-A Cancer Journal for Clinicians, 2010, 60, 99-119.	157.7	405

#	ARTICLE	IF	CITATIONS
193	American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 70-98.	157.7	759
194	Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 68-69.	157.7	17
195	Adherence to cancer screening guidelines across Canadian provinces: an observational study. <i>BMC Cancer</i> , 2010, 10, 304.	1.1	14
196	Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities. <i>BMC Cancer</i> , 2010, 10, 452.	1.1	20
197	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. <i>BMC Cancer</i> , 2010, 10, 635.	1.1	70
198	The development of a web- and a print-based decision aid for prostate cancer screening. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 12.	1.5	41
199	Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 24.	1.5	11
200	Re: Estimating the Benefits of PSA Screening. <i>European Urology</i> , 2010, 57, 175-176.	0.9	1
201	Suicide Risk in Men with Prostate-Specific Antigen- Detected Early Prostate Cancer: A Nationwide Population-Based Cohort Study from PCBaSe Sweden. <i>European Urology</i> , 2010, 57, 390-395.	0.9	90
202	Re: Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy. <i>European Urology</i> , 2010, 57, 539-540.	0.9	2
203	Re: Rethinking Screening for Breast Cancer and Prostate Cancer. <i>European Urology</i> , 2010, 57, 540.	0.9	2
204	Re: Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails. <i>European Urology</i> , 2010, 57, 540-541.	0.9	0
207	Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades. <i>European Urology</i> , 2010, 58, 427-432.	0.9	7
208	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 851-864.	0.9	96
209	Re: Mortality Results from the Göteborg Randomised Population-Based Prostate-Cancer Screening Trial. <i>European Urology</i> , 2010, 58, 938-939.	0.9	0
210	Re: Mortality Results From the Göteborg Randomised Population-Based Prostate-Cancer Screening Trial. <i>European Urology</i> , 2010, 58, 939-940.	0.9	2
211	ERK2 Impedes Prostate Cancer EMT by Destabilizing HIF-1 α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading. <i>Cancer Cell</i> , 2010, 17, 319-332.	7.7	340
212	Prostate Cancer: Beta Control Your Hormones. <i>Cancer Cell</i> , 2010, 17, 311-312.	7.7	6

#	ARTICLE	IF	CITATIONS
213	Expanding the Criteria of Organ Procurement from Donors with Prostate Cancer: The Application of the New Italian Guidelines. <i>American Journal of Transplantation</i> , 2010, 10, 1907-1911.	2.6	15
214	Generational risks for cancers not related to tobacco, screening, or treatment in the United States. <i>Cancer</i> , 2010, 116, 940-948.	2.0	7
215	Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. <i>Cancer</i> , 2010, 116, 544-573.	2.0	1,691
216	Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen. <i>Cancer</i> , 2010, 116, 2612-2620.	2.0	61
217	Underuse of colorectal cancer screening among men screened for prostate cancer. <i>Cancer</i> , 2010, 116, 4703-4710.	2.0	8
218	Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades. <i>Cancer</i> , 2010, 116, 4711-4717.	2.0	23
219	Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. <i>International Journal of Cancer</i> , 2010, 127, 1650-1659.	2.3	88
220	Results of the three rounds of the Finnish Prostate Cancer Screening Trial- The incidence of advanced cancer is decreased by screening. <i>International Journal of Cancer</i> , 2010, 127, 1699-1705.	2.3	11
221	Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. <i>International Journal of Cancer</i> , 2010, 127, 2669-2677.	2.3	29
223	A cell kinetics model for prostate cancer and its application to clinical data and individual patients. <i>Journal of Theoretical Biology</i> , 2010, 264, 420-442.	0.8	8
224	Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2010, 6, 201-209.	1.7	198
225	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 68-91.	2.0	105
226	Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1315-1321.	0.4	48
227	Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1338-1344.	0.4	142
228	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. <i>BMC Medical Genomics</i> , 2010, 3, 8.	0.7	219
229	New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer. <i>Prostate</i> , 2010, 70, 1701-1708.	1.2	18
230	The historical and moral imperatives of comparative effectiveness research. <i>Statistics in Medicine</i> , 2010, 29, 1982-1984.	0.8	6
231	Perceived Barriers to Prostate Cancer Screenings Among Middle-Aged Men in North-Eastern Germany. <i>Public Health Nursing</i> , 2010, 27, 504-512.	0.7	7

#	ARTICLE	IF	CITATIONS
232	How Can Rates of Prostate-specific Antigen Screening Be Reduced in Men Aged 80 and Older?. Journal of the American Geriatrics Society, 2010, 58, 757-759.	1.3	3
233	Translating Research to Promote Healthy Aging: The Complementary Role of Longitudinal Studies and Clinical Trials. Journal of the American Geriatrics Society, 2010, 58, S337-42.	1.3	28
234	Screening in Frail Older People: An Ounce of Prevention or a Pound of Trouble?. Journal of the American Geriatrics Society, 2010, 58, 2016-2021.	1.3	25
235	STEP: Simplified Treatment of the Enlarged Prostate. International Journal of Clinical Practice, 2010, 64, 488-496.	0.8	6
236	Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's health and do they improve traditional non-gender specific determinants to lessen ca. International Journal of Clinical Practice, 2010, 64, 1754-1762.	0.8	5
237	Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. International Journal of Clinical Practice, 2010, 64, 1740-1745.	0.8	35
238	Personal genomics: information can be harmful. European Journal of Clinical Investigation, 2010, 40, 64-68.	1.7	59
239	Genetic risk information for common diseases may indeed be already useful for prevention and early detection. European Journal of Clinical Investigation, 2010, 40, 56-63.	1.7	32
240	False-positive screening results in the Finnish prostate cancer screening trial. British Journal of Cancer, 2010, 102, 469-474.	2.9	38
241	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. British Journal of Cancer, 2010, 102, 1335-1340.	2.9	77
242	DNA methylation of HOXD3 as a marker of prostate cancer progression. Laboratory Investigation, 2010, 90, 1060-1067.	1.7	50
243	Prostate cancer as a model for tumour immunotherapy. Nature Reviews Immunology, 2010, 10, 580-593.	10.6	314
244	SCREENING FOR PROSTATE CANCER. BJU International, 2010, 105, 131-131.	1.3	1
245	SCREENING FOR PROSTATE CANCER: THE WAY AHEAD. BJU International, 2010, 105, 295-297.	1.3	10
246	Why do men opt out of prostate cancer screening? Attitudes and perception among participants and non-participants of a screening trial. BJU International, 2010, 106, 472-477.	1.3	9
247	Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk?. BJU International, 2010, 106, 1298-1302.	1.3	30
248	Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. International Journal of Urology, 2010, 17, 830-838.	0.5	53
249	Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. Clinical Genetics, 2010, 78, 1-7.	1.0	51

#	ARTICLE	IF	CITATIONS
250	Factors Influencing Prostate Cancer Screening in Low-Income African Americans in Tennessee. <i>Journal of Health Care for the Poor and Underserved</i> , 2010, 21, 114-126.	0.4	25
251	Disparities Associated with Advanced Prostate Cancer Stage at Diagnosis. <i>Journal of Health Care for the Poor and Underserved</i> , 2010, 21, 112-131.	0.4	40
252	It's time to depolarise the unhelpful PSA testing debate and put into practice lessons from the two major international screening trials. <i>Medical Journal of Australia</i> , 2010, 192, 393-396.	0.8	15
253	It's time to depolarise the unhelpful PSA testing debate and put into practice lessons from the two major international screening trials. <i>Medical Journal of Australia</i> , 2010, 193, 61-61.	0.8	3
254	PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer. <i>Scientific World Journal</i> , The, 2010, 10, 1919-1931.	0.8	66
255	The novel prostate cancer antigen 3 (PCA3) biomarker. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 665-669.	0.7	38
256	Prevention Strategies in Prostate Cancer. <i>Current Oncology</i> , 2010, 17, 4-10.	0.9	10
257	Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 1005-1011.	0.8	1
259	Novel diagnostic biomarkers for prostate cancer. <i>Journal of Cancer</i> , 2010, 1, 150-177.	1.2	192
260	Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. <i>Cancer Management and Research</i> , 2010, 2, 111.	0.9	17
261	Markers for Detection of Prostate Cancer. <i>Cancers</i> , 2010, 2, 1125-1154.	1.7	39
262	Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations. <i>Scientific World Journal</i> , The, 2010, 10, 2352-2361.	0.8	5
263	A Randomized Trial of a Computer-Tailored Decision Aid to Improve Prostate Cancer Screening Decisions: Results from the <i>Take the Wheel</i> Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2172-2186.	1.1	49
264	Mortality reductions produced by sustained prostate cancer screening have been underestimated. <i>Journal of Medical Screening</i> , 2010, 17, 147-151.	1.1	23
265	Active Surveillance for Early-Stage Prostate Cancer: Defining the Triggers for Intervention. <i>Journal of Clinical Oncology</i> , 2010, 28, 2807-2809.	0.8	14
266	Metabolomic Imaging for Human Prostate Cancer Detection. <i>Science Translational Medicine</i> , 2010, 2, 16ra8.	5.8	44
267	How did the PSA system arise?. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 309-312.	1.1	5
268	Screening and Detection of Breast Cancer and Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1032.	3.8	0

#	ARTICLE	IF	CITATIONS
269	Guidelines for Testosterone Therapy for Men: How to Avoid a Mad (T)ea Party by Getting Personal. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2614-2617.	1.8	17
270	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids, 2010, 24, 697-706.	1.0	150
271	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. Journal of Clinical Oncology, 2010, 28, 2493-2498.	0.8	204
272	Evaluation of cancer service screening: case referent studies recommended. Statistical Methods in Medical Research, 2010, 19, 487-505.	0.7	17
273	Overdiagnosis in Cancer. Journal of the National Cancer Institute, 2010, 102, 605-613.	3.0	1,392
274	Personalized Prostate Cancer Screening: Improving PSA Tests with Genomic Information. Science Translational Medicine, 2010, 2, 62ps55.	5.8	22
275	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science Translational Medicine, 2010, 2, 62ra92.	5.8	140
276	Body-Mass Index and Mortality among 1.46 Million White Adults. New England Journal of Medicine, 2010, 363, 2211-2219.	13.9	1,926
277	Screening for Breast and Prostate Cancers: Moving Toward Transparency. Journal of the National Cancer Institute, 2010, 102, 1008-1011.	3.0	20
278	Reduced Risk of Prostate Cancer in U.S. Men with AIDS. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2910-2915.	1.1	57
279	Active Surveillance for Prostate Cancer: Has the Time Finally Come?. Journal of Clinical Oncology, 2010, 28, e265-e266.	0.8	5
280	Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer. Molecular and Cellular Proteomics, 2010, 9, 298-312.	2.5	113
281	Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. Science Translational Medicine, 2010, 2, 25ra23.	5.8	474
282	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. Journal of Clinical Oncology, 2010, 28, 2653-2659.	0.8	146
283	Characterizing Human Cancer Metabolomics with <i>ex vivo</i> 1H HRMAS MRS. Technology in Cancer Research and Treatment, 2010, 9, 381-391.	0.8	27
284	Screening for prostate cancer: have we resolved the controversy?. Current Opinion in Supportive and Palliative Care, 2010, 4, 121-126.	0.5	3
285	Inherited Variations in <i>AR</i> , <i>ESR1</i> , and <i>ESR2</i> Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1871-1878.	1.1	19
286	A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clinical Cancer Research, 2010, 16, 3232-3239.	3.2	106

#	ARTICLE	IF	CITATIONS
287	Perineal discomfort in prostatic adenocarcinoma. <i>JRSM Short Reports</i> , 2010, 1, 1-4.	0.6	0
289	The Scientific Basis of Urology. , 0, , .		18
290	Probleme der PSA-Bestimmung bei Älteren Patienten: was ist sinnvoll? / PSA measurements in elderly patients: what makes sense?. <i>Laboratoriums Medizin</i> , 2010, 34, 319-324.	0.1	0
291	Efficacy vs Effectiveness in Prostate-Specific Antigen Screening. <i>Journal of the National Cancer Institute</i> , 2010, 102, 288-289.	3.0	7
292	Genome-wide association studies in cancer--current and future directions. <i>Carcinogenesis</i> , 2010, 31, 111-120.	1.3	100
293	Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus. <i>Endocrine Reviews</i> , 2010, 31, 407-446.	8.9	214
294	Why the Evidence for Skin Cancer Screening Is Insufficient. <i>Archives of Dermatology</i> , 2010, 146, 322-4.	1.7	7
295	Screening and Detection of Breast Cancer and Prostate Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1032.	3.8	0
296	Screening and Detection of Breast Cancer and Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1032.	3.8	0
297	The Cautionary Tale of PSA Testing. <i>Archives of Internal Medicine</i> , 2010, 170, 1262-3.	4.3	9
298	Screening and Detection of Breast Cancer and Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1032.	3.8	0
299	Improving Prostate-Specific Antigen Screening. <i>Journal of Clinical Oncology</i> , 2010, 28, 2491-2492.	0.8	5
300	Prostate cancer screening: current status and future perspectives. <i>Nature Reviews Urology</i> , 2010, 7, 487-493.	1.9	64
301	What Is the “True” Incidence of Active Surveillance and Brachytherapy Candidates in Men Undergoing Robot-Assisted Radical Prostatectomy?. <i>Journal of Endourology</i> , 2010, 24, 1671-1674.	1.1	3
302	Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups. <i>Aging Male</i> , 2010, 13, 10-17.	0.9	12
303	Climacteric commentaries. <i>Climacteric</i> , 2010, 13, 192-200.	1.1	0
305	Roundtable Discussion: Focus on Men’s Health. <i>Alternative and Complementary Therapies</i> , 2010, 16, 77-82.	0.1	1
306	Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <i>Clinical Trials</i> , 2010, 7, 303-311.	0.7	128

#	ARTICLE	IF	CITATIONS
307	Controversies in Cancer Screening: Focusing on Colorectal Cancer Recommendations. Integrative Cancer Therapies, 2010, 9, 322-325.	0.8	0
308	Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1201-1207.	1.1	30
309	Is focal therapy the future for prostate cancer?. Future Oncology, 2010, 6, 261-268.	1.1	20
310	Genomic predictors of prostate cancer therapy outcomes. Expert Review of Molecular Diagnostics, 2010, 10, 619-636.	1.5	4
311	Two Decades of Declining Cancer Mortality: Progress with Disparity. Annual Review of Public Health, 2010, 31, 121-132.	7.6	38
312	Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2136-2140.	3.3	100
313	Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer and Prostatic Diseases, 2010, 13, 191-194.	2.0	24
314	Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients. Prostate Cancer and Prostatic Diseases, 2010, 13, 316-319.	2.0	19
315	Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer—Rotterdam. Journal of the National Cancer Institute, 2010, 102, 352-355.	3.0	51
316	The prostate cancer pseudo-epidemic. Acta Oncologica, 2010, 49, 298-304.	0.8	21
317	The implementation of screening for prostate cancer. Prostate Cancer and Prostatic Diseases, 2010, 13, 218-227.	2.0	13
318	Screening for prostate cancer “ will we ever know?. Acta Oncologica, 2010, 49, 275-277.	0.8	3
319	Classification of tumor marker values using heuristic data mining methods. , 2010, , .		11
320	Prostate biopsy in Western Australia 1998–2004. Prostate Cancer and Prostatic Diseases, 2010, 13, 263-269.	2.0	2
321	Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis, 2010, 31, 1948-1955.	1.3	76
322	Perspective: Beyond Storytelling in Medicine: An Encounter-Based Curriculum. Academic Medicine, 2010, 85, 794-798.	0.8	8
323	Genetic variant associated with aggressive not indolent prostate cancer. Cancer Biology and Therapy, 2010, 9, 957-958.	1.5	2
324	Update on radiation-based therapies for prostate cancer. Current Opinion in Oncology, 2010, 22, 257-262.	1.1	13

#	ARTICLE	IF	CITATIONS
325	A Church-Based Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men. <i>Journal of the National Medical Association</i> , 2010, 102, 164-173.	0.6	66
326	Applicability of a Video Intervention to Increase Informed Decision Making for Prostate-Specific Antigen Testing. <i>Journal of the National Medical Association</i> , 2010, 102, 228-236.	0.6	20
327	Management of prostate cancer in HIV-positive patients. <i>Nature Reviews Urology</i> , 2010, 7, 348-357.	1.9	17
328	Circulating Tumor Cells. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 95-112.	0.9	37
329	An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c2073-c2073.	2.4	151
330	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4521-c4521.	2.4	195
331	Tumor angiogenesis as an early marker of long-term prostate cancer mortality. <i>Future Oncology</i> , 2010, 6, 341-345.	1.1	2
332	Saturation biopsy does not accurately localize tumors. <i>Nature Reviews Urology</i> , 2010, 7, 479-480.	1.9	1
335	Predictors of survival in patients with prostate cancer and spinal metastasis. <i>Journal of Neurosurgery: Spine</i> , 2010, 13, 789-794.	0.9	34
336	Should prostate-specific antigen screening be offered to asymptomatic men?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1043-1053.	1.1	4
337	Polymorphisms at the Microseminoprotein-Î ² Locus Associated with Physiologic Variation in Î ² -Microseminoprotein and Prostate-Specific Antigen Levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2035-2042.	1.1	27
338	Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy. <i>Journal of Urology</i> , 2010, 183, 1798-1802.	0.2	20
339	Ageing Male. <i>Clinics in Geriatric Medicine</i> , 2010, 26, 171-184.	1.0	0
340	The Economic Burden of Prostate Cancer Survivorship Care. <i>Journal of Urology</i> , 2010, 184, 532-538.	0.2	34
345	New Developments in the Medical Management of Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2010, 85, 77-86.	1.4	70
346	Clinical Pearls in Men's Health. <i>Mayo Clinic Proceedings</i> , 2010, 85, 668-673.	1.4	2
347	[-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study. <i>Journal of Urology</i> , 2010, 183, 1355-1359.	0.2	146
348	Prostate-specific Antigen Testing and Prostate Cancer Screening. <i>Primary Care - Clinics in Office Practice</i> , 2010, 37, 441-459.	0.7	11

#	ARTICLE	IF	CITATIONS
349	Cancer mortality in Europe, 2000â€“2004, and an overview of trends since 1975. <i>Annals of Oncology</i> , 2010, 21, 1323-1360.	0.6	340
350	Blood and Tissue Biomarkers in Prostate Cancer: State of the Art. <i>Urologic Clinics of North America</i> , 2010, 37, 131-141.	0.8	32
352	Is an ROC-type Response Truly Always Better Than a Binary Response in Observer Performance Studies?. <i>Academic Radiology</i> , 2010, 17, 639-645.	1.3	16
353	Chemoprevention of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2010, 37, 11-21.	0.8	16
354	Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities. <i>Recent Results in Cancer Research</i> , 2010, 188, 21-47.	1.8	21
355	Treatment of localized prostate cancer: when is active surveillance appropriate?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 394-400.	12.5	35
356	Screening Asymptomatic Subjects for Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2010, 56, 106-108.	1.2	33
357	Misinterpretation of Prostate Cancer Data. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1862.	1.2	0
360	PSA Testing of Men in the Haematuria Clinic, a Useful Additional Test or Unnecessary Investigation. <i>British Journal of Medical and Surgical Urology</i> , 2010, 3, 11-14.	0.2	1
361	The Use and Misuse of the PSA Test: A Retrospective Case Note Review of Testing in a UK Teaching Hospital. <i>British Journal of Medical and Surgical Urology</i> , 2010, 3, 167-171.	0.2	2
362	Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2010, 8, 239-246.	0.8	65
363	Biomarkers for prostate cancer detection. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 103-114.	1.1	36
364	Urine biomarkers in prostate cancer. <i>Nature Reviews Urology</i> , 2010, 7, 101-109.	1.9	102
365	Prostate Cancer: To Screen or Not to Screen?. <i>Urologic Clinics of North America</i> , 2010, 37, 1-9.	0.8	13
367	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
368	Polyacrylamide Gel Photopatterning Enables Automated Protein Immunoblotting in a Two-Dimensional Microdevice. <i>Journal of the American Chemical Society</i> , 2010, 132, 2512-2513.	6.6	47
369	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c4543-c4543.	2.4	257
370	Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 5908-5913.	3.2	23

#	ARTICLE	IF	CITATIONS
371	Discovery of prostate cancer biomarkers by microarray gene expression profiling. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 49-64.	1.5	60
373	Abdominal and back pain in a 65-year-old patient with metastatic prostate cancer. <i>Journal of Chiropractic Medicine</i> , 2010, 9, 11-16.	0.3	6
374	Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. <i>European Journal of Cancer</i> , 2010, 46, 377-383.	1.3	56
375	Deciding on PSA-screening – Quality of current consumer information on the Internet. <i>European Journal of Cancer</i> , 2010, 46, 3073-3081.	1.3	8
376	Prostate cancer incidence and mortality trends in 37 European countries: An overview. <i>European Journal of Cancer</i> , 2010, 46, 3040-3052.	1.3	260
377	Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies. <i>European Journal of Cancer</i> , 2010, 46, 3095-3101.	1.3	133
378	Two randomized screening trials with prostate cancer mortality, two interim results. <i>Contemporary Clinical Trials</i> , 2010, 31, 378-380.	0.8	0
379	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. <i>Urology</i> , 2010, 75, 407-413.	0.5	70
380	Association Between Glomerular Filtration Rate, Free, Total, and Percent Free Prostate-specific Antigen. <i>Urology</i> , 2010, 76, 1042-1046.	0.5	23
382	Public Survey and Survival Data Do Not Support Recommendations to Discontinue Prostate-specific Antigen Screening in Men at Age 75. <i>Urology</i> , 2010, 75, 1122-1127.	0.5	12
384	The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis. <i>Urology</i> , 2010, 75, 399-405.	0.5	25
386	Prostate-specific Antigen-based Risk-adapted Discontinuation of Prostate Cancer Screening in Elderly African American and Caucasian American Men. <i>Urology</i> , 2010, 76, 1058-1062.	0.5	8
387	Cost Comparison Between Watchful Waiting With Active Surveillance and Active Treatment of Clinically Localized Prostate Cancer. <i>Urology</i> , 2010, 76, 703-707.	0.5	40
388	Program for Prostate Cancer Screening Using a Mobile Unit: Results From Brazil. <i>Urology</i> , 2010, 76, 1052-1057.	0.5	29
389	Prostate-specific Antigen Self-testing Among British Association of Urological Surgeons (BAUS) Consultant Urologists. <i>Urology</i> , 2010, 76, 1023-1024.	0.5	0
390	Re: Hong et al.: Detection of Subclinical Carbon Dioxide Embolism by Transesophageal Echocardiography During Laparoscopic Radical Prostatectomy (<i>Urology</i> 2010;75:581-584). <i>Urology</i> , 2010, 76, 1024.	0.5	0
392	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 441-448.	0.8	94
393	Prostate cancer screening and mortality: Comparison of recent randomized controlled clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 233-236.	0.8	1

#	ARTICLE	IF	CITATIONS
394	Mass screening of prostate cancer in Vietnam: Current status and our opinions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 673-676.	0.8	10
395	Prostate cancer around the world. An overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 663-667.	0.8	37
396	What can be concluded from the ERSPC and PLCO trial data?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 668-669.	0.8	16
398	Durable Improvements in Prostate Cancer Screening from Online Spaced Education. <i>American Journal of Preventive Medicine</i> , 2010, 39, 472-478.	1.6	58
399	Observational Methods in Comparative Effectiveness Research. <i>American Journal of Medicine</i> , 2010, 123, e16-e23.	0.6	108
400	Is Shared Decision Making in Prostate Cancer Restrained by Evidence-Based Medicine?. <i>European Urology Supplements</i> , 2010, 9, 782-787.	0.1	0
402	Focal therapy meets prostate cancer. <i>Lancet, The</i> , 2010, 376, 1036-1037.	6.3	21
403	The Role of Adaptive and Functional Imaging Modalities in Radiation Therapy: Approach and Application from a Radiation Oncology Perspective. <i>Seminars in Ultrasound, CT and MRI</i> , 2010, 31, 444-461.	0.7	7
404	Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. <i>Lancet Oncology, The</i> , 2010, 11, 725-732.	5.1	843
405	PSA testing for prostate cancer improves survivalâ€”but can we do better?. <i>Lancet Oncology, The</i> , 2010, 11, 702-703.	5.1	15
407	Global Patterns of Cancer Incidence and Mortality Rates and Trends. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1893-1907.	1.1	2,266
408	Disproportionate Presentation of High Risk Prostate Cancer in a Safety Net Health System. <i>Journal of Urology</i> , 2010, 184, 1931-1936.	0.2	20
409	Initial Prostate Specific Antigen 1.5 ng/ml or Greater in Men 50 Years Old or Younger Predicts Higher Prostate Cancer Risk. <i>Journal of Urology</i> , 2010, 183, 946-951.	0.2	21
410	Putative molecular signatures for the imaging of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 65-74.	1.5	17
411	Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964â€”2003 followed up until the end of 2006. <i>Acta OncolÃ³gica</i> , 2010, 49, 644-654.	0.8	47
412	Chemoprevention of prostate cancer: breakthroughs and controversies. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1517-1522.	1.1	2
413	Prostate Cancer: An Evolving Paradigm. <i>Journal of Endourology</i> , 2010, 24, 805-809.	1.1	7
414	Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8760-8765.	3.3	293

#	ARTICLE	IF	CITATIONS
415	When do new biomarkers make economic sense?. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 90-95.	0.6	22
416	Prostate Cancer Proteomics. OMICS A Journal of Integrative Biology, 2011, 15, 169-171.	1.0	2
417	Integrating Evidence and Individual Preferences Using a Web-Based Multi-Criteria Decision Analytic Tool. Patient, 2011, 4, 153-162.	1.1	20
418	Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System. Journal of the National Cancer Institute, 2011, 103, 714-736.	3.0	597
419	Detection and Verification of Glycosylation Patterns of Glycoproteins from Clinical Specimens Using Lectin Microarrays and Lectin-Based Immunosorbent Assays. Analytical Chemistry, 2011, 83, 8509-8516.	3.2	71
420	Quantitative Glycoproteomic Analysis of Optimal Cutting Temperature-Embedded Frozen Tissues Identifying Glycoproteins Associated with Aggressive Prostate Cancer. Analytical Chemistry, 2011, 83, 7013-7019.	3.2	57
422	A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. Journal of Urology, 2011, 185, 1650-1655.	0.2	408
423	Mortality results from the Gärtteborg randomised population-based prostate-cancer screening trial. Yearbook of Urology, 2011, 2011, 58-59.	0.1	0
424	DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Research, 2011, 21, 1017-1027.	2.4	206
425	Advances in electrophysiology in the diagnosis of behavioral disorders. Expert Opinion on Medical Diagnostics, 2011, 5, 441-452.	1.6	8
426	Major Urologic Problems in Geriatrics: Assessment and Management. Medical Clinics of North America, 2011, 95, 253-264.	1.1	13
427	Use and Assessment of PSA in Prostate Cancer. Medical Clinics of North America, 2011, 95, 191-200.	1.1	34
430	Prostate Imaging Modalities that Can Be Used for Complementary and Alternative Medicine Clinical Studies. Urologic Clinics of North America, 2011, 38, 343-357.	0.8	5
431	Robotic Surgery in Urology. Perioperative Nursing Clinics, 2011, 6, 241-258.	0.1	0
432	Tumor Volume Threshold of Insignificant Prostate Cancer—Was Dr. Stamey Right All Along?. Journal of Urology, 2011, 185, 10-11.	0.2	4
433	Screening for Lung Cancer: Challenges for the Thoracic Surgeon. Surgical Oncology Clinics of North America, 2011, 20, 619-635.	0.6	6
434	123 ENGRAILED-2 (EN2): A HIGHLY SPECIFIC URINARY BIOMARKER FOR THE EARLY DIAGNOSIS OF PROSTATE CANCER. European Urology Supplements, 2011, 10, 64.	0.1	0
435	Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study. Actas Urológicas Españolas (English Edition), 2011, 35, 10-14.	0.2	3

#	ARTICLE	IF	CITATIONS
436	Neck mass as the first presentation of metastatic prostatic adenocarcinoma. <i>Journal of the Chinese Medical Association</i> , 2011, 74, 570-573.	0.6	13
437	EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 501-514.	0.2	5
438	Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 589-596.	0.2	17
439	Lycopene for the prevention of prostate cancer. <i>The Cochrane Library</i> , 2011, , CD008007.	1.5	57
440	Antibiotic prophylaxis for transrectal prostate biopsy. <i>The Cochrane Library</i> , 2011, , CD006576.	1.5	149
441	Reducing overtreatment: active surveillance in low-risk disease. <i>Nature Reviews Urology</i> , 2011, 8, 124-125.	1.9	6
442	Disease Prevention and Screening. , 2011, , 49-66.		0
443	Contamination during 4 years of annual CT screening in the Danish Lung Cancer Screening Trial (DLCST). <i>Lung Cancer</i> , 2011, 71, 323-327.	0.9	17
444	Screening for Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2013-2019.	13.9	183
445	MicroRNAs in Cancer Translational Research. , 2011, , .		5
446	Nanotechnology Research Directions for Societal Needs in 2020. , 2011, , .		202
448	The Prostate Cancer Risk Calculator From the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in Contemporary Referral Patients. <i>Journal of Urology</i> , 2011, 185, 483-488.	0.2	18
449	Fully automated solid-phase microextractionâ€“fast gas chromatographyâ€“mass spectrometry method using a new ionic liquid column for high-throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sediments. <i>Analytica Chimica Acta</i> , 2011, 707, 197-203.	2.6	61
450	Patterns and Correlates of Prostate Cancer Treatment in Older Men. <i>American Journal of Medicine</i> , 2011, 124, 235-243.	0.6	45
451	CLSI EP17-A protocol: A useful tool for better understanding the low end performance of total prostate-specific antigen assays. <i>Clinica Chimica Acta</i> , 2011, 412, 1143-1145.	0.5	25
452	The influence of information and private versus public provision on preferences for screening for prostate cancer: A willingness-to-pay study. <i>Health Policy</i> , 2011, 101, 277-289.	1.4	17
453	The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The GÅrteborg randomised population-based prostate cancer screening trial. <i>European Journal of Cancer</i> , 2011, 47, 545-553.	1.3	34
454	Trade-off between benefit and harm is crucial in health screening recommendations. Part I: General principles. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 231-239.	2.4	31

#	ARTICLE	IF	CITATIONS
455	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1412-1417.	2.4	43
456	Number needed to screen—How can we project outside context?. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1275-1276.	2.4	1
458	Cancer screening in older adults: What to do when we don't know. <i>Journal of Geriatric Oncology</i> , 2011, 2, 149-160.	0.5	7
459	The decision-making process in prostate cancer screening in primary care with a prostate-specific antigen: A systematic review. <i>Journal of Geriatric Oncology</i> , 2011, 2, 161-176.	0.5	7
460	The Prostate-Specific Antigen Screening Conundrum: Examining the Evidence. <i>Seminars in Oncology Nursing</i> , 2011, 27, 251-259.	0.7	6
461	Active Surveillance as a Treatment Option for Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2011, 27, 260-266.	0.7	5
462	ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program. <i>Urology</i> , 2011, 77, 763.e1-763.e6.	0.5	47
463	Repeat Prostate Biopsy and the Incremental Risk of Clinically Insignificant Prostate Cancer. <i>Urology</i> , 2011, 77, 548-552.	0.5	35
464	Acceptance and Durability of Surveillance as a Management Choice in Men with Screen-detected, Low-risk Prostate Cancer: Improved Outcomes with Stringent Enrollment Criteria. <i>Urology</i> , 2011, 77, 980-984.	0.5	28
465	Barriers and Facilitators to Digital Rectal Examination Screening Among African-American and African-Caribbean Men. <i>Urology</i> , 2011, 77, 891-898.	0.5	41
466	Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer. <i>Urology</i> , 2011, 77, 1265.e9-1265.e16.	0.5	210
467	Difference in Willingness-to-pay for Prostate Cancer Screening Between Ill-informed and Well-informed Men: A Contingent Valuation Survey. <i>Urology</i> , 2011, 77, 1325-1329.	0.5	12
470	Editorial Comment. <i>Urology</i> , 2011, 78, 248-249.	0.5	0
471	Robotic Transperineal Prostate Biopsy: Pilot Clinical Study. <i>Urology</i> , 2011, 78, 1203-1208.	0.5	44
472	Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 593-601.	0.8	38
473	Screening for prostate cancer. <i>European Journal of Cancer</i> , 2011, 47, S164-S170.	1.3	25
475	Future of Treatment for Low-Risk Prostate Cancer: For All, for Some, or for None?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1940-1943.	0.8	4
476	Transgenic Adenocarcinoma of the Mouse Prostate: A Validated Model for the Identification and Characterization of Molecular Targets and The Evaluation of Therapeutic Agents. , 2011, , 397-421.		0

#	ARTICLE	IF	CITATIONS
477	Size, follow-up, data analysisâ€™ good; post hoc analysis, interpretationâ€™ not so much. Community Oncology, 2011, 8, 379-380.	0.2	2
478	The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 124-129.	0.8	47
479	Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy. Journal of Urology, 2011, 186, 86-90.	0.2	39
480	Predicting Prostate Biopsy Result in Men With Prostate Specific Antigen 2.0 to 10.0 ng/ml Using an Investigational Prostate Cancer Methylation Assay. Journal of Urology, 2011, 186, 2101-2106.	0.2	46
481	Complications After Prostate Biopsy: Data From SEER-Medicare. Journal of Urology, 2011, 186, 1830-1834.	0.2	589
482	Does Urological Cancer Mortality Increase With Low Population Density of Physicians?. Journal of Urology, 2011, 186, 2342-2346.	0.2	12
485	Diagnostic Strategies for Prostate Cancer. European Urology Supplements, 2011, 10, e26-e37.	0.1	5
486	Radical External Beam Radiotherapy for Clinically Localized Prostate Cancer in Japan: Changing Trends in the Patterns of Care Process Survey. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1310-1318.	0.4	14
487	Early assessment of cancer outcomes in New York City firefighters after the 9/11 attacks: an observational cohort study. Lancet, The, 2011, 378, 898-905.	6.3	122
488	Prostate Cancer: Essential Diagnostic and Therapeutic Considerations. , 0, , .		0
489	The Debate over Prostate Cancer Screening Guidelines. AMA Journal of Ethics, 2011, 13, 10-15.	0.4	1
490	Trends in Prostate Cancer Incidence and Mortality before and after the Introduction of PSA Testing in the Slovak and Czech Republics. Tumori, 2011, 97, 149-155.	0.6	4
491	PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian Journal of Andrology, 2011, 13, 219-224.	0.8	21
492	Comparative Effectiveness Research under the Patient Protection and Affordable Care Act: Can New Bottles Accommodate Old Wine?. American Journal of Law and Medicine, 2011, 37, 522-566.	0.5	13
493	Methods to Predict and Lower the Risk of Prostate Cancer. Scientific World Journal, The, 2011, 11, 742-748.	0.8	2
494	Evidence-based National Cancer Screening program of Korea. Journal of the Korean Medical Association, 2011, 54, 1028.	0.1	7
496	Urbanâ€™rural differences in prostate cancer outcomes in Australia: what has changed?. Medical Journal of Australia, 2011, 194, 293-296.	0.8	99
497	The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities. International Journal of Proteomics, 2011, 2011, 1-17.	2.0	13

#	ARTICLE	IF	CITATIONS
498	Analysis of Normal-Tumour Tissue Interaction in Tumours: Prediction of Prostate Cancer Features from the Molecular Profile of Adjacent Normal Cells. PLoS ONE, 2011, 6, e16492.	1.1	17
499	Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. PLoS ONE, 2011, 6, e22486.	1.1	80
501	Prostate Cancer Staging and Grading at Radical Prostatectomy Over Time. Advances in Anatomic Pathology, 2011, 18, 159-164.	2.4	30
502	Cancer screening. European Journal of Cancer Prevention, 2011, 20, S2-S4.	0.6	1
503	Primary care perspectives on Prostate cancer screening. Nurse Practitioner, 2011, 36, 39-44.	0.2	1
504	Cancer mortality trend analysis in Italy, 1970-2007. European Journal of Cancer Prevention, 2011, 20, 364-374.	0.6	32
505	The Current Status of Cryotherapy and High-Intensity Focused UltraSound in the Treatment of Low-Grade Prostate Cancer. Reviews on Recent Clinical Trials, 2011, 6, 171-176.	0.4	2
506	Screening for prostate cancer. European Journal of Cancer Prevention, 2011, 20, S33-S35.	0.6	4
507	Role of Medical Surveillance in Risk Management. Journal of Occupational and Environmental Medicine, 2011, 53, S18-S21.	0.9	10
508	Update on Screening in Prostate Cancer Based on Recent Clinical Trials. Reviews on Recent Clinical Trials, 2011, 6, 7-15.	0.4	6
509	Prostate-specific antigen screening in elderly men. Aging Health, 2011, 7, 219-229.	0.3	0
510	The use of MRI scanning to triage patients. British Journal of Nursing, 2011, 20, 1310-1314.	0.3	1
511	Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2011, 155, 762.	2.0	485
512	Screening for Lung Cancer: It Works, but Does It Really Work?. Annals of Internal Medicine, 2011, 155, 537.	2.0	37
513	Response to SatgÃ© and Vekemans. Clinical Genetics, 2011, 79, 291-292.	1.0	0
514	Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU International, 2011, 107, 466-470.	1.3	20
515	Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39.	1.3	83
516	Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU International, 2011, 108, 44-48.	1.3	5

#	ARTICLE	IF	CITATIONS
517	Focal therapy in the management of localized prostate cancer. <i>BJU International</i> , 2011, 107, 1362-1368.	1.3	24
518	An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer. <i>BJU International</i> , 2011, 108, E190-E195.	1.3	14
519	Are men on 5 α -reductase inhibitors appropriately referred to urology? A survey of primary care physicians. <i>BJU International</i> , 2011, 108, 1269-1273.	1.3	4
520	Screening for prostate cancer: an updated Cochrane systematic review. <i>BJU International</i> , 2011, 107, 882-891.	1.3	147
521	Maximizing outcomes in genitourinary cancers across the treatment continuum. <i>BJU International</i> , 2011, 107, 1-12.	1.3	1
522	Management of low (favourable)-risk prostate cancer. <i>BJU International</i> , 2011, 108, 1684-1695.	1.3	27
523	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011, 108, 1402-1408.	1.3	63
524	Dramatic increase in prostate cancer cases by 2021. <i>BJU International</i> , 2011, 108, 1734-1738.	1.3	35
525	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , 2011, 108, E237-E244.	1.3	62
526	Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa City, Japan. <i>International Journal of Urology</i> , 2011, 18, 592-596.	0.5	13
527	Recent developments in prostate cancer biomarker research: therapeutic implications. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 157-174.	1.1	20
528	Translating Medical Evidence to Promote Informed Health Care Decisions. <i>Health Services Research</i> , 2011, 46, 1200-1223.	1.0	11
529	Perspective on prostate cancer screening. <i>International Journal of Clinical Practice</i> , 2011, 65, 31-34.	0.8	3
530	Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 85-89.	2.0	3
531	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. <i>British Journal of Cancer</i> , 2011, 104, 1656-1663.	2.9	153
532	Controversies in Sexual Medicine. <i>Journal of Sexual Medicine</i> , 2011, 8, 946-955.	0.3	20
533	Factors Predicting Early and Late Phase Decline of Sexual Health-Related Quality of Life Following Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2011, 8, 2935-2943.	0.3	23
534	Population-based screening for prostate cancer: the clinical conundrum. <i>Journal of Men's Health</i> , 2011, 8, 170-174.	0.1	0

#	ARTICLE	IF	CITATIONS
535	Barcode lateral flow immunochromatographic strip for prostate acid phosphatase determination. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 1035-1040.	1.4	50
536	Validity of a low literacy version of the Decisional Conflict Scale. <i>Patient Education and Counseling</i> , 2011, 85, 521-524.	1.0	62
537	Novedades de los cribados del c�ncer. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2011, 18, 330-338.	0.0	2
538	Global cancer statistics. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 69-90.	157.7	32,172
539	Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. <i>European Urology</i> , 2011, 59, 135-141.	0.9	259
540	Is Prostate Cancer Screening Bad or Good? Summary of a Debate at the Innovation in Urology Meeting, September 17�19, 2010, Milan, Italy. <i>European Urology</i> , 2011, 59, 359-362.	0.9	6
541	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. <i>European Urology</i> , 2011, 59, 61-71.	0.9	1,299
542	Re: Prostate Specific Antigen Concentration at Age 60 and Death or Metastasis From Prostate Cancer: Case-Control Study. <i>European Urology</i> , 2011, 59, 304-305.	0.9	0
543	Is Population Screening for Prostate Cancer Good or Bad?. <i>European Urology</i> , 2011, 59, 363-364.	0.9	1
544	Screening for Prostate Cancer: Practical Analysis of the ESRPC and PLCO Trials. <i>European Urology</i> , 2011, 59, 365-369.	0.9	6
545	Prostate Cancer Incidence and Disease-Specific Survival of Men with Initial Prostate-Specific Antigen Less Than 3.0ng/ml Who Are Participating in ERSPC Rotterdam. <i>European Urology</i> , 2011, 59, 498-505.	0.9	30
548	In Vivo Assessment of Prostate Cancer Aggressiveness Using Magnetic Resonance Spectroscopic Imaging at 3 T with an Endorectal Coil. <i>European Urology</i> , 2011, 60, 1074-1080.	0.9	91
549	Trends in Mortality From Urologic Cancers in Europe, 1970�2008. <i>European Urology</i> , 2011, 60, 1-15.	0.9	139
550	Re: Comorbidity and Mortality Results from a Randomised Prostate Cancer Screening Trial. <i>European Urology</i> , 2011, 60, 867.	0.9	1
551	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. <i>European Urology</i> , 2011, 60, 1045-1054.	0.9	148
552	Re: Randomised Prostate Cancer Screening Trial: 20 Year Follow-up. <i>European Urology</i> , 2011, 60, 1306-1307.	0.9	2
553	Re: Early Versus Late Rehabilitation of Erectile Function After Nerve-Sparing Radical Cystoprostatectomy: A Prospective Randomized Study. <i>European Urology</i> , 2011, 60, 1307-1308.	0.9	0
554	Reversed association between levels of prostate specific antigen and levels of blood cadmium and urinary cadmium. <i>Chemosphere</i> , 2011, 83, 1188-1191.	4.2	18

#	ARTICLE	IF	CITATIONS
555	Comparison of Clinical and Pathologic Findings of Prostate Cancers Detected Through Screening Versus Conventional Referral in Brazil. <i>Clinical Genitourinary Cancer</i> , 2011, 9, 104-108.	0.9	13
556	Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 310-316.	0.8	17
557	Prostate cancer screening, detection and treatment practices, among Sub-Saharan African urologists. <i>African Journal of Urology</i> , 2011, 17, 85-91.	0.1	8
558	Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology. <i>Neuropsychopharmacology</i> , 2011, 36, 2375-2394.	2.8	379
562	Factors Influencing Men's Decisions Regarding Prostate Cancer Screening: A Qualitative Study. <i>Journal of Community Health</i> , 2011, 36, 839-844.	1.9	42
563	The prognostic role of cancer-specific beliefs among prostate cancer survivors. <i>Cancer Causes and Control</i> , 2011, 22, 251-260.	0.8	7
564	Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models. <i>International Urology and Nephrology</i> , 2011, 43, 23-30.	0.6	14
565	Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologists' practice patterns. <i>International Urology and Nephrology</i> , 2011, 43, 31-37.	0.6	3
566	The effect of prostate cancer screening on stage IV disease in America. <i>International Urology and Nephrology</i> , 2011, 43, 391-396.	0.6	2
567	Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. <i>Human Genetics</i> , 2011, 129, 675-685.	1.8	50
569	Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. <i>European Journal of Health Economics</i> , 2011, 12, 363-371.	1.4	21
571	Comparative effectiveness research in urology. <i>World Journal of Urology</i> , 2011, 29, 277-282.	1.2	6
572	The role of randomized controlled trials in evidence-based urology. <i>World Journal of Urology</i> , 2011, 29, 257-263.	1.2	6
580	A stochastic approach to risk management for prostate cancer patients on active surveillance. <i>Journal of Theoretical Biology</i> , 2011, 284, 61-70.	0.8	2
581	Helping men make an informed decision about prostate cancer screening: A pilot study of telephone counseling. <i>Patient Education and Counseling</i> , 2011, 82, 193-200.	1.0	19
582	A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT. <i>Patient Education and Counseling</i> , 2011, 84, e44-e51.	1.0	37
583	Assessing critical illness trends: the facts behind the stats. <i>European Actuarial Journal</i> , 2011, 1, 61-84.	0.5	1
584	Designing clinical trials for early (pre-dementia) Alzheimer's disease: Determining the appropriate population for treatment. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 22-24.	1.5	10

#	ARTICLE	IF	CITATIONS
585	Correlates of Colorectal Cancer Screening Adherence Among Men Who have been Screened for Prostate Cancer. <i>Journal of Cancer Education</i> , 2011, 26, 301-307.	0.6	9
586	Patterns of Information Behavior and Prostate Cancer Knowledge Among African-American Men. <i>Journal of Cancer Education</i> , 2011, 26, 708-716.	0.6	22
587	Battling Prostate Cancer with 5-Alpha-Reductase Inhibitors: a Pyrrhic Victory?. <i>Journal of General Internal Medicine</i> , 2011, 26, 798-801.	1.3	3
588	Older age does not impact perioperative complications after robot-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2011, 5, 201-208.	1.0	7
589	Treating Prostate Cancer in Elderly Men: How Does Aging Affect the Outcome?. <i>Current Treatment Options in Oncology</i> , 2011, 12, 263-275.	1.3	16
590	Cancer Screening in Patients Infected with HIV. <i>Current HIV/AIDS Reports</i> , 2011, 8, 142-152.	1.1	63
591	Prostate Cancer Screening. <i>Current Oncology Reports</i> , 2011, 13, 57-62.	1.8	22
592	Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. <i>BMC Cancer</i> , 2011, 11, 148.	1.1	15
593	The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches. <i>BMC Cancer</i> , 2011, 11, 511.	1.1	27
594	Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. <i>BMC Clinical Pathology</i> , 2011, 11, 14.	1.8	20
595	Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. <i>Prostate</i> , 2011, 71, 421-430.	1.2	38
596	Passive bioelectrical properties for assessing high- and low-grade prostate adenocarcinoma. <i>Prostate</i> , 2011, 71, 1759-1767.	1.2	15
597	Kallikrein-related peptidase 4 gene (<i>KLK4</i>) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. <i>Prostate</i> , 2011, 71, 1780-1789.	1.2	28
598	Targeted expression of <i>Escherichia coli</i> purine nucleoside phosphorylase and Fludara® for prostate cancer therapy. <i>Journal of Gene Medicine</i> , 2011, 13, 680-691.	1.4	17
599	CE methods for analysis of isoforms of prostate-specific antigen compatible with online derivatization for LIF detection. <i>Electrophoresis</i> , 2011, 32, 2036-2043.	1.3	14
600	A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. <i>Genetic Epidemiology</i> , 2011, 35, n/a-n/a.	0.6	71
601	Screening, risk assessment, and the approach to therapy in patients with prostate cancer. <i>Cancer</i> , 2011, 117, 1123-1135.	2.0	87
602	Editorial for "prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50". <i>Cancer</i> , 2011, 117, 1110-1112.	2.0	0

#	ARTICLE	IF	CITATIONS
603	Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. <i>Cancer</i> , 2011, 117, 1210-1219.	2.0	121
604	Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. <i>International Journal of Cancer</i> , 2011, 128, 2444-2452.	2.3	41
605	Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. <i>International Journal of Cancer</i> , 2011, 129, 1881-1888.	2.3	47
606	Speaker abstracts. <i>International Journal of Cancer</i> , 2011, 128, 1-28.	2.3	0
608	Cardiorespiratory fitness and risk of prostate cancer: Findings from the Aerobics Center Longitudinal Study. <i>Cancer Epidemiology</i> , 2011, 35, 59-65.	0.8	32
609	Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. <i>Patient Education and Counseling</i> , 2011, 83, 64-72.	1.0	25
610	Mediated decision support in prostate cancer screening: A randomized controlled trial of decision counseling. <i>Patient Education and Counseling</i> , 2011, 83, 240-246.	1.0	39
611	Barbershop Communications on Prostate Cancer Screening Using Barber Health Advisers. <i>American Journal of Men's Health</i> , 2011, 5, 129-139.	0.7	58
612	What Are the Consequences if I Postpone Treatment of My PSA-Detected Prostate Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 727-728.	1.1	0
613	Prostate-specific antigen testing across the spectrum of prostate cancer. <i>Biomarkers in Medicine</i> , 2011, 5, 515-526.	0.6	31
614	Is there an optimal prostate-specific antigen threshold for prostate biopsy?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1215-1221.	1.1	5
615	Breast Cancer Screening: A 35-Year Perspective. <i>Epidemiologic Reviews</i> , 2011, 33, 165-175.	1.3	39
617	Randomised prostate cancer screening trial: 20 year follow-up. <i>BMJ: British Medical Journal</i> , 2011, 342, d1539-d1539.	2.4	134
618	Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase. <i>BMJ: British Medical Journal</i> , 2011, 342, d199-d199.	2.4	104
620	Modifiable Prostate Cancer Risk Reduction and Early Detection Behaviors in Black Men. <i>American Journal of Health Behavior</i> , 2011, 35, 470-84.	0.6	14
622	PSA testing: Molecular technologies and men's experience of prostate cancer survivorship. <i>Health, Risk and Society</i> , 2011, 13, 183-198.	0.9	12
623	What's Wrong With Chemoprevention of Prostate Cancer?. <i>American Journal of Bioethics</i> , 2011, 11, 21-25.	0.5	6
624	Prognostic Determinants in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 429-437.	1.0	48

#	ARTICLE	IF	CITATIONS
625	Deceiving Numbers. <i>Medical Decision Making</i> , 2011, 31, 386-394.	1.2	54
626	Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer Patients. <i>Cancer Research</i> , 2011, 71, 550-560.	0.4	287
627	Fatherhood and incident prostate cancer in a prospective US cohort. <i>International Journal of Epidemiology</i> , 2011, 40, 480-487.	0.9	26
628	Prostate Cancer Screening: A Survey of Attitudes and Practices among Finnish Physicians in 1999 and 2007. <i>Journal of Medical Screening</i> , 2011, 18, 46-49.	1.1	6
629	Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators. <i>Journal of Clinical Oncology</i> , 2011, 29, 2959-2964.	0.8	86
630	Addressing the Challenge of Informed Decision Making in Prostate Cancer Community Outreach to African American Men. <i>American Journal of Men's Health</i> , 2011, 5, 508-516.	0.7	19
631	Making the Call. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2649.	3.8	11
632	Grading the New US Preventive Services Task Force Prostate Cancer Screening Recommendation. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2715.	3.8	20
633	PSA Quo Vadis? It Is Reasonable to Start with Prostate-Specific Antigen Testing at the Age of 40!. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1190-1195.	1.1	8
634	Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 355-361.	0.8	150
635	A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 255-261.	1.1	84
636	Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1196-1203.	1.1	48
637	Report bias favours screening. <i>BMJ: British Medical Journal</i> , 2011, 342, d3703-d3703.	2.4	2
638	Screening for prostate cancer – The controversy continues, but can it be resolved?. <i>Acta Oncologica</i> , 2011, 50, 4-11.	0.8	16
639	When is active surveillance the appropriate treatment for prostate cancer?. <i>Acta Oncologica</i> , 2011, 50, 120-126.	0.8	15
640	Screening for prostate cancer: Defining critical issues. <i>Acta Oncologica</i> , 2011, 50, 2-3.	0.8	1
641	The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context. <i>Acta Oncologica</i> , 2011, 50, 12-17.	0.8	7
642	Barriers and Facilitators of Prostate Cancer Screening Among Filipino Men in Hawaii. <i>Oncology Nursing Forum</i> , 2011, 38, 227-233.	0.5	27

#	ARTICLE	IF	CITATIONS
643	Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evidence-Based Medicine, 2011, 16, 20-21.	0.6	11
644	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2011, 5, 235-240.	0.3	50
645	Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. Journal of Clinical Oncology, 2011, 29, 1736-1743.	0.8	100
646	Decreased Prostate Cancer-Specific Survival of Men with <i>BRCA2</i> Mutations from Multiple Breast Cancer Families. Cancer Prevention Research, 2011, 4, 1002-1010.	0.7	100
647	Social and Cultural Factors Influence African American Men's Medical Help Seeking. Research on Social Work Practice, 2011, 21, 337-347.	1.1	75
648	The Genetics of Cancer Risk. Cancer Journal (Sudbury, Mass), 2011, 17, 416-422.	1.0	50
649	HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16392-16397.	3.3	51
650	Efficacy and Safety of Dutasteride on Prostate Cancer Risk Reduction in Asian Men: The Results from the REDUCE Study. Japanese Journal of Clinical Oncology, 2011, 41, 417-423.	0.6	8
651	Missing the Mark on Prostate-Specific Antigen Screening. JAMA - Journal of the American Medical Association, 2011, 306, 2719.	3.8	18
652	Prostate Cancer Screening—The Evidence, the Recommendations, and the Clinical Implications. JAMA - Journal of the American Medical Association, 2011, 306, 2721.	3.8	38
653	Pros and Cons of Focal Therapy for Localised Prostate Cancer. Prostate Cancer, 2011, 2011, 1-8.	0.4	15
654	Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation?. International Journal for Quality in Health Care, 2011, 23, 611-620.	0.9	15
655	Serum Prostate-Specific Antigen for the Early Detection of Prostate Cancer: Always, Never, or Only Sometimes?. Journal of Clinical Oncology, 2011, 29, 345-347.	0.8	23
656	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2—ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	2.9	57
657	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3342-3347.	3.3	175
658	Safely Doing Less: A Missing Component of the Patient Safety Dialogue. Pediatrics, 2011, 128, e1596-e1597.	1.0	40
659	Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer. Clinical Cancer Research, 2011, 17, 1090-1098.	3.2	100
660	Shared Decision Making After MacIntyre. Journal of Medicine and Philosophy, 2011, 36, 148-169.	0.4	12

#	ARTICLE	IF	CITATIONS
661	SIGLEC12, a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas. <i>Journal of Biological Chemistry</i> , 2011, 286, 23003-23011.	1.6	48
662	Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. <i>Science Translational Medicine</i> , 2011, 3, 94ra72.	5.8	313
663	Do Men Make Informed Decisions about Prostate Cancer Screening? Baseline Results from the "Take the Wheel" Trial. <i>Medical Decision Making</i> , 2011, 31, 108-120.	1.2	21
664	Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1335-1341.	0.8	266
665	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 740-750.	1.1	43
666	Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 346-353.	2.0	29
667	Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 235-241.	0.8	321
668	Biomarker research in prostate cancer "towards utility, not futility. <i>Nature Reviews Urology</i> , 2011, 8, 131-138.	1.9	35
669	Robotic prostate biopsy and its relevance to focal therapy of prostate cancer. <i>Nature Reviews Urology</i> , 2011, 8, 579-585.	1.9	8
670	Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 169-172.	1.1	2
671	Tumor control probability in radiation treatment. <i>Medical Physics</i> , 2011, 38, 574-583.	1.6	58
672	The Science and Art of Prostate Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2011, 103, 450-451.	3.0	7
673	Influence of Publication of US and European Prostate Cancer Screening Trials on PSA Testing Practices. <i>Journal of the National Cancer Institute</i> , 2011, 103, 520-523.	3.0	57
674	Clinical MRI of the Abdomen. , 2011, , .		12
675	Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.3	9
676	An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer. <i>Prostate Cancer</i> , 2011, 2011, 1-8.	0.4	7
677	Components of Cell-Matrix Linkage as Potential New Markers for Prostate Cancer. <i>Cancers</i> , 2011, 3, 883-896.	1.7	8
678	Identification of cancer diagnosis estimation models using evolutionary algorithms. , 2011, , .		24

#	ARTICLE	IF	CITATIONS
679	Early detection of prostate cancer with emphasis on genetic markers. <i>Acta Oncologica</i> , 2011, 50, 18-23.	0.8	18
680	High accuracy of Swedish death certificates in men participating in screening for prostate cancer: A comparative study of official death certificates with a cause of death committee using a standardized algorithm. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 226-232.	1.4	46
681	Early detection of prostate cancer: Is screening in general practice justifiable?. <i>Scandinavian Journal of Primary Health Care</i> , 2011, 29, 133-134.	0.6	2
682	To Screen or Not to Screen: Ongoing Debate in the Early Detection of Prostate Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 97-98.	0.3	2
683	Male pattern baldness and the risk of prostate cancer. <i>Annals of Oncology</i> , 2011, 22, 1824-1827.	0.6	43
684	Chemoprevention of prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 127-136.	0.8	10
685	Screening for Prostatic Tumors in Metabolic Syndrome Patients in Romania. <i>Acta Endocrinologica</i> , 2011, 7, 47-58.	0.1	1
686	Measuring Mortality Reductions in Cancer Screening Trials. <i>Epidemiologic Reviews</i> , 2011, 33, 36-45.	1.3	41
687	Sunlight, Vitamin D and Prostate Cancer Epidemiology. , 2011, , 965-978.		2
688	Active Surveillance for Prostate Cancer: An Underutilized Opportunity for Reducing Harm. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 175-183.	0.9	19
689	Prostate cancer screening: Attitudes and practices of family physicians in Ontario. <i>Canadian Urological Association Journal</i> , 2012, 6, 188-193.	0.3	12
690	The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment. <i>Journal of Public Health</i> , 2012, 34, 108-114.	1.0	12
691	Hitting old targets better and identifying new targets. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 70-72.	12.5	10
692	Commentary on the State-of-the-Science Conference on the Role of Active Surveillance in the Management of Men With Localized Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 135-139.	0.9	5
693	Why I Cannot Find the Prostate? Behind the Subjectivity of Rectal Exam. <i>ISRN Urology</i> , 2012, 2012, 1-4.	1.5	13
695	Presenting Treatment Options to Men with Clinically Localized Prostate Cancer: The Acceptability of Active Surveillance/Monitoring. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 191-196.	0.9	18
696	Overdiagnosis of Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 146-151.	0.9	88
697	Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review. <i>Journal of Clinical Oncology</i> , 2012, 30, 2581-2584.	0.8	114

#	ARTICLE	IF	CITATIONS
698	Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men. Evidence-Based Medicine, 2012, 17, 25-26.	0.6	0
699	Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 3071-3076.	0.8	129
700	Current Challenges in Development of Differentially Expressed and Prognostic Prostate Cancer Biomarkers. Prostate Cancer, 2012, 2012, 1-9.	0.4	19
701	Optimization of PSA Screening Policies. Medical Decision Making, 2012, 32, 337-349.	1.2	41
702	Reconciling Primary Care and Specialist Perspectives on Prostate Cancer Screening. Annals of Family Medicine, 2012, 10, 568-571.	0.9	10
703	Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of Clinical Oncology, 2012, 30, 2768-2775.	0.8	67
704	Limited PSA Testing in Indigent Men in South Texas: An Appropriate Care or Missing a Prevention Opportunity?. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1489-1496.	1.1	3
705	Optimization of Prostate Biopsy Referral Decisions. Manufacturing and Service Operations Management, 2012, 14, 529-547.	2.3	72
706	Active surveillance for prostate cancer. Current Opinion in Oncology, 2012, 24, 243-250.	1.1	41
707	Intraprostatic targeting. Current Opinion in Urology, 2012, 22, 97-103.	0.9	17
708	Next-generation Prostate Cancer Biobanking. Diagnostic Molecular Pathology, 2012, 21, 61-68.	2.1	31
709	Relationship Between Prostate-specific Antigen, Age, and Body Mass Index in a Prostate Cancer Screening Population. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 490-492.	0.6	18
711	Role of Active Surveillance in the Management of Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 202-206.	0.9	13
712	The Ethics of Testing a Test: Randomized Trials of the Health Impact of Diagnostic Tests for Infectious Diseases. Clinical Infectious Diseases, 2012, 55, 1522-1526.	2.9	14
713	Prostate Cancer Screening Among Asian American and Pacific Island Men. Home Health Care Management and Practice, 2012, 24, 56-58.	0.4	1
714	From Figures to Values: The Implicit Ethical Judgements in our Measures of Health. Public Health Ethics, 2012, 5, 22-28.	0.4	8
715	It Takes Two to Talk About Prostate Cancer. American Journal of Men's Health, 2012, 6, 472-484.	0.7	45
716	Androgen Deprivation Therapy as Primary Treatment for Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 360-365.	1.8	32

#	ARTICLE	IF	CITATIONS
717	Prostate-Specific Antigen Screening for Prostate Cancer in Older Men in the United States of America. <i>Gerontology</i> , 2012, 58, 331-336.	1.4	2
718	Prostate Cancer " Uncertainty and a Way Forward. <i>New England Journal of Medicine</i> , 2012, 367, 270-271.	13.9	64
719	Prostate-Cancer Mortality after PSA Screening. <i>New England Journal of Medicine</i> , 2012, 366, 2228-2231.	13.9	8
720	New Data on Prostate-Cancer Mortality after PSA Screening. <i>New England Journal of Medicine</i> , 2012, 366, 1047-1048.	13.9	48
721	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 372-390.	1.2	42
722	DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer. <i>DNA and Cell Biology</i> , 2012, 31, 187-192.	0.9	39
723	Circulating microRNAs: macro-utility as markers of prostate cancer?. <i>Endocrine-Related Cancer</i> , 2012, 19, R99-R113.	1.6	40
724	Risk profiles of prostate cancers identified from UK primary care using national referral guidelines. <i>British Journal of Cancer</i> , 2012, 106, 436-439.	2.9	32
725	Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 278-282.	2.0	24
726	Prostate Anatomy and Prostate Cancer Screening, Diagnosis, Staging, and Prevention. , 2012, , 29-40.		0
727	Construct validity in a high-fidelity prostate exam simulator. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 63-69.	2.0	16
728	PSA screening: determinants of primary-care physician practice patterns. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 189-194.	2.0	22
729	Translational genomics: The challenge of developing cancer biomarkers. <i>Genome Research</i> , 2012, 22, 183-187.	2.4	94
730	The United States Preventive Services Task Force Recommendation against Prostate-Specific Antigen Screening"Counterpoint. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 395-397.	1.1	5
731	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6686-6691.	3.3	49
732	Psychological Research and the Prostate-Cancer Screening Controversy. <i>Psychological Science</i> , 2012, 23, 547-553.	1.8	50
733	Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. <i>Journal of the National Cancer Institute</i> , 2012, 104, 125-132.	3.0	947
734	Recommendations on Use of Prostate-Specific Antigen for Prostate Cancer Screening"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1372.	3.8	0

#	ARTICLE	IF	CITATIONS
735	What Is the Risk Posed by Prostate Cancer?. Journal of the National Cancer Institute Monographs, 2012, 2012, 169-174.	0.9	7
736	Historical Prostate Cancer Screening and Treatment Outcomes from a Single Institution. Clinical Medicine and Research, 2012, 10, 97-105.	0.4	7
737	Regional Cell Proliferation in Microdissected Human Prostate Specimens after Heavy Water Labeling <i>In Vivo</i> : Correlation with Prostate Epithelial Cells Isolated from Seminal Fluid. Clinical Cancer Research, 2012, 18, 3250-3260.	3.2	10
738	Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1320-1331.	1.9	25
739	Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biological Chemistry, 2012, 393, 301-317.	1.2	79
740	Call It Cancer. Oncologist, 2012, 17, 149-150.	1.9	7
741	Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. Journal of Cancer Epidemiology, 2012, 2012, 1-13.	0.5	13
742	Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. Urologia Internationalis, 2012, 89, 126-135.	0.6	25
743	Response: Re: Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. Journal of the National Cancer Institute, 2012, 104, 793-794.	3.0	2
744	The confusion surrounding prostate cancer screening faced by family physicians. Canadian Urological Association Journal, 2012, 6, 194-195.	0.3	6
745	Intake of Grains and Dietary Fiber and Prostate Cancer Aggressiveness by Race. Prostate Cancer, 2012, 2012, 1-10.	0.4	18
746	36P Automated Quantitative Her2 Assessment in Circulating Tumor Cells: Discrepancies with Primary Tumor in Neoadjuvant and Metastatic Trials. Annals of Oncology, 2012, 23, ii25.	0.6	3
747	Cancer overdiagnosis and overtreatment. Current Opinion in Urology, 2012, 22, 203-209.	0.9	61
748	Recommendations on Use of Prostate-Specific Antigen for Prostate Cancer Screening. JAMA - Journal of the American Medical Association, 2012, 307, 1372.	3.8	0
749	Underestimating the Value of Reassurance. JAMA - Journal of the American Medical Association, 2012, 307, 1035.	3.8	9
750	The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study: Figure 1. BMJ Open, 2012, 2, e000587.	0.8	4
751	Ten Years of Progress in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 136-140.	2.3	1
752	Screening for Prostate Cancer. Annals of Internal Medicine, 2012, 156, 540.	2.0	0

#	ARTICLE	IF	CITATIONS
753	Screening for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 539.	2.0	1
754	Screening for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 539.	2.0	0
756	Prostate cancer screening. <i>Pathology</i> , 2012, 44, 99-109.	0.3	8
757	Technology Growth and Expenditure Growth in Health Care. <i>Journal of Economic Literature</i> , 2012, 50, 645-680.	4.5	208
758	Photoacoustic imaging of prostate cancer using cylinder diffuse radiation. , 2012, , .		4
759	The Influence of Stress, Depression, and Anxiety on PSA Screening Rates in a Nationally Representative Sample. <i>Medical Care</i> , 2012, 50, 1037-1044.	1.1	25
760	Shaping a Modern Academic Department of Surgery. <i>Annals of Surgery</i> , 2012, 256, 395-401.	2.1	2
761	Probabilistic Persuasion: A Brunswikian Theory of Argumentation. , 2012, , 103-134.		5
762	Epidemiology of prostate cancer and treatment remarks. <i>World Journal of Radiology</i> , 2012, 4, 241.	0.5	29
763	Comparison of the uncertainty level of radical prostatectomy recipients with or without psychological support. <i>International Journal of Urological Nursing</i> , 2012, 6, 76-82.	0.1	3
764	Q: Should I have a PSA screening?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 56.	0.1	0
766	Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2012, 157, 120.	2.0	1,872
767	Simple Heuristics: The Foundations of Adaptive Social Behavior. , 2012, , 3-36.		4
768	Do Physicians Understand Cancer Screening Statistics? A National Survey of Primary Care Physicians in the United States. <i>Annals of Internal Medicine</i> , 2012, 156, 340.	2.0	230
769	Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases.. <i>Health Psychology</i> , 2012, 31, 562-570.	1.3	9
770	Prostate cancer overview. Part 1: non-metastatic disease. <i>British Journal of Nursing</i> , 2012, 21, S23-S28.	0.3	8
771	Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>New England Journal of Medicine</i> , 2012, 367, 1861-1862.	13.9	5
772	Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>New England Journal of Medicine</i> , 2012, 367, 595-605.	13.9	364

#	ARTICLE	IF	CITATIONS
773	Helping doctors utilize the prostate-specific antigen effectively: an online randomized controlled trial (The DUPE trial). ANZ Journal of Surgery, 2012, 82, 633-638.	0.3	2
774	UK PROSTATE CHARITIES MERGE. BJU International, 2012, 110, 1098-1099.	1.3	0
775	Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU International, 2012, 110, 1648-1652.	1.3	21
776	The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 2012, 14, 409-414.	0.8	124
777	Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology. Clinical Chemistry, 2012, 58, 732-740.	1.5	28
778	Molecular markers for cancer prognosis and treatment: Have we struck gold?. Cancer Letters, 2012, 327, 142-152.	3.2	33
779	Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomarkers in Medicine, 2012, 6, 587-596.	0.6	21
781	Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Management Science, 2012, 15, 293-309.	1.5	22
782	Predictors of Attendance for Prostate-Specific Antigen Screening Tests and Prostate Biopsy. European Urology, 2012, 62, 649-655.	0.9	22
783	Reply to Alain Braillon and G�rard Dubois� Letter to the Editor re: Fritz H. Schr�der, Jonas Hugosson, Sigr�d Carlsson, et al. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012;62:745-52. European Urology, 2012, 62, e90-e91.	0.9	0
784	Potential Years of Life Lost Due to Urogenital Cancer in the United States: Trends From 1972 to 2006 Based on Data From the SEER Database. Journal of Urology, 2012, 187, 868-871.	0.2	32
785	Association Between Smoking Status, and Free, Total and Percent Free Prostate Specific Antigen. Journal of Urology, 2012, 187, 1228-1233.	0.2	16
786	Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme. Public Health, 2012, 126, 1075-1077.	1.4	12
787	Prostate cancer chemoprevention with 5�-reductase inhibitors. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 553-554.	0.8	1
789	Towards more eclectic evidence-based medicine in cancer prevention and control. Preventive Medicine, 2012, 55, 552-553.	1.6	3
790	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA Journal, 2012, 3, 3.	3.3	23
791	C�ncer de pr�stata: diagn�stico y estudio de extensi�n. EMC - Urolog�a, 2012, 44, 1-8.	0.0	0
793	1929 ASSOCIATION BETWEEN FAMILY HISTORY OF PROSTATE CANCER AND POSITIVE BIOPSIES IN A BRAZILIAN SCREENING PROGRAM. Journal of Urology, 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
794	Detección precoz del cáncer de próstata. EMC - Urología, 2012, 44, 1-8.	0.0	0
795	Cancer and Age: General Considerations. Clinics in Geriatric Medicine, 2012, 28, 1-18.	1.0	63
796	The Riddle of Psychiatric Disorders in Parkinson Disease: From Phenomenology to Treatment. American Journal of Geriatric Psychiatry, 2012, 20, 99-103.	0.6	3
797	Vitamin D ₃ Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2315-2324.	1.8	112
798	Peroxiredoxins 3 and 4 Are Overexpressed in Prostate Cancer Tissue and Affect the Proliferation of Prostate Cancer Cells in Vitro. Journal of Proteome Research, 2012, 11, 2452-2466.	1.8	46
799	A novel enzymatic technique for determination of sarcosine in urine samples. Analytical Methods, 2012, 4, 141-146.	1.3	31
801	Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). Medical Decision Making, 2012, 32, 11-30.	1.2	27
802	Men's Use of an Internet-Based Decision Aid for Prostate Cancer Screening. Journal of Health Communication, 2012, 17, 677-697.	1.2	22
803	Oncology Biomarkers: Discovery, Validation, and Clinical Use. Seminars in Oncology Nursing, 2012, 28, 93-98.	0.7	16
804	Biomarkers as Surrogate Endpoints in Cancer Trials. Seminars in Oncology Nursing, 2012, 28, 99-108.	0.7	7
805	A Prospective, Controlled Phase II Study of Neoadjuvant Exisulind Therapy Before Radical Prostatectomy: Effect on Apoptosis. Urology, 2012, 80, 484.e17-484.e22.	0.5	8
806	Association of Healthcare Barriers With Prostate-specific Antigen Screening Among African-American and Afro-Caribbean Men. Urology, 2012, 80, 556-563.	0.5	14
807	Effect of Prostate-specific Antigen Screening on Metastatic Disease Burden 10 Years After Diagnosis. Urology, 2012, 80, 367-373.	0.5	8
808	Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 155-160.	0.8	38
809	Prostate-specific antigen (PSA) should drive doing prostate biopsies. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 1-2.	0.8	4
810	Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Clinical Oncology, 2012, 30, 3020-3025.	0.8	128
811	Genome Abnormalities Precede Prostate Cancer and Predict Clinical Relapse. American Journal of Pathology, 2012, 180, 2240-2248.	1.9	33
812	Biopsy Follow-Up of Prostate-Specific Antigen Tests. American Journal of Preventive Medicine, 2012, 42, 37-43.	1.6	20

#	ARTICLE	IF	CITATIONS
814	Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. <i>Journal of Proteomics</i> , 2012, 75, 4747-4757.	1.2	43
815	A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. <i>Cancer Epidemiology</i> , 2012, 36, e128-e136.	0.8	45
816	Insensitivity to the growth inhibitory effects of activin A: An acquired capability in prostate cancer progression. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 119-125.	3.2	15
817	Glycosylation of prostate specific antigen and its potential diagnostic applications. <i>Clinica Chimica Acta</i> , 2012, 413, 1500-1505.	0.5	79
818	MRI of the prostate: Interobserver agreement compared with histopathologic outcome after radical prostatectomy. <i>European Journal of Radiology</i> , 2012, 81, 456-460.	1.2	98
819	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. <i>Science Translational Medicine</i> , 2012, 4, 127rv3.	5.8	378
820	Gene expression anti-profiles as a basis for accurate universal cancer signatures. <i>BMC Bioinformatics</i> , 2012, 13, 272.	1.2	41
821	Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. <i>BMC Family Practice</i> , 2012, 13, 100.	2.9	14
822	A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006. <i>BMC Cancer</i> , 2012, 12, 222.	1.1	6
823	A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. <i>BMC Urology</i> , 2012, 12, 16.	0.6	43
824	Is a prostate cancer screening anxiety measure invariant across two different samples of age-appropriate men?. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 52.	1.5	4
825	Design of a prostate cancer patient navigation intervention for a Veterans Affairs hospital. <i>BMC Health Services Research</i> , 2012, 12, 340.	0.9	14
826	Landmarks in prostate cancer screening. <i>BJU International</i> , 2012, 110, 3-7.	1.3	30
827	Zinc α 2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. <i>BJU International</i> , 2012, 110, E688-E693.	1.3	30
828	Informed prostate cancer risk-adjusted testing: a new paradigm. <i>BJU International</i> , 2012, 110, 30-34.	1.3	6
829	Prostate Cancer: Multiparametric MRI for Index Lesion Localization—A Multiple-Reader Study. <i>American Journal of Roentgenology</i> , 2012, 199, 830-837.	1.0	73
830	Quality of Life and Guidelines for PSA Screening. <i>New England Journal of Medicine</i> , 2012, 367, 669-671.	13.9	39
831	Role of Transrectal Ultrasonography in Prostate Cancer. <i>Radiologic Clinics of North America</i> , 2012, 50, 1061-1073.	0.9	21

#	ARTICLE	IF	CITATIONS
833	Mortality due to prostate cancer in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Results after a 15-year follow-up. <i>Actas Urológicas Españolas (English)</i> 2012, 56, 107-111.	0.0	10
834	PSA Testing and Its Relationship with Social Deprivation. <i>British Journal of Medical and Surgical Urology</i> , 2012, 5, 74-77.	0.2	5
835	Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <i>Cancer Epidemiology</i> , 2012, 36, e401-e406.	0.8	15
836	Beyond Prostate-specific Antigen: Future Biomarkers for the Early Detection and Management of Prostate Cancer. <i>Clinical Oncology</i> , 2012, 24, 545-555.	0.6	11
837	Remaining life expectancy measurement and PSA screening of older men. <i>Journal of Geriatric Oncology</i> , 2012, 3, 196-204.	0.5	14
838	Effectiveness of the Combined Evaluation of <i>KLK3</i> Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis. <i>Journal of Urology</i> , 2012, 188, 1124-1130.	0.2	9
839	Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346). <i>Journal of Urology</i> , 2012, 188, 1164-1169.	0.2	86
840	Expectant Management of Localized Prostate Cancer: Who, What, When, Where and How?. <i>Journal of Urology</i> , 2012, 188, 696-697.	0.2	0
841	A spline-based non-linear diffeomorphism for multimodal prostate registration. <i>Medical Image Analysis</i> , 2012, 16, 1259-1279.	7.0	37
842	Cancer/testis antigens and urological malignancies. <i>Nature Reviews Urology</i> , 2012, 9, 386-396.	1.9	45
843	Atypical Metastases From Prostate Cancer: 10-Year Experience at a Single Institution. <i>American Journal of Roentgenology</i> , 2012, 199, 367-372.	1.0	107
844	Scanometric MicroRNA Array Profiling of Prostate Cancer Markers Using Spherical Nucleic Acid-Gold Nanoparticle Conjugates. <i>Analytical Chemistry</i> , 2012, 84, 4153-4160.	3.2	147
845	Potential Usefulness of Single Nucleotide Polymorphisms to Identify Persons at High Cancer Risk: An Evaluation of Seven Common Cancers. <i>Journal of Clinical Oncology</i> , 2012, 30, 2157-2162.	0.8	37
847	Controversies and Opportunities for PSA Screening. , 2012, , 23-28.		0
848	A dimerized urea-based inhibitor of the prostate-specific membrane antigen for ⁶⁸ Ga-PET imaging of prostate cancer. <i>EJNMMI Research</i> , 2012, 2, 23.	1.1	134
849	Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 130.	1.5	38
850	Blood-Based Biomarkers of Aggressive Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e45802.	1.1	36
851	Proton Beam Therapy and Treatment for Localized Prostate Cancer: If You Build It, They Will Come. <i>Archives of Internal Medicine</i> , 2012, 172, 280.	4.3	4

#	ARTICLE	IF	CITATIONS
852	Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level 10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?. Journal of Oncology, 2012, 2012, 1-6.	0.6	8
854	Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2012, 13, 45-57.	0.9	8
855	Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Canadian Urological Association Journal, 2012, 6, .	0.3	0
856	Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Medical Journal of Australia, 2012, 196, 395-398.	0.8	20
857	How Does Health Insurance Impact Health? The Case of Medicare and Cancer Detection. SSRN Electronic Journal, 2012, , .	0.4	0
858	Screening for prostate cancer: Can randomized studies optimize the trade-off between over - and under-diagnosis?. Journal of Solid Tumors, 2012, 2, .	0.1	0
859	Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level. Yonsei Medical Journal, 2012, 53, 1136.	0.9	9
860	PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 489-495.	0.7	19
861	PSA testing in general practice. Journal of Primary Health Care, 2012, 4, 199.	0.2	11
862	Cancer Screening and Prevention in the Older Patient. , 2012, , 19-28.		0
863	The Prostate Cancer Screening Controversy: Addressing Bioethical Concerns at a Community Health Promotion Event for Men. Journal of Health Care for the Poor and Underserved, 2012, 23, 11-14.	0.4	4
864	Review of guidelines on diagnosis and treatment of testosterone deficiency. , 2012, , 408-420.		7
865	Correlation between age and Chromogranin A determination in prostate diseases. Cancer Biomarkers, 2012, 10, 117-123.	0.8	3
866	Potential predictive factors of positive prostate biopsy in the Chinese population. African Journal of Biotechnology, 2012, 11, 1226-1230.	0.3	0
867	Cancer in the Azores: initial results from a recently established population-based cancer registry. Revista Brasileira De Epidemiologia, 2012, 15, 285-297.	0.3	0
868	â€œs Prostate Cancer Screening Worthy in Southern European Male Populations? A Case Study in Eleusina, Greece: Prostate Cancer Screening in Eleusina. Urologia, 2012, 79, 1-6.	0.3	3
869	Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. Tumori, 2012, 98, 722-727.	0.6	4
870	The Association between pre-operative PSA and prostate cancer-specific mortality in patients with long-term follow-up after radical prostatectomy. Prostate, 2012, 72, 24-29.	1.2	5

#	ARTICLE	IF	CITATIONS
871	Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. <i>Prostate</i> , 2012, 72, 173-180.	1.2	17
872	Functionalized radioactive gold nanoparticles in tumor therapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2012, 4, 42-51.	3.3	51
873	Role of screening in urological malignancies. <i>Trends in Urology & Men's Health</i> , 2012, 3, 27-32.	0.2	1
874	Perceptions of prostate cancer in Black African and Black Caribbean men: a systematic review of the literature. <i>Psycho-Oncology</i> , 2012, 21, 457-468.	1.0	58
875	The Epigenetic promise for prostate cancer diagnosis. <i>Prostate</i> , 2012, 72, 1248-1261.	1.2	126
876	Competing risks and the clinical community: irrelevance or ignorance?. <i>Statistics in Medicine</i> , 2012, 31, 1089-1097.	0.8	229
877	The Dynamics of Death in Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 137, 957-962.	0.4	10
878	Protective effects of <i>Echinops echinatus</i> on testosterone-induced prostatic hyperplasia in rats. <i>European Journal of Integrative Medicine</i> , 2012, 4, e177-e185.	0.8	18
879	⁶⁸ Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. <i>Bioconjugate Chemistry</i> , 2012, 23, 688-697.	1.8	709
880	When to randomize, or "Evidence" based medicine needs "Evidence" based evidence™. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 6-12.	0.9	16
881	Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. <i>International Journal of Cancer</i> , 2012, 131, 1367-1375.	2.3	17
882	Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. <i>British Journal of Surgery</i> , 2012, 99, 693-698.	0.1	32
883	Selective detection of histologically aggressive prostate cancer. <i>Cancer</i> , 2012, 118, 2651-2658.	2.0	20
884	Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. <i>Cancer</i> , 2012, 118, 3145-3152.	2.0	16
885	Statin use and fatal prostate cancer. <i>Cancer</i> , 2012, 118, 4046-4052.	2.0	54
886	Explaining racial differences in prostate cancer mortality. <i>Cancer</i> , 2012, 118, 4280-4289.	2.0	91
887	Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation. <i>Cancer</i> , 2012, 118, 5768-5776.	2.0	45
888	Does skin cancer screening save lives?. <i>Cancer</i> , 2012, 118, 5395-5402.	2.0	232

#	ARTICLE	IF	CITATIONS
889	The prostate cancer conundrum revisited. <i>Cancer</i> , 2012, 118, 5955-5963.	2.0	125
890	Epigenetic markers of prostate cancer in plasma circulating DNA. <i>Human Molecular Genetics</i> , 2012, 21, 3619-3631.	1.4	50
891	Screening for Prostate Cancer: Early Detection or Overdetection?. <i>Annual Review of Medicine</i> , 2012, 63, 161-170.	5.0	43
892	Developing Partnerships and Recruiting Dyads for a Prostate Cancer Informed Decision Making Program: Lessons Learned From a Community-Academic-Clinical Team. <i>Journal of Cancer Education</i> , 2012, 27, 243-249.	0.6	37
894	The impact of PLCO control arm contamination on perceived PSA screening efficacy. <i>Cancer Causes and Control</i> , 2012, 23, 827-835.	0.8	61
895	Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands. <i>Familial Cancer</i> , 2012, 11, 195-200.	0.9	6
896	Cancer in the older person. <i>Psycho-oncologie</i> , 2012, 6, 7-13.	0.0	0
897	SEOM clinical guidelines for treatment of prostate cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 520-527.	1.2	5
899	Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. <i>World Journal of Urology</i> , 2012, 30, 137-142.	1.2	7
900	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012, 30, 149-155.	1.2	101
903	A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer. <i>BJU International</i> , 2012, 109, 207-213.	1.3	5
904	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. <i>BJU International</i> , 2012, 109, 1-7.	1.3	17
905	THE PHANTOM MENACE OF PROSTATE CANCER SCREENING. <i>BJU International</i> , 2012, 109, 324-326.	1.3	0
906	Population screening for prostate cancer: An overview of available studies and meta-analysis. <i>International Journal of Urology</i> , 2012, 19, 100-108.	0.5	29
907	Editorial Comment to Population screening for prostate cancer: An overview of available studies and meta-analysis. <i>International Journal of Urology</i> , 2012, 19, 108-109.	0.5	0
908	Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis. <i>Histopathology</i> , 2012, 60, 1-3.	1.6	4
909	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. <i>Histopathology</i> , 2012, 60, 187-198.	1.6	52
910	Pathological Outcomes of Men Eligible for Active Surveillance After Undergoing Radical Prostatectomy: Are Results Predictable?. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 32-36.	0.9	5

#	ARTICLE	IF	CITATIONS
911	Baseline Prostate-Specific Antigen Testing at a Young Age. <i>European Urology</i> , 2012, 61, 1-7.	0.9	85
912	Prostate-Specific Antigen-Based Risk Assessment in Younger Men. <i>European Urology</i> , 2012, 61, 8-9.	0.9	3
914	The Challenges of Harnessing New Technology. <i>European Urology</i> , 2012, 61, 269-270.	0.9	1
915	Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population. <i>European Urology</i> , 2012, 61, 865-874.	0.9	40
916	The Impact of Interscreening Interval and Age on Prostate Cancer Screening With Prostate-Specific Antigen. <i>European Urology</i> , 2012, 61, 1011-1018.	0.9	17
917	Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. <i>European Urology</i> , 2012, 61, 851-854.	0.9	11
918	International Variation in Prostate Cancer Incidence and Mortality Rates. <i>European Urology</i> , 2012, 61, 1079-1092.	0.9	1,252
919	A specific molecular beacon probe for the detection of human prostate cancer cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3632-3638.	1.0	6
920	Comparison of health-related quality of life between subjects treated with radical prostatectomy and brachytherapy. <i>Journal of Clinical Nursing</i> , 2012, 21, 1906-1912.	1.4	8
921	Genetic variants associated with predisposition to prostate cancer and potential clinical implications. <i>Journal of Internal Medicine</i> , 2012, 271, 353-365.	2.7	80
922	An Editorial Response to the USPTF. <i>Journal of Men's Health</i> , 2012, 9, 5-8.	0.1	2
923	Disciplined doctors: The electronic medical record and physicians' changing relationship to medical knowledge. <i>Social Science and Medicine</i> , 2012, 74, 1021-1028.	1.8	48
924	Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. <i>Patient Education and Counseling</i> , 2012, 87, 369-374.	1.0	99
925	Resisting the screening imperative: patienthood, populations and politics in prostate cancer detection technologies for the UK. <i>Sociology of Health and Illness</i> , 2012, 34, 221-233.	1.1	14
926	The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program. <i>BJU International</i> , 2012, 109, 1304-1308.	1.3	12
927	Cost-effectiveness of Prostate Health Index for prostate cancer detection. <i>BJU International</i> , 2012, 110, 353-362.	1.3	41
928	Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. <i>BJU International</i> , 2012, 110, E50-6.	1.3	38
929	Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. <i>BJU International</i> , 2012, 109, 508-513.	1.3	39

#	ARTICLE	IF	CITATIONS
930	Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. <i>BJU International</i> , 2012, 110, 1485-1490.	1.3	25
931	Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia. <i>BJU International</i> , 2012, 109, 52-56.	1.3	7
932	Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of ≤ 2.5 ng/mL and the risk of death. <i>BJU International</i> , 2012, 110, 1636-1641.	1.3	10
933	Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. <i>Cancer</i> , 2012, 118, 973-980.	2.0	25
934	The rapid uptake of robotic prostatectomy and its collateral effects. <i>Cancer</i> , 2012, 118, 4-7.	2.0	9
935	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. <i>International Journal of Cancer</i> , 2012, 130, 885-895.	2.3	23
936	Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. <i>International Journal of Public Health</i> , 2012, 57, 57-62.	1.0	39
938	Genetic polymorphism and prostate cancer aggressiveness: A case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. <i>Prostate</i> , 2013, 73, 11-22.	1.2	72
939	A cohort study reporting clinical risk factors and individual risk perceptions of prostate cancer: implications for PSA testing. <i>BJU International</i> , 2013, 111, 389-395.	1.3	5
940	Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer. <i>International Archive of Medicine</i> , 2013, 6, 2.	1.2	1
941	Older Korean American Men's Prostate Cancer Screening Behavior: The Prime Role of Culture. <i>Journal of Immigrant and Minority Health</i> , 2013, 15, 1030-1037.	0.8	7
942	Early Detection of Prostate Cancer: European Association of Urology Recommendation. <i>European Urology</i> , 2013, 64, 347-354.	0.9	133
944	Prostate Cancer Diagnosis. , 2013, , .		3
945	Molecular Risk Profiling. , 2013, , 207-213.		0
946	Racial Disparities and the Global Picture. , 2013, , 301-310.		0
947	Natural History of Prostate Cancer. , 2013, , 311-316.		0
948	Screening for Prostate Cancer. , 2013, , 333-346.		2
949	Next Generation Screening Tests. , 2013, , 347-354.		0

#	ARTICLE	IF	CITATIONS
950	Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. <i>BJU International</i> , 2013, 111, 1245-1252.	1.3	22
952	Does Robotic Prostatectomy Meet Its Promise in the Management of Prostate Cancer?. <i>Current Urology Reports</i> , 2013, 14, 184-191.	1.0	11
953	Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 367-377.	1.4	47
954	Early Detection of Prostate Cancer: AUA Guideline. <i>Journal of Urology</i> , 2013, 190, 419-426.	0.2	945
955	Classifying the Reasons Men Consider to be Important in Prostate-Specific Antigen (PSA) Testing Decisions: Evaluating Risks, Lay Beliefs, and Informed Decisions. <i>Annals of Behavioral Medicine</i> , 2013, 46, 322-335.	1.7	3
956	What are we learning from the life satisfaction literature?. <i>International Review of Economics</i> , 2013, 60, 113-155.	0.7	28
957	Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. <i>Cancer Causes and Control</i> , 2013, 24, 1465-1480.	0.8	1
958	Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer. <i>Annals of Internal Medicine</i> , 2013, 158, 853.	2.0	108
959	Decision Making in Prostate Cancer Screening Using Decision Aids vs Usual Care. <i>JAMA Internal Medicine</i> , 2013, 173, 1704-12.	2.6	61
960	Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 744-748.	0.8	33
961	Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 60-71.	3.3	21
962	Pelvic applications of MR-guided high intensity focused ultrasound. <i>Abdominal Imaging</i> , 2013, 38, 1120-1129.	2.0	14
963	Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. <i>International Urology and Nephrology</i> , 2013, 45, 727-733.	0.6	13
964	Managing localized prostate cancer in the era of prostate-specific antigen screening. <i>Cancer</i> , 2013, 119, 3906-3909.	2.0	16
965	On-capillary fluorescent labeling and capillary electrophoresis laser-induced fluorescence analysis of glycoforms of intact prostate-specific antigen. <i>Electrophoresis</i> , 2013, 34, 2295-2302.	1.3	7
966	Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation. <i>Cancer</i> , 2013, 119, 1113-1114.	2.0	10
967	Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation. <i>Cancer</i> , 2013, 119, 1113-1113.	2.0	1
968	Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral <scp>PDE5</scp> inhibitor Tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. <i>BJU International</i> , 2013, 112, E169-76.	1.3	32

#	ARTICLE	IF	CITATIONS
969	Detection of prostate specific antigen in serum at the femto-gram per milliliter level using the intrinsic amplification of a field-effect enzymatic immuno-sensing system. <i>Electrochimica Acta</i> , 2013, 111, 92-98.	2.6	6
970	Men (Aged 40-49 Years) With a Single Baseline Prostate-specific Antigen Below 1.0 ng/mL Have a Very Low Long-term Risk of Prostate Cancer: Results From a Prospectively Screened Population Cohort. <i>Urology</i> , 2013, 82, 1211-1219.	0.5	9
972	American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale. <i>BJU International</i> , 2013, 112, 543-547.	1.3	114
973	Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 136, 233-237.	1.2	27
974	Traumatic Intracranial Hemorrhage, Value in Health Care, and Being Important. <i>Annals of Emergency Medicine</i> , 2013, 61, 518-519.	0.3	0
975	High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study. <i>Cancer Letters</i> , 2013, 331, 154-157.	3.2	8
976	Epigenetics and Cancer. , 2013, , .		5
977	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1748-1757.	0.8	641
978	Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. <i>Annals of Oncology</i> , 2013, 24, 2657-2671.	0.6	270
979	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	1.1	41
980	Prostate Cancer Screening: Biases and the Need for Consensus. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1522-1524.	3.0	11
981	From Papanicolaou to Papillomaviruses: Evolving Challenges in Cervical Cancer Screening in the Era of Human Papillomavirus Vaccination. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1524-1526.	3.0	5
982	Biomarkers in prostate cancer surveillance and screening: past, present, and future. <i>Therapeutic Advances in Urology</i> , 2013, 5, 318-329.	0.9	99
983	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. <i>Clinical Cancer Research</i> , 2013, 19, 2442-2450.	3.2	132
984	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 566-571.	0.8	181
985	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 2949-2959.	1.3	287
986	Defining prostate cancer risk before prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1408-1418.	0.8	21
987	A comparison of US and Australian men's values and preferences for PSA screening. <i>BMC Health Services Research</i> , 2013, 13, 388.	0.9	11

#	ARTICLE	IF	CITATIONS
988	The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and Its Associated Research Resource. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1684-1693.	3.0	62
989	Attitudes and Knowledge of Primary Care Physicians Regarding Prostate Cancer Screening. <i>Journal of Cancer Education</i> , 2013, 28, 679-683.	0.6	7
990	The Evaluation and Treatment of Prostate-Related LUTS in the Primary Care Setting: The Next STEP. <i>Current Urology Reports</i> , 2013, 14, 595-605.	1.0	4
991	Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa. <i>BMC Urology</i> , 2013, 13, 74.	0.6	19
992	Prostate-Specific Antigen and Prostate Cancer Mortality. <i>American Journal of Preventive Medicine</i> , 2013, 45, 318-326.	1.6	17
993	Biomarkers in Oncology. , 2013, , .		1
994	Circulating microRNAs predict biochemical recurrence in prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 641-650.	2.9	117
995	Prostate Cancer Chemoprevention. <i>Seminars in Oncology</i> , 2013, 40, 276-285.	0.8	23
996	Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. <i>Clinical Obesity</i> , 2013, 3, 73-83.	1.1	83
997	PSA screening and deaths from prostate cancer after diagnosis—a population based analysis. <i>Prostate</i> , 2013, 73, 1365-1369.	1.2	14
998	Novel approaches for the identification of biomarkers of aggressive prostate cancer. <i>Genome Medicine</i> , 2013, 5, 56.	3.6	11
1000	Risk stratification in prostate cancer screening. <i>Nature Reviews Urology</i> , 2013, 10, 38-48.	1.9	97
1001	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
1002	The Long Journey of Cancer Biomarkers from the Bench to the Clinic. <i>Clinical Chemistry</i> , 2013, 59, 147-157.	1.5	127
1003	Editorial Comment. <i>Urology</i> , 2013, 82, 340.	0.5	0
1004	Validating a Claims-based Method for Assessing Severe Rectal and Urinary Adverse Effects of Radiotherapy. <i>Urology</i> , 2013, 82, 335-340.	0.5	16
1005	Re: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. <i>European Urology</i> , 2013, 64, 512.	0.9	5
1006	Re: The Challenges Facing Academic Urology Training Programs: An Impending Crisis. <i>European Urology</i> , 2013, 64, 511-512.	0.9	0

#	ARTICLE	IF	CITATIONS
1007	The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1464-1469.	0.8	3
1008	Testosterone Administration in Older Men. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 271-286.	1.2	28
1009	Candidacy for active surveillance may be associated with improved functional outcomes after prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 187-192.	0.8	2
1010	Re: Early Detection of Prostate Cancer: AUA guideline. <i>Journal of Urology</i> , 2013, 190, 1134-1139.	0.2	16
1012	Prostate-Specific Antigen Testing. <i>American Journal of Preventive Medicine</i> , 2013, 45, 182-189.	1.6	36
1013	A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. <i>Mayo Clinic Proceedings</i> , 2013, 88, 790-798.	1.4	300
1014	Prostate Cancer Detection by Using Digital Rectal Examination: Contemporary Practice Patterns in the United States. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 263-269.	0.9	6
1016	PSA: Please Stop Agonizing (Over Prostate-Specific Antigen Interpretation). <i>Mayo Clinic Proceedings</i> , 2013, 88, 1-3.	1.4	5
1017	The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≥ 15 ng/ml and normal digital rectal examination: A 10-year prospective follow-up study of 427 consecutive patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1489-1496.	0.8	1
1018	Oncology Scan of Genitourinary Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 891-893.	0.4	2
1019	Cardiovascular Comorbidity and Mortality in Men With Prostate Cancer Treated With Brachytherapy-Based Radiation With or Without Hormonal Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e209-e215.	0.4	11
1020	To test or not: A registry-based observational study of an online decision support for prostate-specific antigen tests. <i>International Journal of Medical Informatics</i> , 2013, 82, 973-979.	1.6	7
1021	Effect of Physical Activity and Sedentary Behavior on Serum Prostate-Specific Antigen Concentrations: Results From the National Health and Nutrition Examination Survey (NHANES), 2003-2006. <i>Mayo Clinic Proceedings</i> , 2013, 88, 11-21.	1.4	46
1022	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. <i>European Journal of Cancer</i> , 2013, 49, 3041-3048.	1.3	12
1023	Re: To Biopsy or Not to Biopsy: Minimizing the Risk of Prostate Needle Biopsy. <i>Journal of Urology</i> , 2013, 190, 1139-1140.	0.2	0
1024	Quantifying lead-time bias in risk factor studies of cancer through simulation. <i>Annals of Epidemiology</i> , 2013, 23, 735-741.e1.	0.9	7
1025	Screening for prostate cancer: an updated review. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 101-108.	1.1	11
1026	Cancer screening in the United States, 2013. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 87-105.	157.7	249

#	ARTICLE	IF	CITATIONS
1027	Cell-based selection provides novel molecular probes for cancer stem cells. <i>International Journal of Cancer</i> , 2013, 132, 2578-2588.	2.3	49
1028	Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation. <i>Health Affairs</i> , 2013, 32, 596-602.	2.5	34
1029	Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers. <i>Medical Principles and Practice</i> , 2013, 22, 4-11.	1.1	203
1030	Advances in the Multimodality Management of High-risk Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 375-394.	0.6	1
1031	The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 2573-2581.	2.9	90
1032	Response to the U.S. Preventative Services Task Force Decision on Prostate Cancer Screening. <i>Current Urology Reports</i> , 2013, 14, 168-173.	1.0	1
1033	Prostate Specific Antigen:The Past, Present and Future. <i>Current Urology</i> , 2013, 6, 175-178.	0.4	2
1034	Pharmacogenomics in Cancer Therapeutics. , 2013, , 89-116.		0
1035	microRNA biomarkers in body fluids of prostate cancer patients. <i>Methods</i> , 2013, 59, 132-137.	1.9	51
1036	Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. <i>World Journal of Urology</i> , 2013, 31, 1273-1278.	1.2	4
1037	Screening for prostate cancer. <i>The Cochrane Library</i> , 2013, 2013, CD004720.	1.5	452
1038	5-Alpha Reductase Inhibitors in Patients on Active Surveillance: Do the Benefits Outweigh the Risk?. <i>Current Urology Reports</i> , 2013, 14, 223-226.	1.0	0
1040	Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. <i>Cancer</i> , 2013, 119, 2223-2229.	2.0	49
1041	Prostate cancer screening in black men—new questions, few answers. <i>Cancer</i> , 2013, 119, 2206-2208.	2.0	2
1042	HIV and Prostate Cancer. , 2013, , 123-134.		0
1043	Molecular Imaging in Diagnostics. , 2013, , 193-205.		0
1044	Prostate Specific Antigen Best Practice Statement: 2009 Update. <i>Journal of Urology</i> , 2013, 189, S2-S11.	0.2	74
1045	Primer of Geriatric Urology. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
1046	Ubiquitin-Proteasome Pathway and Prostate Cancer. <i>Onkologie</i> , 2013, 36, 592-596.	1.1	15
1047	Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. <i>Cancer</i> , 2013, 119, 593-601.	2.0	20
1048	Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 45-57.	0.9	19
1049	Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. <i>Prostate International</i> , 2013, 1, 65-68.	1.2	15
1050	The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend?. <i>Future Oncology</i> , 2013, 9, 917-919.	1.1	53
1051	Prostate Cancer and the Increasing Role of Active Surveillance. <i>Postgraduate Medicine</i> , 2013, 125, 109-116.	0.9	7
1052	Defining the threshold for significant versus insignificant prostate cancer. <i>Nature Reviews Urology</i> , 2013, 10, 473-482.	1.9	98
1053	Evaluation of New Technologies for Cancer Control Based on Population Trends in Disease Incidence and Mortality. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 117-123.	0.9	5
1054	The Impact of PSA Screening on Prostate Cancer Mortality and Overdiagnosis of Prostate Cancer in the United States. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 56-61.	1.7	40
1055	Optimal use of prostate specific antigen for prostate cancer screening. <i>Vojnosanitetski Pregled</i> , 2013, 70, 501-503.	0.1	1
1056	Lung Cancer Screening. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 727-737.	0.8	2
1057	Barriers to Prostate Cancer Care. <i>Qualitative Health Research</i> , 2013, 23, 375-384.	1.0	10
1058	Deriving benefit of early detection from biomarker-based prognostic models. <i>Biostatistics</i> , 2013, 14, 15-27.	0.9	4
1059	Prostate Cancer Screening and Health Care System Distrust in Philadelphia. <i>Journal of Aging and Health</i> , 2013, 25, 737-757.	0.9	10
1060	A Community-Driven Intervention for Prostate Cancer Screening in African Americans. <i>Health Education and Behavior</i> , 2013, 40, 11-18.	1.3	13
1061	Quantification of harms in cancer screening trials: literature review. <i>BMJ, The</i> , 2013, 347, f5334-f5334.	3.0	101
1062	PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. <i>Acta Oncologica</i> , 2013, 52, 1609-1614.	0.8	23
1063	Psychological Impact of Prostate Biopsy: Physical Symptoms, Anxiety, and Depression. <i>Journal of Clinical Oncology</i> , 2013, 31, 4235-4241.	0.8	81

#	ARTICLE	IF	CITATIONS
1064	MicroRNAs in prostate cancer. <i>Prostate International</i> , 2013, 1, 3-9.	1.2	57
1065	There are calls for a national screening programme for prostate cancer: what is the evidence to justify such a national screening programme?. <i>Scottish Medical Journal</i> , 2013, 58, 64-68.	0.7	0
1066	Prostate-Specific Antigen Testing in Men Aged 40-64 Years: Impact of Publication of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2013, 105, 743-745.	3.0	13
1067	Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. <i>BMJ, The</i> , 2013, 347, f4706-f4706.	3.0	253
1068	Predicting high-risk disease using tissue biomarkers. <i>Current Opinion in Urology</i> , 2013, 23, 245-251.	0.9	18
1069	Clinical Applications of Recent Molecular Advances in Urologic Malignancies. <i>Advances in Anatomic Pathology</i> , 2013, 20, 175-203.	2.4	26
1070	Hospital workers's perceptions of waste: a qualitative study involving photo-elicitation. <i>BMJ Quality and Safety</i> , 2013, 22, 826-835.	1.8	17
1071	Prostate specific antigen testing: age-related interpretation in early prostate cancer detection. <i>Pathology</i> , 2013, 45, 343-345.	0.3	3
1072	The epidemiology of high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 331-336.	0.9	48
1073	Prostate cancer overdiagnosis and overtreatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 204-209.	1.2	105
1074	Prostate-specific antigen screening can be beneficial to younger and at-risk men. <i>Cmaj</i> , 2013, 185, 47-51.	0.9	5
1075	Pairing Physician Education With Patient Activation to Improve Shared Decisions in Prostate Cancer Screening: A Cluster Randomized Controlled Trial. <i>Annals of Family Medicine</i> , 2013, 11, 324-334.	0.9	33
1076	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. <i>Advances in Anatomic Pathology</i> , 2013, 20, 39-44.	2.4	24
1077	Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3450-3461.	3.2	22
1078	Recent Updates on Epigenetic Biomarkers for Prostate Cancer. , 2013, , 129-150.		2
1079	Controlling the local false discovery rate in the adaptive Lasso. <i>Biostatistics</i> , 2013, 14, 653-666.	0.9	12
1080	The Influence of Family Ties on Men's Prostate Cancer Screening, Biopsy, and Treatment Decisions. <i>American Journal of Men's Health</i> , 2013, 7, 461-471.	0.7	18
1081	Shared Decision Making in Prostate-Specific Antigen Testing. <i>Journal of Primary Care and Community Health</i> , 2013, 4, 67-74.	1.0	17

#	ARTICLE	IF	CITATIONS
1082	Physician Communication Regarding Prostate Cancer Screening: Analysis of Unannounced Standardized Patient Visits. <i>Annals of Family Medicine</i> , 2013, 11, 315-323.	0.9	40
1083	Prostate Cancer Screening and Incidence: A Question of Causality. <i>JAMA Internal Medicine</i> , 2013, 173, 392.	2.6	0
1084	American Society of Clinical Oncology 2013 Top Five List in Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 4362-4370.	0.8	126
1085	Shared Decision Making in Prostate-Specific Antigen Testing With Men Older Than 70 Years. <i>Journal of the American Board of Family Medicine</i> , 2013, 26, 401-408.	0.8	13
1086	Bridging the Gap between Biologic, Individual, and Macroenvironmental Factors in Cancer: A Multilevel Approach. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 485-495.	1.1	89
1087	Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. <i>Prostate Cancer</i> , 2013, 2013, 1-10.	0.4	48
1088	What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?. <i>International Journal of Molecular Imaging</i> , 2013, 2013, 1-6.	1.3	14
1089	Attachment and Health Care Utilization Among Middle-Aged and Older African-Descent Men. <i>American Journal of Men's Health</i> , 2013, 7, 382-393.	0.7	6
1090	^{99m} Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1369-1376.	2.8	193
1091	Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer: A Survey Comprising 174 GPs. <i>International Journal of Family Medicine</i> , 2013, 2013, 1-6.	1.2	12
1092	PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness. <i>Prostate</i> , 2013, 73, 1731-1737.	1.2	17
1093	Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. <i>Obesity</i> , 2013, 21, 1975-1981.	1.5	139
1094	A tale of four prostates. <i>Trends in Urology & Men's Health</i> , 2013, 4, 29-31.	0.2	2
1095	Using age-referenced prostate-specific antigen percentile to predict survival outcomes in screened Taiwanese men. <i>International Journal of Cancer</i> , 2013, 132, 1927-1932.	2.3	6
1096	Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml. <i>International Journal of Clinical Practice</i> , 2013, 67, 552-557.	0.8	1
1097	Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS 2: ETS fusion gene markers. <i>Cancer Medicine</i> , 2013, 2, 63-75.	1.3	7
1098	The perils of overdiagnosis. <i>Trends in Urology & Men's Health</i> , 2013, 4, 19-23.	0.2	1
1099	Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. <i>Prostate</i> , 2013, 73, 1824-1835.	1.2	29

#	ARTICLE	IF	CITATIONS
1100	Agent Orange as a risk factor for high-grade prostate cancer. <i>Cancer</i> , 2013, 119, 2399-2404.	2.0	38
1101	Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. <i>British Journal of Cancer</i> , 2013, 108, 149-154.	2.9	35
1102	Men's preferences for prostate cancer screening: a discrete choice experiment. <i>British Journal of Cancer</i> , 2013, 108, 533-541.	2.9	54
1103	Controversies on individualized prostate cancer care: gaps in current practice. <i>Therapeutic Advances in Urology</i> , 2013, 5, 233-244.	0.9	6
1104	Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. <i>Family Practice</i> , 2013, 30, 648-654.	0.8	15
1105	Primary Care Physicians' Use of an Informed Decision-Making Process for Prostate Cancer Screening. <i>Annals of Family Medicine</i> , 2013, 11, 67-74.	0.9	47
1106	Robotic and standard open radical prostatectomy: oncological and quality-of-life outcomes. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 293-299.	0.6	13
1108	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1050-1058.	3.0	208
1109	Comparative Effectiveness of Collaborative Chronic Care Models for Mental Health Conditions Across Primary, Specialty, and Behavioral Health Care Settings: Systematic Review and Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2013, 11, 552-567.	0.4	0
1110	Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. <i>Annals of Internal Medicine</i> , 2013, 158, 761.	2.0	234
1111	Probability, Uncertainty, and Prostate Cancer. <i>Annals of Internal Medicine</i> , 2013, 158, 211.	2.0	5
1112	Screening for prostate cancer in the elderly. <i>Aging Health</i> , 2013, 9, 359-360.	0.3	0
1113	Limitations of Basing Screening Policies on Screening Trials. <i>Medical Care</i> , 2013, 51, 295-300.	1.1	63
1114	Modeling prostate cancer response to continuous versus intermittent androgen ablation therapy. <i>Discrete and Continuous Dynamical Systems - Series B</i> , 2013, 18, 945-967.	0.5	20
1115	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. <i>Scientific Reports</i> , 2013, 3, 2059.	1.6	26
1116	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	2.0	144
1117	Cancer Screening Guidelines and Mortality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1118	The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. <i>Cancers</i> , 2013, 5, 998-1019.	1.7	33

#	ARTICLE	IF	CITATIONS
1119	Association between Literacy, Compliance with Prostate Cancer Screening, and Cancer Aggressiveness: Results from a Brazilian Screening Study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 328-334.	0.7	11
1120	Prostate cancer screening: Attitudes and practices of family. <i>Canadian Urological Association Journal</i> , 2013, 6, 188-93.	0.3	1
1121	Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review. <i>Annals of Laboratory Medicine</i> , 2013, 33, 233-241.	1.2	21
1122	Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	0.3	0
1123	Does screening for prostate cancer reduce prostate cancer mortality?. <i>Canadian Urological Association Journal</i> , 2013, 3, 187.	0.3	2
1124	Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer. <i>Korean Journal of Urology</i> , 2013, 54, 417.	1.2	2
1125	Radical Transurethral Resection for Prostate Cancer Might Affect the Disputes about Prostate-Specific Antigen Screening: Suggestions Obtained from Radical Transurethral Surgery. <i>Cancer and Clinical Oncology</i> , 2013, 2, .	0.2	0
1126	Reflexive ordering of percent free PSA in patients: Do we need to ask the question?. <i>Canadian Urological Association Journal</i> , 2013, 4, 321.	0.3	1
1127	Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. <i>Thrombosis and Haemostasis</i> , 2013, 110, 484-492.	1.8	43
1128	Variations in prostate biopsy practice: A quantitative questionnaire-based study. <i>Canadian Urological Association Journal</i> , 2013, 7, 732.	0.3	3
1129	The burden of prostate cancer in Canada. <i>Canadian Urological Association Journal</i> , 2013, 3, 102.	0.3	19
1130	African American Men's and Women's Perceptions of Clinical Trials Research: Focusing on Prostate Cancer among a High-Risk Population in the South. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 1784-1800.	0.4	44
1131	Should we screen for prostate cancer? A re-examination of the evidence. <i>Medical Journal of Australia</i> , 2013, 198, 525-527.	0.8	14
1132	Prostate Cancer: Current Treatment and Prevention Strategies. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, 279-284.	0.5	68
1133	Prostate Cancer Disparities throughout the Cancer Control Continuum. <i>Social Sciences</i> , 2013, 2, 247-269.	0.7	5
1134	Future Prospects in the Diagnosis and Management of Localized Prostate Cancer. <i>Scientific World Journal</i> , The, 2013, 2013, 1-9.	0.8	6
1135	Prostate cancer screening. <i>Medical Journal of Australia</i> , 2013, 199, 585-585.	0.8	0
1136	Overall- and Disease-Specific Survival in Prostate Cancer: Too Long to Wait?. <i>Medical Radiology</i> , 2013, , 65-73.	0.0	1

#	ARTICLE	IF	CITATIONS
1137	Counterpoint. Medical Care, 2013, 51, 301-303.	1.1	16
1138	The top 100 cited articles in urology: An update. Canadian Urological Association Journal, 2013, 7, 16.	0.3	46
1139	Screening for Prostate Cancer: Shaping the Debate on Benefits and Harms. , 2013, , ED000067.		15
1140	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2013, 5, 235.	0.3	0
1141	The confusion surrounding prostate cancer screening faced by family. Canadian Urological Association Journal, 2013, 6, 194-5.	0.3	0
1142	A Glance at the Complexity of Nutrition and the Prostate: Considering Molecular Targets to Unravel the Most Recent Controversy Between Omega-3 Fatty Acids and Their Impact on Prostate Cancer Risk. , 0, , .		0
1143	Does the reflexive measurement of free PSA have a role in a tertiary cancer centre?. Canadian Urological Association Journal, 2013, 4, 317.	0.3	0
1144	Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies. Canadian Urological Association Journal, 2013, 4, 12.	0.3	15
1145	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget, 2014, 5, 11091-11102.	0.8	160
1146	DNA Aptamer Evolved by Cell-SELEX for Recognition of Prostate Cancer. PLoS ONE, 2014, 9, e100243.	1.1	52
1147	The C-Terminal Fragment of Prostate-Specific Antigen, a 2331 Da Peptide, as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer. PLoS ONE, 2014, 9, e107234.	1.1	12
1148	A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. Journal of Biomarkers, 2014, 2014, 1-12.	1.0	10
1149	Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL. Journal of Korean Medical Science, 2014, 29, 338.	1.1	15
1150	Biomarkers and mechanisms associated with recurrent prostate cancer. Frontiers in Bioscience - Landmark, 2014, 19, 339.	3.0	3
1152	Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up program. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 745-752.	0.7	2
1153	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget, 2014, 5, 824-840.	0.8	52
1155	Affecting African American Men's Prostate Cancer Screening Decision-making through a Mobile Tablet-Mediated Intervention. Journal of Health Care for the Poor and Underserved, 2014, 25, 1262-1277.	0.4	16
1156	Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African American men. BJU International, 2014, 114, E50-E55.	1.3	6

#	ARTICLE	IF	CITATIONS
1157	Androgen Receptor Polymorphism-Dependent Variation in Prostate-Specific Antigen Concentrations of European Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2048-2056.	1.1	8
1158	RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. <i>BMC Cancer</i> , 2014, 14, 808.	1.1	35
1160	Serum prostate-specific antigen levels and type of work in tire manufacturing workers. <i>Annals of Occupational and Environmental Medicine</i> , 2014, 26, 50.	0.3	2
1161	Progress and controversies: Radiation therapy for prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 389-407.	157.7	44
1162	Key papers in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1379-1384.	1.1	9
1163	The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2014, 111, 1238-1240.	2.9	60
1165	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	2.0	0
1166	Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening For Prostate Cancer (ERSPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 187-191.	2.0	19
1167	How should prostate specific antigen be interpreted?. <i>Turk Uroloji Dergisi</i> , 2014, 39, 188-193.	0.4	13
1168	Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Recent Results in Cancer Research</i> , 2014, 202, 53-57.	1.8	11
1169	DWI of Prostate Cancer: Optimal $\text{b} < \text{Value} >$ in Clinical Practice. <i>Prostate Cancer</i> , 2014, 2014, 1-9.	0.4	26
1170	Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-16.	0.9	0
1171	Further Evidence That Prostate-Specific Antigen Screening Reduces Prostate Cancer Mortality. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju026-dju026.	3.0	7
1172	Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. <i>Prostate Cancer</i> , 2014, 2014, 1-6.	0.4	13
1173	Noncoding RNAs as Novel Biomarkers in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	83
1174	Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	90
1175	Role of miRNA <i>Let-7</i> and Its Major Targets in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	45
1176	Predictive values for extracapsular extension in prostate cancer patients with PSA values below 10 ng/mL. <i>Turk Uroloji Dergisi</i> , 2014, 40, 130-133.	0.4	2

#	ARTICLE	IF	CITATIONS
1177	Kallikreins as Biomarkers for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	43
1178	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1387-1405.	1.2	117
1179	Impact of Race in Using PSA Velocity to Predict for Prostate Cancer. <i>Military Medicine</i> , 2014, 179, 329-332.	0.4	3
1180	Screening for Prostate Cancer: Are Digital Rectal Examinations Being Performed?. <i>Hospital Practice (1995)</i> , 2014, 42, 103-107.	0.5	5
1181	It is time to start active treatment in senior adults with prostate cancer. <i>Future Oncology</i> , 2014, 10, 5-8.	1.1	2
1182	Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. <i>CMAJ Open</i> , 2014, 2, E60-E68.	1.1	19
1184	Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1349-1358.	1.1	8
1185	Benefits and Risks of Prostate Cancer Screening. <i>Oncology Research and Treatment</i> , 2014, 37, 29-37.	0.8	12
1186	Pre-Screening Age African-American Males: What Do They Know About Prostate Cancer Screening, Knowledge, and Risk Perceptions?. <i>Social Work in Health Care</i> , 2014, 53, 268-288.	0.8	14
1187	Mortality and complications after prostate biopsy in the <sc>P</sc>rostate, <sc>L</sc>ung, <sc>C</sc>olorectal and <sc>O</sc>varian <sc>C</sc>ancer <sc>S</sc>creening (<sc>PLCO</sc>) trial. <i>BJU International</i> , 2014, 113, 254-259.	1.3	68
1188	Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju010-dju010.	3.0	25
1189	No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. <i>Cancer</i> , 2014, 120, 818-823.	2.0	112
1190	Long-Term Testosterone Treatment in Elderly Men with Hypogonadism and Erectile Dysfunction Reduces Obesity Parameters and Improves Metabolic Syndrome and Health-Related Quality of Life. <i>Journal of Sexual Medicine</i> , 2014, 11, 1567-1576.	0.3	131
1191	National trends in prostate cancer screening among older American men with limited 9-year life expectancies: Evidence of an increased need for shared decision making. <i>Cancer</i> , 2014, 120, 1491-1498.	2.0	64
1192	Meta-analyses of methylation markers for prostate cancer. <i>Tumor Biology</i> , 2014, 35, 10449-10455.	0.8	18
1193	A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. <i>BJU International</i> , 2014, 113, E106-11.	1.3	14
1194	American Geriatrics Society Identifies Another Five Things That Healthcare Providers and Patients Should Question. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 950-960.	1.3	78
1195	Low-grade prostate cancer diverges early from high grade and metastatic disease. <i>Cancer Science</i> , 2014, 105, 1079-1085.	1.7	46

#	ARTICLE	IF	CITATIONS
1196	Prostate-specific antigen screening: A critical review of current research and guidelines. Journal of the American Association of Nurse Practitioners, 2014, 26, 574-581.	0.5	8
1197	Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. International Journal of Clinical Practice, 2014, 68, 314-329.	0.8	158
1198	Urologists' personal feelings on PSA screening and prostate cancer treatment. Journal of Evaluation in Clinical Practice, 2014, 20, 408-410.	0.9	3
1200	PSA in Screening for Prostate Cancer. Advances in Clinical Chemistry, 2014, , 1-23.	1.8	26
1201	Screening for Prostate Cancer With the Prostate-Specific Antigen Test. JAMA - Journal of the American Medical Association, 2014, 311, 1143.	3.8	296
1202	NF- κ B Gene Signature Predicts Prostate Cancer Progression. Cancer Research, 2014, 74, 2763-2772.	0.4	99
1203	Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. International Journal of Clinical Oncology, 2014, 19, 793-799.	1.0	5
1204	Radical prostatectomy outcomes during prostate-specific antigen era in Ireland compared to a matched American population. Journal of Clinical Urology, 2014, 7, 170-175.	0.1	0
1205	Safety and Chemopreventive Effect of Polyphenon E in Preventing Early and Metastatic Progression of Prostate Cancer in TRAMP Mice. Cancer Prevention Research, 2014, 7, 435-444.	0.7	23
1206	Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acyl ethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness. Molecular and Cellular Proteomics, 2014, 13, 1753-1768.	2.5	165
1207	Technology and the Digitization of Health Care. AACN Advanced Critical Care, 2014, 25, 15-17.	0.6	2
1208	Genomic analysis in active surveillance. Current Opinion in Urology, 2014, 24, 303-310.	0.9	7
1209	“We Remain Very Much the Second Sex”. American Journal of Men's Health, 2014, 8, 15-25.	0.7	5
1210	Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncology, 2014, 10, 1679-1694.	1.1	11
1211	The More, The Merrier: Including a Medical Oncologist in Treatment Planning for Localized Prostate Cancer. Journal of Oncology Practice, 2014, 10, 113-114.	2.5	2
1212	The clinic-pathological characteristics of prostate cancer in an Irish subpopulation with a serum PSA less than 4.0ng/ml. Journal of Clinical Urology, 2014, 7, 338-343.	0.1	0
1213	Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals, 2014, 7, 779-796.	1.7	323
1214	Reducing Prostate Cancer Racial Disparity: Evidence for Aggressive Early Prostate Cancer PSA Testing of African American Men. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1505-1511.	1.1	54

#	ARTICLE	IF	CITATIONS
1215	RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	4
1217	Impact of Psychological Distress on Prostate Cancer Screening in U.S. Military Veterans. <i>American Journal of Men's Health</i> , 2014, 8, 399-408.	0.7	15
1218	MRI-Guided Prostate Biopsy. , 2014, , 297-311.		0
1219	Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 995.	3.8	34
1220	Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida. <i>American Journal of Men's Health</i> , 2014, 8, 316-326.	0.7	13
1221	Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: A meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 218.	0.3	28
1222	Prostate Cancer Incidence and Prostate-Specific Antigen Testing Among HIV-Positive and HIV-Negative Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 495-502.	0.9	38
1223	Elasticity as a biomarker for prostate cancer: a systematic review. <i>BJU International</i> , 2014, 113, 523-534.	1.3	62
1224	What Do the Screening Trials Really Tell Us and Where Do We Go From Here?. <i>Urologic Clinics of North America</i> , 2014, 41, 223-228.	0.8	15
1225	Screening Mammography: Revisiting Assumptions About Early Detection. <i>Journal for Nurse Practitioners</i> , 2014, 10, 183-188.	0.4	5
1226	Modified Gleason Grade of Prostatic Adenocarcinomas Detected in the PLCO Cancer Screening Trial. <i>Journal of Urology</i> , 2014, 192, 391-395.	0.2	1
1227	Immunoaffinity chromatographic isolation of prostate-specific antigen from seminal plasma for capillary electrophoresis analysis of its isoforms. <i>Analytica Chimica Acta</i> , 2014, 820, 47-55.	2.6	8
1228	The Impact of Recent Screening Recommendations on Prostate Cancer Screening in a Large Health Care System. <i>Journal of Urology</i> , 2014, 191, 1737-1742.	0.2	53
1229	The Politics of Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 249-255.	0.8	12
1230	An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province. <i>Arab Journal of Urology Arab Association of Urology</i> , 2014, 12, 187-191.	0.7	11
1231	Valor diagnÃ³stico y predictivo del estudio en orina del gen PCA3 para el manejo clÃ­nico de pacientes con antÃ¡geno prostÃ¡tico especÃ­fico alterado. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2014, 38, 150-155.	0.3	5
1232	International Perspectives on Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 237-247.	0.8	2
1233	Advanced Methods and Applications in Computational Intelligence. <i>Topics in Intelligent Engineering and Informatics</i> , 2014, , .	0.4	8

#	ARTICLE	IF	CITATIONS
1234	Intrinsic Religiousness as a Mediator Between Fatalism and Cancer-Specific Fear: Clarifying the Role of Fear in Prostate Cancer Screening. <i>Journal of Religion and Health</i> , 2014, 53, 760-772.	0.8	8
1235	Audit of rapid access introduction reveals high prevalence of prostate cancer in Western Region. <i>Irish Journal of Medical Science</i> , 2014, 183, 173-179.	0.8	3
1236	Highlights of recent developments and trends in cancer nanotechnology research—View from NCI Alliance for Nanotechnology in Cancer. <i>Biotechnology Advances</i> , 2014, 32, 666-678.	6.0	53
1238	The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. <i>World Journal of Urology</i> , 2014, 32, 323-328.	1.2	18
1239	Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients. <i>Archives of Toxicology</i> , 2014, 88, 901-911.	1.9	11
1240	A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients. <i>BMC Urology</i> , 2014, 14, 8.	0.6	12
1241	Advances in molecular analysis of biomarkers for autoimmune and carcinogenic diseases. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 15-20.	1.9	6
1242	The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. <i>Tumor Biology</i> , 2014, 35, 3881-3890.	0.8	23
1245	An Intergenerational Approach to Prostate Cancer Education: Findings from a Pilot Project in the Southeastern USA. <i>Journal of Cancer Education</i> , 2014, 29, 649-656.	0.6	21
1246	Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 657-671.	2.7	49
1247	Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4Ång/mL. <i>World Journal of Urology</i> , 2014, 32, 481-487.	1.2	2
1248	Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 30-51.	157.7	167
1250	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
1251	Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 389-402.	1.6	51
1252	Variability of assay methods for total and free PSA after WHO standardization. <i>Tumor Biology</i> , 2014, 35, 1867-1873.	0.8	24
1253	Tumor Microenvironment—Released Peptides: Could They Form the Basis for an Early-Diagnosis Breast Cancer Test?. <i>Clinical Chemistry</i> , 2014, 60, 4-6.	1.5	0
1254	Role of Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer. <i>Current Urology Reports</i> , 2014, 15, 387.	1.0	13
1255	Imaging in Clinical Oncology. , 2014, , .		2

#	ARTICLE	IF	CITATIONS
1256	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intentâ€”Update 2013. <i>European Urology</i> , 2014, 65, 124-137.	0.9	1,613
1257	Physical activity and cancer-specific mortality in the NIH-AARP Diet and Health Study cohort. <i>International Journal of Cancer</i> , 2014, 135, 423-431.	2.3	81
1258	Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. <i>Current Medical Research and Opinion</i> , 2014, 30, 1025-1031.	0.9	89
1259	Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. <i>Contemporary Clinical Trials</i> , 2014, 39, 327-334.	0.8	3
1260	Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. <i>Prostate</i> , 2014, 74, 714-721.	1.2	12
1261	Highâ€”resolution magic angle spinning ¹ H MRS in prostate cancer. <i>NMR in Biomedicine</i> , 2014, 27, 90-99.	1.6	19
1262	The cost implications of prostate cancer screening in the Medicare population. <i>Cancer</i> , 2014, 120, 96-102.	2.0	50
1263	Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children. <i>Pediatrics</i> , 2014, 134, 1013-1023.	1.0	153
1264	DNA methylation markers for early detection of womenâ€™s cancer: promise and challenges. <i>Epigenomics</i> , 2014, 6, 311-327.	1.0	76
1265	Cancer trends among the extreme elderly in the era of cancer screening. <i>Journal of Geriatric Oncology</i> , 2014, 5, 408-414.	0.5	5
1266	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	0.8	234
1267	Effect of VIA Screening by Primary Health Workers: Randomized Controlled Study in Mumbai, India. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju009-dju009.	3.0	185
1268	The genetic epidemiology of prostate cancer and its clinical implications. <i>Nature Reviews Urology</i> , 2014, 11, 18-31.	1.9	207
1269	Pathology Consultation on Prostate-Specific Antigen Testing. <i>American Journal of Clinical Pathology</i> , 2014, 142, 7-15.	0.4	4
1270	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 173-199.	2.7	33
1271	Prostate-specific antigen screening, why have the guidelines changed?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1277-1281.	1.1	9
1272	Teaching laparoscopic radical prostatectomy during the primary surgeon's early learning curve â€” analysis of our first 207 cases. <i>BJU International</i> , 2014, 114, 38-44.	1.3	6
1273	The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level $\leq 2.5\text{ng/ml}$. <i>Cancer Epidemiology</i> , 2014, 38, 613-618.	0.8	4

#	ARTICLE	IF	CITATIONS
1274	Loss of miR-378 in prostate cancer, a common regulator of <i>KLK2</i> and <i>KLK4</i> , correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. <i>Biological Chemistry</i> , 2014, 395, 1095-1104.	1.2	29
1276	The Association of Long-term Treatment-related Side Effects With Cancer-specific and General Quality of Life Among Prostate Cancer Survivors. <i>Urology</i> , 2014, 84, 300-306.	0.5	53
1277	Screening for Pancreatic Cancer. <i>Advances in Surgery</i> , 2014, 48, 115-136.	0.6	20
1278	Re: Prostate Biopsy for the Interventional Radiologist. <i>Journal of Urology</i> , 2014, 192, 765-767.	0.2	0
1279	Re: What is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?. <i>Journal of Urology</i> , 2014, 192, 766-766.	0.2	0
1280	The complexity of PSA interpretation in clinical practice. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2014, 12, 323-327.	0.8	7
1281	A decade of progress in detection and treatment. <i>Nature Reviews Urology</i> , 2014, 11, 618-620.	1.9	1
1282	The Impact of GWAS Findings on Cancer Etiology and Prevention. <i>Current Epidemiology Reports</i> , 2014, 1, 130-137.	1.1	3
1283	Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 121.	2.9	6
1284	Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study. <i>BMC Cancer</i> , 2014, 14, 528.	1.1	5
1285	Do robotic prostatectomy positive surgical margins occur in the same location as extraprostatic extension?. <i>World Journal of Urology</i> , 2014, 32, 761-767.	1.2	9
1286	Random biopsy: when, how many and where to take the cores?. <i>World Journal of Urology</i> , 2014, 32, 859-869.	1.2	30
1287	Application of the 2013 American Urological Association early detection of prostate cancer guideline: Who will we miss?. <i>World Journal of Urology</i> , 2014, 32, 959-964.	1.2	13
1288	Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1413-1419.	1.2	35
1289	Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes. <i>Journal of Behavioral Medicine</i> , 2014, 37, 1242-1251.	1.1	13
1290	Utilization of paramagnetic microparticles for automated isolation of free circulating mRNA as a new tool in prostate cancer diagnostics. <i>Electrophoresis</i> , 2014, 35, 306-315.	1.3	1
1291	Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 547-553.	0.9	50
1292	Implications of the New AUA Guidelines on Prostate Cancer Detection in the U.S.. <i>Current Urology Reports</i> , 2014, 15, 420.	1.0	19

#	ARTICLE	IF	CITATIONS
1293	Screening: the information individuals need to support their decision: per protocol analysis is better than intention-to-treat analysis at quantifying potential benefits and harms of screening. <i>BMC Medical Ethics</i> , 2014, 15, 28.	1.0	8
1294	Predictions for the future of kallikrein-related peptidases in molecular diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 713-722.	1.5	17
1295	New concepts concerning prostate cancer screening. <i>Experimental Biology and Medicine</i> , 2014, 239, 793-804.	1.1	3
1296	Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Less Cost at the Expense of More Genitourinary Toxicity Is a Concerning But Testable Hypothesis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1183-1185.	0.8	15
1297	Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 615-626.	1.2	75
1299	Evolution and Immediate Future of US Screening Guidelines. <i>Urologic Clinics of North America</i> , 2014, 41, 229-235.	0.8	3
1300	Reconstruction of the natural history of metastatic cancer and assessment of the effects of surgery: Gompertzian growth of the primary tumor. <i>Mathematical Biosciences</i> , 2014, 247, 47-58.	0.9	21
1301	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014, 110, 2829-2836.	2.9	26
1302	Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 390-396.	1.0	73
1303	Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostate-specific antigen. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 150-155.	0.2	2
1304	Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy. <i>Journal of Urology</i> , 2014, 191, 1743-1748.	0.2	98
1306	Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 41.e23-41.e30.	0.8	74
1307	Anestesia en cirugía urológica del adulto. <i>EMC - Anestesia-Reanimación</i> , 2014, 40, 1-16.	0.1	0
1308	Prostate Biopsy for the Interventional Radiologist. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 675-684.	0.2	15
1309	Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 285-289.	0.2	2
1310	Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. <i>Clinical Oncology</i> , 2014, 26, 210-215.	0.6	17
1311	Decision Making and Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 257-266.	0.8	14
1312	Screening for Abdominal Aortic Aneurysm in 65-Year-old Men Remains Cost-effective with Contemporary Epidemiology and Management. <i>European Journal of Vascular and Endovascular Surgery</i> , 2014, 47, 357-365.	0.8	89

#	ARTICLE	IF	CITATIONS
1313	SÃndrome metabÃ³lico en pacientes con cÃ¡ncer de prÃ³stata sometidos a supresiÃ³n androgÃ©nica. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 285-289.	0.3	4
1314	Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. British Journal of Cancer, 2014, 110, 2405-2411.	2.9	60
1315	Noncoding RNAs in Prostate Cancer: The Long and the Short of It. Clinical Cancer Research, 2014, 20, 35-43.	3.2	59
1316	Mitochondrial protein cyclophilin-D-mediated programmed necrosis attributes to berberine-induced cytotoxicity in cultured prostate cancer cells. Biochemical and Biophysical Research Communications, 2014, 450, 697-703.	1.0	48
1317	A lab-in-a-briefcase for rapid prostate specific antigen (PSA) screening from whole blood. Lab on A Chip, 2014, 14, 2918-2928.	3.1	57
1318	microRNA and non-canonical TGF-Î² signalling: Implications for prostate cancer therapy. Critical Reviews in Oncology/Hematology, 2014, 92, 49-60.	2.0	13
1319	How are we communicating about clinical trials?. Contemporary Clinical Trials, 2014, 38, 275-283.	0.8	37
1320	Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene, 2014, 33, 135-147.	2.6	108
1321	Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Letters, 2014, 342, 248-256.	3.2	78
1322	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
1323	Association Between Atrial Fibrillation and Silent Cerebral Infarctions. Annals of Internal Medicine, 2014, 161, 650.	2.0	127
1324	Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiologia Brasileira, 2014, 47, 292-300.	0.3	20
1325	Early Biomarkers in Breast Cancer. , 2014, , 569-638.		0
1326	Online prostate cancer screening decision aid for at-risk men: A randomized trial.. Health Psychology, 2014, 33, 986-997.	1.3	22
1327	Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate International, 2014, 2, 133-139.	1.2	49
1329	Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 768-771.	2.3	8
1331	US Primary Care Physiciansâ€™ Prostate Cancer Screening Practices. Health Services Research and Managerial Epidemiology, 2014, 1, 233339281456290.	0.5	2
1332	PSA Screening: A Discussion Based on the USPSTF Recommendations and the AUA and EAU Guidelines. Journal of Men's Health, 2014, 11, 10-17.	0.1	1

#	ARTICLE	IF	CITATIONS
1333	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. <i>European Urology Focus</i> , 2015, 1, 137-146.	1.6	18
1334	Screening for Prostate Cancer: Current Status and Future Directions. <i>European Urology Focus</i> , 2015, 1, 147-148.	1.6	1
1335	The ONCOTYROL Prostate Cancer Outcome and Policy Model. <i>Medical Decision Making</i> , 2015, 35, 758-772.	1.2	8
1337	Re: Determinants of participation in prostate cancer screening: A simple analytical framework to account for healthyâ€user bias. <i>Cancer Science</i> , 2015, 106, 1479-1480.	1.7	0
1338	Men's preferences and tradeâ€offs for prostate cancer screening: a discrete choice experiment. <i>Health Expectations</i> , 2015, 18, 3123-3135.	1.1	29
1339	Editorial Comment from Dr Izumi to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostateâ€specific antigenâ€based screening in Yokosuka and those detected by other means. <i>International Journal of Urology</i> , 2015, 22, 752-753.	0.5	0
1340	Family history in the <scp>F</scp>innish <scp>P</scp>rostate <scp>C</scp>ancer <scp>S</scp>creening <scp>T</scp>rial. <i>International Journal of Cancer</i> , 2015, 136, 2172-2177.	2.3	20
1341	Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review. <i>Psycho-Oncology</i> , 2015, 24, 1303-1315.	1.0	30
1342	Prostate cancer and the PCP: the screening dilemma. <i>International Journal of Clinical Practice</i> , 2015, 69, 1438-1447.	0.8	3
1343	Prostateâ€specific antigenâ€based prostate cancer screening: Past and future. <i>International Journal of Urology</i> , 2015, 22, 524-532.	0.5	59
1344	Editorial Comment to Prostateâ€specific antigenâ€based prostate cancer screening: Past and future. <i>International Journal of Urology</i> , 2015, 22, 532-533.	0.5	0
1345	Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues. <i>Biomedical Optics Express</i> , 2015, 6, 4781.	1.5	22
1346	Re: Effect of Individual Omega-3 Fatty Acids on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. <i>Journal of Epidemiology</i> , 2015, 25, 559-560.	1.1	0
1347	Prostate Cancer. <i>Annals of Internal Medicine</i> , 2015, 163, ITC1-ITC16.	2.0	3
1348	What tumours should we treat with focal therapy based on risk category, grade, size and location?. <i>Current Opinion in Urology</i> , 2015, 25, 212-219.	0.9	10
1350	The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?. <i>European Urology Focus</i> , 2015, 1, 97-98.	1.6	1
1351	Increased expression of Six1 correlates with progression and prognosis of prostate cancer. <i>Cancer Cell International</i> , 2015, 15, 63.	1.8	17
1352	Prostate cancer survivors' beliefs about screening and treatment decision-making experiences in an era of controversy. <i>Psycho-Oncology</i> , 2015, 24, 1073-1079.	1.0	18

#	ARTICLE	IF	CITATIONS
1353	Prostate cancer screening using risk stratification based on a multi-state model of genetic variants. <i>Prostate</i> , 2015, 75, 825-835.	1.2	2
1354	PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. <i>Prostate</i> , 2015, 75, 1951-1957.	1.2	18
1355	Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. <i>Therapeutic Advances in Urology</i> , 2015, 7, 378-387.	0.9	91
1357	An introduction to implementation science for the non-specialist. <i>BMC Psychology</i> , 2015, 3, 32.	0.9	1,143
1358	The Effectiveness of Health Screening. <i>Health Economics (United Kingdom)</i> , 2015, 24, 913-935.	0.8	20
1359	Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means. <i>International Journal of Urology</i> , 2015, 22, 747-752.	0.5	5
1360	Discussions with healthcare providers about prostate-specific antigen testing: evidence from the Behavioral Risk Factor Surveillance System in the USA. <i>Journal of Pharmaceutical Health Services Research</i> , 2015, 6, 47-52.	0.3	2
1361	Gene Expression Signatures Based on Variability can Robustly Predict Tumor Progression and Prognosis. <i>Cancer Informatics</i> , 2015, 14, CIN.S23862.	0.9	21
1362	The Case for Tailored Prostate Cancer Screening: An NCCN Perspective. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1576-1583.	2.3	16
1363	Accelerated echo planar J-resolved spectroscopic imaging in prostate cancer: a pilot validation of non-linear reconstruction using total variation and maximum entropy. <i>NMR in Biomedicine</i> , 2015, 28, 1366-1373.	1.6	13
1364	Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial. <i>Prostate</i> , 2015, 75, 1322-1328.	1.2	22
1365	Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice. <i>Journal of Restorative Medicine</i> , 2015, 4, 24-32.	0.7	2
1366	Observational studies and the natural history of screen-detected prostate cancer. <i>Current Opinion in Urology</i> , 2015, 25, 232-237.	0.9	54
1367	Multigene Methylation Biomarker Analysis in Prostate Cancer. <i>Epigenetic Diagnosis & Therapy</i> , 2015, 1, 19-27.	0.1	0
1368	Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. <i>BioMed Research International</i> , 2015, 2015, 1-23.	0.9	44
1369	Green Tea Catechins for Prostate Cancer Chemoprevention. , 0, , .		0
1370	Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2015, 06, .	0.4	1
1371	Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 258-264.	0.7	14

#	ARTICLE	IF	CITATIONS
1372	A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group. <i>Journal of Clinical Medicine</i> , 2015, 4, 1369-1379.	1.0	84
1373	MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families. <i>PLoS ONE</i> , 2015, 10, e0127427.	1.1	9
1374	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. <i>PLoS ONE</i> , 2015, 10, e0132343.	1.1	28
1375	Detection of Core2 Î²-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0138520.	1.1	19
1376	Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program. <i>PLoS ONE</i> , 2015, 10, e0134134.	1.1	15
1377	Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4â€“10â€‰ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	10
1378	Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	19
1379	Treatment Patterns among Canadian Men Diagnosed with Localized Low-Risk Prostate Cancer. <i>Current Oncology</i> , 2015, 22, 427-429.	0.9	6
1380	Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. <i>BMC Cancer</i> , 2015, 15, 259.	1.1	37
1381	Screening for Cancer: Lessons Learned from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>European Urology</i> , 2015, 68, 545-546.	0.9	6
1382	Reducing PSA-Based Prostate Cancer Screening in Men Agedâ‰‰75ÂˆYears and Older with the Use of Highly Specific Computerized Clinical Decision Support. <i>Journal of General Internal Medicine</i> , 2015, 30, 1133-1139.	1.3	30
1383	The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. <i>BMC Urology</i> , 2015, 15, 28.	0.6	18
1384	A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. <i>European Urology</i> , 2015, 68, 464-470.	0.9	320
1385	PROMIS â€” Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. <i>Contemporary Clinical Trials</i> , 2015, 42, 26-40.	0.8	89
1386	A boosting approach for prostate cancer detection using multi-parametric MRI. <i>Proceedings of SPIE</i> , 2015, , .	0.8	11
1387	Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. <i>BMC Medical Imaging</i> , 2015, 15, 27.	1.4	140
1388	Screening: Diagnostic dilemma. <i>Nature</i> , 2015, 528, S120-S122.	13.7	18
1389	Gama-glutamyl transferasa en suero, adyuvante del antÃ©geno prostÃ©tico especÃ©fico en el diagnÃ³stico del cÃ¡ncer de prÃ³stata. <i>Revista Mexicana De Urologia</i> , 2015, 75, 325-331.	0.0	1

#	ARTICLE	IF	CITATIONS
1390	Cancer Epidemiology and Screening. , 2015, , 3-14.		0
1391	Prostate Cancer Detection via a Quantitative Radiomics-Driven Conditional Random Field Framework. IEEE Access, 2015, 3, 2531-2541.	2.6	32
1392	Impact of age, race and socio-economic status on temporal trends in late-stage prostate cancer diagnosis in Florida. Spatial Statistics, 2015, 14, 321-337.	0.9	12
1393	Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values. Kaohsiung Journal of Medical Sciences, 2015, 31, 315-319.	0.8	6
1394	Malpractice Litigation in the Setting of Prostate Cancer Diagnosis. Urology Practice, 2015, 2, 17-21.	0.2	1
1395	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. Expert Review of Gastroenterology and Hepatology, 2015, 9, 731-746.	1.4	11
1396	First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. BJU International, 2015, 115, 50-57.	1.3	146
1397	Testosterone therapy and cancer risk. BJU International, 2015, 115, 317-321.	1.3	20
1398	How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. European Urology, 2015, 67, 637-645.	0.9	105
1399	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	0.9	190
1400	Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. International Journal of Epidemiology, 2015, 44, 264-277.	0.9	109
1401	Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2015, 65, 30-54.	157.7	299
1402	Polymorphisms Influencing Prostate-Specific Antigen Concentration May Bias Genome-Wide Association Studies on Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 88-93.	1.1	4
1403	Ultrasensitive Prostate Specific Antigen and its Role after Radical Prostatectomy: A Systematic Review. Journal of Urology, 2015, 193, 1525-1531.	0.2	22
1404	Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9. European Urology, 2015, 67, e19-e20.	0.9	2
1405	Molecular Basis of Prostate Cancer. , 2015, , 549-560.e1.		1
1406	Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities. Journal of Cancer Education, 2015, 30, 623-628.	0.6	18
1407	Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. Journal of Urology, 2015, 194, 46-51.	0.2	24

#	ARTICLE	IF	CITATIONS
1408	Innovative and Community-Guided Evaluation and Dissemination of a Prostate Cancer Education Program for African-American Men and Women. <i>Journal of Cancer Education</i> , 2015, 30, 779-785.	0.6	17
1409	PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 15.	3.5	68
1410	A urine-based methylation signature for risk stratification within low-risk prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 802-808.	2.9	16
1411	The Relationship Between Education and Prostate-Specific Antigen Testing Among Urban African American Medicare Beneficiaries. <i>Journal of Racial and Ethnic Health Disparities</i> , 2015, 2, 176-183.	1.8	10
1412	Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening. <i>Translational Behavioral Medicine</i> , 2015, 5, 189-197.	1.2	8
1413	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. <i>Human Genetics</i> , 2015, 134, 439-450.	1.8	45
1414	Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial. <i>European Urology</i> , 2015, 68, 354-360.	0.9	110
1415	Highlights of the University of Toronto Urology Update 2014. <i>Canadian Urological Association Journal</i> , 2015, 9, 3.	0.3	0
1416	Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. <i>British Journal of Cancer</i> , 2015, 113, 460-468.	2.9	32
1417	Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010. <i>Clinica Chimica Acta</i> , 2015, 448, 220-227.	0.5	9
1418	Finding a Needle in a Haystack: The Diagnosis of a Rectal Neuroendocrine Tumor by Transrectal Prostate Biopsy. <i>GE Portuguese Journal of Gastroenterology</i> , 2015, 22, 221-225.	0.3	0
1419	Responses to a Decision Aid on Prostate Cancer Screening in Primary Care Practices. <i>American Journal of Preventive Medicine</i> , 2015, 49, 520-525.	1.6	30
1420	Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers. <i>Current Urology Reports</i> , 2015, 16, 63.	1.0	4
1421	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e19-202.e28.	0.8	8
1422	National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2416-2423.	0.8	184
1423	Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 383.e9-383.e16.	0.8	24
1424	Therapeutic Applications of the Prostate Cancer Epigenome. , 2015, , 233-268.		0
1425	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	0.9	23

#	ARTICLE	IF	CITATIONS
1426	Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012. <i>Urology</i> , 2015, 86, 498-505.	0.5	15
1427	Editorial: Miles to Go on the SCENIC Route: Should Chromoendoscopy Become the Standard of Care in IBD Surveillance?. <i>American Journal of Gastroenterology</i> , 2015, 110, 1035-1037.	0.2	22
1428	Clinical performance of serum isoform [â€²]pro<scp>PSA</scp> (<scp>p2PSA</scp>), and its derivatives %<scp>p2PSA</scp> and the Prostate Health Index, in men aged <lt;60 years: results from a multicentric <scp>E</scp>uropean study. <i>BJU International</i> , 2015, 115, 913-920.	1.3	32
1429	DNA aptamer-based detection of prostate cancer. <i>Chemical Papers</i> , 2015, 69, .	1.0	41
1431	Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 897.	3.4	132
1432	Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. <i>Journal of Urology</i> , 2015, 194, 1587-1593.	0.2	113
1433	Screening for Cervical, Prostate, and Breast Cancer. <i>American Journal of Preventive Medicine</i> , 2015, 49, 274-285.	1.6	24
1434	Commentary on N Saquib et al. Does screening for disease save lives in asymptomatic adults? Systematic review of 5 meta-analyses and randomized trials. <i>International Journal of Epidemiology</i> , 2015, 44, 277-278.	0.9	2
1435	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. <i>Journal of Urology</i> , 2015, 193, 1519-1524.	0.2	90
1436	Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study. <i>Urology</i> , 2015, 85, 1111-1116.	0.5	7
1437	Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: A review. <i>Computers in Biology and Medicine</i> , 2015, 60, 8-31.	3.9	270
1438	Do national cancer screening guidelines reduce mortality?. <i>Journal of Population Economics</i> , 2015, 28, 1075-1095.	3.5	4
1439	Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3393-3404.	1.9	11
1440	Secondary prevention at 360Â°: the important role of diagnostic imaging. <i>Radiologia Medica</i> , 2015, 120, 511-525.	4.7	0
1442	Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 255-259.	2.0	22
1443	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015, 15, 80.	0.9	16
1444	Prostate-specific antigen-based screening: controversy and guidelines. <i>BMC Medicine</i> , 2015, 13, 61.	2.3	84
1445	Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data. <i>Journal of Applied Statistics</i> , 2015, 42, 1223-1239.	0.6	11

#	ARTICLE	IF	CITATIONS
1446	Two susceptibility loci identified for prostate cancer aggressiveness. <i>Nature Communications</i> , 2015, 6, 6889.	5.8	88
1447	The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria. <i>BMC Public Health</i> , 2015, 15, 425.	1.2	13
1448	Secondary solid cancer screening following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1013-1023.	1.3	136
1449	Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 637-652.	1.1	60
1450	Urinary biomarkers for prostate cancer. <i>Current Opinion in Urology</i> , 2015, 25, 77-82.	0.9	15
1451	Altered Glycosylation in Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 126, 345-382.	1.9	91
1452	Gene interference strategies as a new tool for the treatment of prostate cancer. <i>Endocrine</i> , 2015, 49, 588-605.	1.1	27
1453	Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. <i>British Journal of Cancer</i> , 2015, 113, 382-389.	2.9	126
1454	Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 456-463.	0.8	35
1455	A contemporary approach to validity arguments: a practical guide to Kane's framework. <i>Medical Education</i> , 2015, 49, 560-575.	1.1	371
1456	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. <i>Human Molecular Genetics</i> , 2015, 24, 7406-7420.	1.4	17
1457	Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. <i>Analytical Chemistry</i> , 2015, 87, 10830-10838.	3.2	32
1458	Efficacy of Prostate-Specific Antigen Screening. <i>JAMA Oncology</i> , 2015, 1, 984.	3.4	13
1459	Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium. <i>American Journal of Epidemiology</i> , 2015, 182, 381-389.	1.6	42
1460	Prostate Cancer Screening and the Associated Controversy. <i>Surgical Clinics of North America</i> , 2015, 95, 1023-1039.	0.5	69
1461	Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. <i>American Journal of Health Promotion</i> , 2015, 29, 393-401.	0.9	9
1462	Epidemiology of Cancer in the Tropical Areas. , 2015, , 17-23.		3
1463	Molecular Updates in Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2015, 8, 561-580.	0.7	7

#	ARTICLE	IF	CITATIONS
1464	Improving What Matters. <i>European Urology</i> , 2015, 68, 384-385.	0.9	5
1465	Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 662-665.	0.6	20
1466	Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 277-289.	0.8	9
1467	Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2054.	3.8	382
1468	Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. <i>British Journal of Cancer</i> , 2015, 113, 1502-1511.	2.9	20
1469	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
1470	Use of Biomarkers in Screening for Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 27-39.	0.8	45
1471	Radiotherapy in Prostate Cancer. <i>Medical Radiology</i> , 2015, , .	0.0	6
1472	An exploratory study of inactive health information seekers. <i>International Journal of Medical Informatics</i> , 2015, 84, 119-133.	1.6	30
1473	Impact of the 2012 United States Preventive Services Task Force Statement on Prostate-specific Antigen Screening: Analysis of Urologic and Primary Care Practices. <i>Urology</i> , 2015, 85, 85-91.	0.5	31
1474	Impact of Prostate-specific Antigen on a Baseline Prostate Cancer Risk Assessment Including Genetic Risk. <i>Urology</i> , 2015, 85, 165-171.	0.5	2
1475	Increased Risk of Cancer in Infertile Men: Analysis of U.S. Claims Data. <i>Journal of Urology</i> , 2015, 193, 1596-1601.	0.2	135
1476	Editorial Comment. <i>Urology</i> , 2015, 85, 170-171.	0.5	0
1477	Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries. <i>Journal of Urology</i> , 2015, 193, 80-86.	0.2	79
1478	Impact of Family History on Prostate Cancer Mortality in White Men Undergoing Prostate Specific Antigen Based Screening. <i>Journal of Urology</i> , 2015, 193, 75-79.	0.2	40
1479	Diagnostic value of biparametric magnetic resonance imaging (<scp>MRI</scp>) as an adjunct to prostate-specific antigen (<scp>PSA</scp>) based detection of prostate cancer in men without prior biopsies. <i>BJU International</i> , 2015, 115, 381-388.	1.3	128
1480	Interpreting Health Benefits and Risks. , 2015, , .		4
1481	Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. <i>European Journal of Cancer</i> , 2015, 51, 1164-1187.	1.3	403

#	ARTICLE	IF	CITATIONS
1482	Beyond the Black Box: A Systematic Review of Breast, Prostate, Colorectal, and Cervical Screening Among Native and Immigrant African-Descent Caribbean Populations. <i>Journal of Immigrant and Minority Health</i> , 2015, 17, 905-924.	0.8	56
1483	Advances in Image-Guided Urologic Surgery. , 2015, , .		3
1484	Screening for prostate cancer in the US? Reduce the harms and keep the benefit. <i>International Journal of Cancer</i> , 2015, 136, 1600-1607.	2.3	22
1485	Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e29-69.e34.	0.8	8
1486	Prostate Magnetic Resonance Imaging: Challenges of Implementation. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 26-37.	0.6	7
1487	Redefining Androgen Receptor Function: Clinical Implications in Understanding Prostate Cancer Progression and Therapeutic Resistance. , 0, , .		0
1488	Prostate-Specific Antigen-Based Prostate Cancer Screening. , 0, , .		1
1489	Is "Active Surveillance" an Acceptable Alternative?: A Qualitative Study of Couples' Decision Making about Early-Stage, Localized Prostate Cancer. <i>Narrative Inquiry in Bioethics</i> , 2016, 6, 51-61.	0.0	13
1491	In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 88, 195.	0.4	8
1492	Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort. <i>Journal of Korean Medical Science</i> , 2016, 31, 1802.	1.1	9
1493	Prostate cancer screening in Brazil: should it be done or not?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 1069-1080.	0.7	8
1494	Cancer Biomarkers. , 0, , .		6
1495	Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 2211.	1.0	87
1496	Factors influencing Nigerian men's decision to undergo prostate specific antigen testing. <i>African Health Sciences</i> , 2016, 16, 524.	0.3	10
1497	Conocimiento, percepción y disposición sobre el examen de próstata en hombres mayores de 40 años. <i>Revista Facultad De Medicina</i> , 2016, 64, 223.	0.0	2
1498	Current status of active surveillance in prostate cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, 14.	1.0	22
1499	Nudge vs. Boost: Agency Dynamics Under 'Libertarian Paternalism'. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
1500	Testicular Disorders. , 2016, , 694-784.		12

#	ARTICLE	IF	CITATIONS
1501	Evolving Recommendations on Prostate Cancer Screening. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e80-e87.	1.8	8
1502	What Prevents Men Aged 40-64 Years from Prostate Cancer Screening in Namibia?. Journal of Cancer Epidemiology, 2016, 2016, 1-9.	0.5	17
1503	Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. Journal of Cancer, 2016, 7, 523-531.	1.2	16
1504	Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening. Cancer Management and Research, 2016, 8, 45.	0.9	13
1505	Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Frontiers in Oncology, 2016, 6, 157.	1.3	22
1506	Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review. PLoS ONE, 2016, 11, e0153417.	1.1	11
1507	Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. PLoS ONE, 2016, 11, e0154507.	1.1	48
1508	Opening up New Therapeutic Avenues. Oncology Issues, 2016, 31, 48-53.	0.0	2
1509	Multiplexed cancer biomarker detection using chip-integrated silicon photonic sensor arrays. Analyst, The, 2016, 141, 5358-5365.	1.7	39
1510	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	1.2	19
1511	Clinical Perspective of Prostate Cancer. Topics in Magnetic Resonance Imaging, 2016, 25, 103-108.	0.7	11
1512	Development and Applications of Lectins as Biological Tools in Biomedical Research. Medicinal Research Reviews, 2016, 36, 221-247.	5.0	101
1513	The genetic classification of prostate cancer: what's on the horizon?. Future Oncology, 2016, 12, 729-733.	1.1	5
1514	<i>NCOA2</i> is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Genes Chromosomes and Cancer, 2016, 55, 365-374.	1.5	14
1515	<i>Sleeping Beauty</i> screen reveals <i>Pparg</i> activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8290-8295.	3.3	91
1516	External validation of a PCA-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy. Prostate, 2016, 76, 1019-1023.	1.2	9
1517	Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men. International Journal of Cancer, 2016, 138, 2522-2528.	2.3	6
1518	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 509-519.	2.3	268

#	ARTICLE	IF	CITATIONS
1519	Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate International, 2016, 4, 125-129.	1.2	36
1520	Risk Factors for Prostate Cancer: Which Are Truly Predictive of Clinically Significant Disease?. Journal of Clinical Oncology, 2016, 34, 4310-4311.	0.8	1
1521	Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study. BMJ Open, 2016, 6, e011467.	0.8	6
1522	In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Scientific Reports, 2016, 6, 23314.	1.6	36
1523	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.4	6
1524	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia, 2016, 18, 489-499.	2.3	55
1525	Analysis of recommendations against prostate cancer screening with prostate specific antigen. Medicina Clínica (English Edition), 2016, 147, 361-365.	0.1	0
1526	Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study. BMJ Open, 2016, 6, e010191.	0.8	7
1527	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology, 2016, 2, 882.	3.4	458
1528	Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?. Medical Hypotheses, 2016, 93, 71-73.	0.8	3
1529	Population-based screening for cancer: hope and hype. Nature Reviews Clinical Oncology, 2016, 13, 550-565.	12.5	98
1531	Reevaluating PSA Testing Rates in the PLCO Trial. New England Journal of Medicine, 2016, 374, 1795-1796.	13.9	158
1532	Lethal Prostate Cancer in the PLCO Cancer Screening Trial. European Urology, 2016, 70, 2-5.	0.9	9
1533	How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the US Guideline Screening Initiation Ages. Forum for Health Economics and Policy, 2016, 19, 87-139.	0.2	12
1534	Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10655-10660.	3.3	127
1535	Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy. Bulletin Du Cancer, 2016, 103, 730-734.	0.6	7
1536	Prostate-Specific Antigen. Transplantation Proceedings, 2016, 48, 1374-1377.	0.3	3
1537	The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. Urology, 2016, 96, 128-135.	0.5	14

#	ARTICLE	IF	CITATIONS
1538	Editorial Comment. Urology, 2016, 97, 116-117.	0.5	0
1539	Screening for Cancer in Persons Living with HIV Infection. Trends in Cancer, 2016, 2, 416-428.	3.8	28
1540	Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. Cancer, 2016, 122, 3785-3793.	2.0	23
1541	Post-9/11 cancer incidence in World Trade Center-exposed New York City firefighters as compared to a pooled cohort of firefighters from San Francisco, Chicago and Philadelphia (9/11/2001-2009). American Journal of Industrial Medicine, 2016, 59, 722-730.	1.0	33
1543	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 2016, 96, 116-120.	0.5	11
1544	Health Care Maintenance for the Pediatric Patient With Inflammatory Bowel Disease. Pediatrics, 2016, 138, .	1.0	32
1545	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. European Urology, 2016, 70, 499-505.	0.9	6
1546	A History of Prostate Cancer. , 2016, , .		4
1547	Consistent Bayesians Are No More Accurate Than Non-Bayesians: Economists Surveyed About PSA. Review of Behavioral Economics, 2016, 3, 189-219.	0.2	9
1548	Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population. Annals of Surgical Oncology, 2016, 23, 4284-4292.	0.7	20
1549	Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Medicine, 2016, 5, 136-141.	1.3	50
1550	Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Science, 2016, 107, 1022-1028.	1.7	31
1551	Prostate-specific antigen testing rates and referral patterns from general practice data in England. International Journal of Clinical Practice, 2016, 70, 312-318.	0.8	18
1552	Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. Ca-A Cancer Journal for Clinicians, 2016, 66, 290-308.	157.7	644
1553	Intron retention in mRNA: No longer nonsense. BioEssays, 2016, 38, 41-49.	1.2	163
1554	Overtreatment in cancer " is it a problem?. Expert Opinion on Pharmacotherapy, 2016, 17, 1-5.	0.9	22
1555	Cancer Prevention in the Older Individual. Seminars in Oncology Nursing, 2016, 32, 314-324.	0.7	15
1556	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1456-1463.	1.1	22

#	ARTICLE	IF	CITATIONS
1557	Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum. <i>Journal of Clinical Oncology</i> , 2016, 34, 3499-3501.	0.8	7
1559	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
1560	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
1561	Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States. <i>Urology</i> , 2016, 97, 111-117.	0.5	15
1562	On the generalizability of prostate cancer studies: why race matters. <i>Annals of Oncology</i> , 2016, 27, 2146-2148.	0.6	6
1563	Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. <i>Journal of the Egyptian National Cancer Institute</i> , 2016, 28, 235-242.	0.6	46
1564	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016, 118, 869-879.	1.3	52
1565	The impact of the United States Preventive Services Task Force (<scp>USPTSTF</scp>) recommendations against prostate-specific antigen (<scp>PSA</scp>) testing on <scp>PSA</scp> testing in Australia. <i>BJU International</i> , 2017, 119, 110-115.	1.3	22
1566	Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection. <i>Oncology Letters</i> , 2016, 12, 1132-1138.	0.8	3
1567	Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. <i>International Urology and Nephrology</i> , 2016, 48, 1631-1637.	0.6	25
1568	Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men with Late-Onset Hypogonadism. <i>Journal of Sexual Medicine</i> , 2016, 13, 1199-1211.	0.3	38
1569	Why the prostate arm of the PLCO trial failed and what it has taught us. <i>Nature Reviews Urology</i> , 2016, 13, 439-440.	1.9	1
1570	Randomized trials are frequently fragmented in multiple secondary publications. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 130-139.	2.4	22
1571	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016, 27, 1465-1474.	0.8	17
1572	Enhanced dual-stage correlated diffusion imaging. , 2016, 2016, 5537-5540.		3
1573	Transcultural Adaptation and Validation of Champion's Health Belief Model Scales for Prostate Cancer Screening. <i>Journal of Nursing Measurement</i> , 2016, 24, 296-313.	0.2	1
1575	PSA request analysis: how should this be interpreted? What may be overlooked / PSA istem analizi: Nasıl yorumlanmalı? Gâzden kaşanlar nelerdir?. <i>Turkish Journal of Biochemistry</i> , 2016, 41, .	0.3	2
1576	More on Reevaluating PSA Testing Rates in the PLCO Trial. <i>New England Journal of Medicine</i> , 2016, 375, 1500-1501.	13.9	10

#	ARTICLE	IF	CITATIONS
1577	Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1361-1370.	0.8	79
1578	Preparation and biodistribution assessment of ⁶⁸ Ga-DKFZ-PSMA-617 for PET prostate cancer imaging. <i>Nuclear Science and Techniques/Hewuli</i> , 2016, 27, 1.	1.3	3
1579	To Screen or Not to Screen. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1594-1605.	1.4	17
1581	Chemoprevention in African American Men with Prostate Cancer. <i>Cancer Control</i> , 2016, 23, 415-423.	0.7	5
1582	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31802.	3.6	70
1583	Secular trends and evaluation of complex interventions: the rising tide phenomenon. <i>BMJ Quality and Safety</i> , 2016, 25, 303-310.	1.8	76
1584	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016, 17, 497.	0.7	5
1585	The potential of PAI-1 expression in needle biopsies as a predictive marker for prostate cancer. <i>Cogent Medicine</i> , 2016, 3, 1183275.	0.7	6
1586	The influence of ethnicity on diagnosis of cancer. <i>Family Practice</i> , 2016, 33, 325-326.	0.8	9
1587	Total and Free PSA, PCA3, PSA Density and Velocity. , 2016, , 83-90.		1
1588	Velocity and doubling time of prostate-specific antigen: mathematics can matter. <i>Journal of Investigative Medicine</i> , 2016, 64, 400-404.	0.7	5
1589	Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Actas Urológicas Españolas (English Edition)</i> , 2016, 40, 164-172.	0.2	0
1590	93 A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer. <i>European Urology Supplements</i> , 2016, 15, e93.	0.1	0
1591	Contaminación de antígeno específico prostático a largo plazo en la rama española del Estudio Aleatorizado Europeo de Screening del Cáncer de Próstata (ERSPC). <i>Actas Urológicas Españolas</i> , 2016, 40, 164-172.	0.3	3
1592	Multi-sequence texture analysis in classification of in vivo MR images of the prostate. <i>Biocybernetics and Biomedical Engineering</i> , 2016, 36, 537-552.	3.3	7
1593	Australian patterns of prostate cancer care: Are they evolving?. <i>Prostate International</i> , 2016, 4, 20-24.	1.2	8
1594	Nuclear Medicine Imaging of Prostate Cancer. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2016, 188, 1037-1044.	0.7	9
1595	Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1049-1058.	0.8	30

#	ARTICLE	IF	CITATIONS
1596	A functional variant in miR-143 promoter contributes to prostate cancer risk. Archives of Toxicology, 2016, 90, 403-414.	1.9	43
1597	Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. World Journal of Urology, 2016, 34, 1107-1113.	1.2	4
1598	Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. Preventive Medicine, 2016, 82, 83-91.	1.6	38
1599	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2016, 387, 945-956.	6.3	791
1600	Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995â€“2012. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 259-263.	1.1	32
1601	Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomographyâ€”Should Patients Receive Further Evaluation?. Journal of Urology, 2016, 195, 907-912.	0.2	10
1602	MAPS: A Quantitative Radiomics Approach for Prostate Cancer Detection. IEEE Transactions on Biomedical Engineering, 2016, 63, 1145-1156.	2.5	142
1603	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	7.3	397
1604	Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum. Advances in Experimental Medicine and Biology, 2016, 882, 33-68.	0.8	34
1605	The Charms and Harms of Personalized Medicine11A shorter version of the text of this chapter was published in the European Journal of Epidemiology (James, 2014).. , 2016, , 245-281.		0
1606	Prostate Cancer Prevention: Concepts and Clinical Trials. Current Urology Reports, 2016, 17, 35.	1.0	8
1608	Trends in Metastatic Breast and Prostate Cancer. New England Journal of Medicine, 2016, 374, 594-596.	13.9	17
1609	The Psychological Impact of Prostate Biopsy: Anxiety and Depression Associated with a Positive Biopsy Result. Urology Practice, 2016, 3, 32-35.	0.2	2
1610	Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. Journal of Urology, 2016, 195, 66-73.	0.2	73
1611	Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012. Preventive Medicine, 2016, 82, 73-76.	1.6	6
1612	A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer. American Journal of Epidemiology, 2016, 183, 227-236.	1.6	19
1613	Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer. World Journal of Surgery, 2016, 40, 895-905.	0.8	15
1614	Biomarker detection technologies and future directions. Analyst, The, 2016, 141, 740-755.	1.7	182

#	ARTICLE	IF	CITATIONS
1615	Interventional Urology. , 2016, , .		4
1616	4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. Urologic Clinics of North America, 2016, 43, 39-46.	0.8	27
1617	Multiple biomarkers biosensor with just-in-time functionalization: Application to prostate cancer detection. Biosensors and Bioelectronics, 2016, 77, 1192-1200.	5.3	27
1618	Prostate-Specific Antigen Screening Guidelines. , 2016, , 111-116.		3
1619	Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: A survey of U.S. transplantation centers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e9-57.e13.	0.8	18
1621	Finasteride and Bladder Cancer. European Urology, 2016, 69, 411-412.	0.9	0
1622	History of Prostate-Specific Antigen, from Detection to Overdiagnosis. , 2016, , 3-16.		2
1623	Operations research models and methods in the screening, detection, and treatment of prostate cancer: A categorized, annotated review. Operations Research for Health Care, 2016, 8, 9-21.	0.8	4
1624	Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. European Urology, 2016, 69, 407-410.	0.9	51
1625	Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. Journal of Urology, 2016, 195, 612-618.	0.2	57
1626	Digital Solutions for Informed Decision Making. American Journal of Men's Health, 2016, 10, 207-219.	0.7	16
1627	Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer. , 2016, , 2467-2484.e5.		0
1628	Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology, 2017, 71, 55-65.	0.9	43
1629	Experiences of Uncertainty in Men With an Elevated PSA. American Journal of Men's Health, 2017, 11, 24-34.	0.7	14
1630	Ever and Annual Use of Prostate Cancer Screening in African American Men. American Journal of Men's Health, 2017, 11, 99-107.	0.7	16
1631	Barbershop Prostate Cancer Education. American Journal of Men's Health, 2017, 11, 116-125.	0.7	3
1633	Prostate Cancer Education, Detection, and Follow-Up in a Community-Based Multiethnic Cohort of Medically Underserved Men. American Journal of Men's Health, 2017, 11, 82-91.	0.7	9
1634	Circulating biomarkers in cancer care: What possible use?. Practical Laboratory Medicine, 2017, 7, 45-48.	0.6	2

#	ARTICLE	IF	CITATIONS
1635	Predictors of prostate cancer screening intention among older men in Jordan. <i>International Journal of Urological Nursing</i> , 2017, 11, 31-41.	0.1	8
1636	Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. <i>Lancet, The</i> , 2017, 389, 767-768.	6.3	4
1637	Impact of a Prostate Specific Antigen Screening Decision Aid on Clinic Function. <i>Urology Practice</i> , 2017, 4, 448-453.	0.2	7
1638	Histomorphological changes in induced benign prostatic hyperplasia with exogenous testosterone and estradiol in adult male rats treated with aqueous ethanol extract of <i>Secamone afzelii</i> . <i>Egyptian Journal of Basic and Applied Sciences</i> , 2017, 4, 15-21.	0.2	12
1639	Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. <i>European Urology</i> , 2017, 71, 515-516.	0.9	4
1640	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 210-217.	0.2	1
1641	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <i>Health Affairs</i> , 2017, 36, 108-115.	2.5	25
1642	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <i>Nature Communications</i> , 2017, 8, 14248.	5.8	58
1643	Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3692-3699.	3.2	18
1644	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 50-57.	0.2	24
1645	Is prostate cancer stage migration continuing for black men in the PSA era?. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 210-215.	2.0	7
1646	Radiotherapy in the Management of Prostate Cancer. <i>Medical Radiology</i> , 2017, , 87-112.	0.0	0
1647	Outcomes of Prostate Cancer Screening by 5 α -Reductase Inhibitor Use. <i>Journal of Urology</i> , 2017, 198, 305-309.	0.2	3
1648	Cancer-related outcomes in kidney allograft recipients in England versus New York State: a comparative population-cohort analysis between 2003 and 2013. <i>Cancer Medicine</i> , 2017, 6, 563-571.	1.3	3
1649	Role of Magnetic Resonance Imaging in Prostate Cancer Assessment. <i>Current Clinical Urology</i> , 2017, , 161-176.	0.0	0
1650	Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 460.e9-460.e20.	0.8	22
1651	Screening for prostate cancer. <i>Seminars in Oncology</i> , 2017, 44, 47-56.	0.8	20
1654	Commentary: Prostate cancer screening—A long run for a short slide. <i>Seminars in Oncology</i> , 2017, 44, 57-59.	0.8	0

#	ARTICLE	IF	CITATIONS
1656	Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy. <i>Urology</i> , 2017, 105, 123-128.	0.5	59
1657	Finding a HOME for outcome measures in atopic dermatitis. <i>British Journal of Dermatology</i> , 2017, 176, 852-853.	1.4	0
1658	The challenge of skin surveillance: observe or biopsy?. <i>British Journal of Dermatology</i> , 2017, 176, 851-852.	1.4	1
1659	Declining Incidence Rates of Prostate Cancer in the United States. <i>JAMA Oncology</i> , 2017, 3, 1623.	3.4	10
1660	Neutering of pet rabbits. <i>Veterinary Record</i> , 2017, 180, 454-454.	0.2	0
1661	ACR Appropriateness Criteria® Prostate Cancer—Pretreatment Detection, Surveillance, and Staging. <i>Journal of the American College of Radiology</i> , 2017, 14, S245-S257.	0.9	44
1662	Enriching gene expression profiles will help personalize prostate cancer management for African-Americans: A perspective. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 315-321.	0.8	8
1663	Prostate cancer in black men: Is it time for personalized screening approaches?. <i>Cancer</i> , 2017, 123, 2203-2205.	2.0	2
1664	Insights from the PLCO trial about prostate cancer screening. <i>Cancer</i> , 2017, 123, 546-548.	2.0	2
1665	Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. <i>Cancer</i> , 2017, 123, 592-599.	2.0	178
1666	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. <i>Annals of Oncology</i> , 2017, 28, 1098-1104.	0.6	42
1667	What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e977-e985.	0.9	4
1668	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	3.4	120
1669	Updated Review of Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1192-1208.	1.1	64
1670	PSA. , 2017, , 451-458.		0
1671	Updates on the diagnosis and treatment of prostate cancer. <i>British Journal of Radiology</i> , 2017, 90, 20170180.	1.0	14
1672	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. <i>Medical Decision Making</i> , 2017, 37, 815-826.	1.2	12
1673	Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations. <i>American Journal of Preventive Medicine</i> , 2017, 53, 533-536.	1.6	1

#	ARTICLE	IF	CITATIONS
1674	Prostate Cancer Screening. <i>Seminars in Oncology Nursing</i> , 2017, 33, 156-164.	0.7	17
1675	When public health intervention is not successful: Cost sharing, crowd-out, and selection in Korea's National Cancer Screening Program. <i>Journal of Health Economics</i> , 2017, 53, 100-116.	1.3	12
1676	Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 251-258.	2.0	82
1677	Malignant Mesothelioma Biomarkers. <i>Chest</i> , 2017, 152, 143-149.	0.4	72
1678	The Conception and Evaluation of Sexual Health Literature. <i>Sexual Medicine Reviews</i> , 2017, 5, 135-145.	1.5	3
1679	Comparison of DRE and PSA in the Detection of Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, S208-S209.	0.2	3
1680	Breast, prostate, and thyroid cancer screening tests and overdiagnosis. <i>Current Problems in Cancer</i> , 2017, 41, 71-79.	1.0	14
1681	The Language of Stewardship: Is the "Low-Value" Label Overused?. <i>Mayo Clinic Proceedings</i> , 2017, 92, 11-14.	1.4	2
1682	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
1683	Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer. <i>Molecular Medicine Reports</i> , 2017, 16, 6443-6458.	1.1	10
1684	Current Role of Magnetic Resonance Imaging in Prostate Cancer. <i>Current Radiology Reports</i> , 2017, 5, 1.	0.4	1
1685	Vasectomy and Risk of Prostate Cancer in a Screening Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1653-1659.	1.1	9
1686	African-American Prostate Cancer Disparities. <i>Current Urology Reports</i> , 2017, 18, 81.	1.0	77
1687	New surgical approaches for clinically high-risk or metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1013-1031.	1.1	9
1688	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017, 167, 449.	2.0	160
1689	Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms. <i>Annals of Internal Medicine</i> , 2017, 167, 509.	2.0	28
1690	Prevalence and associations of general practitioners' ordering of "non-symptomatic" prostate-specific antigen tests: A cross-sectional analysis. <i>International Journal of Clinical Practice</i> , 2017, 71, e12998.	0.8	3
1691	Early Stage Cancer in Older Adults. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	1.0	9

#	ARTICLE	IF	CITATIONS
1692	Cancer Screening in the Elderly. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 246-253.	1.0	34
1693	Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. <i>Cancer</i> , 2017, 123, 4139-4146.	2.0	8
1694	Perceptions and knowledge about prostate cancer and attitudes towards prostate cancer screening among male teachers in the Sunyani Municipality, Ghana. <i>African Journal of Urology</i> , 2017, 23, 184-191.	0.1	22
1695	PatologĂa prostĂtica. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017, 24, 1-40.	0.0	0
1696	Development of carbon-graphene-based aptamer biosensor for EN2 protein detection. <i>Analytical Biochemistry</i> , 2017, 534, 99-107.	1.1	40
1697	Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 663.e1-663.e7.	0.8	24
1698	Barbershop Prostate Cancer Education: Factors Associated With Client Knowledge. <i>American Journal of Men's Health</i> , 2017, 11, 1415-1425.	0.7	7
1700	Controversies in PSA screening. <i>Evidence-Based Medicine</i> , 2017, 22, 198-198.	0.6	5
1701	Increased expression of tumor protein D54 is associated with clinical progression and poor prognosis in patients with prostate cancer. <i>Oncology Letters</i> , 2017, 14, 7739-7744.	0.8	5
1703	The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 424-429.	2.0	19
1704	Managing BRCA Mutation Carriers. , 2017, , .		0
1705	NIR Ratiometric Luminescence Detection of pH Fluctuation in Living Cells with Hemicyanine Derivative-Assembled Upconversion Nanophosphors. <i>Analytical Chemistry</i> , 2017, 89, 8863-8869.	3.2	65
1706	Telomeres and telomerase in prostate cancer development and therapy. <i>Nature Reviews Urology</i> , 2017, 14, 607-619.	1.9	85
1707	Increased PSA expression on prostate cancer exosomes in in-vitro condition and in cancer patients. <i>Cancer Letters</i> , 2017, 403, 318-329.	3.2	196
1708	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	1.2	12
1709	Quantification of microRNAs directly from body fluids using a base-stacking isothermal amplification method in a point-of-care device. <i>Biomedical Microdevices</i> , 2017, 19, 45.	1.4	7
1710	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. <i>Journal of Urology</i> , 2017, 197, 1041-1047.	0.2	23
1711	Re: Reevaluating PSA Testing Rates in the PLCO Trial. <i>European Urology</i> , 2017, 71, 300.	0.9	1

#	ARTICLE	IF	CITATIONS
1712	Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. <i>Journal of Urology</i> , 2017, 197, 1014-1019.	0.2	20
1713	Active Surveillance: A Ten-year Journey. <i>European Urology</i> , 2017, 72, 542-543.	0.9	3
1714	Bioresponsive materials. <i>Nature Reviews Materials</i> , 2017, 2, .	23.3	1,117
1715	A Cost-Utility Analysis of Prostate Cancer Screening in Australia. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 95-111.	1.0	12
1716	Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 1343-1350.	0.8	6
1717	Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. <i>Journal of Urology</i> , 2017, 197, 363-368.	0.2	20
1718	The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race. <i>Journal of the National Medical Association</i> , 2017, 109, 49-54.	0.6	4
1720	Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center. <i>Urology</i> , 2017, 100, 169-174.	0.5	0
1721	Gleason Score ≥ 6 Prostate Cancer at Radical Prostatectomy: Does a High-Risk Setting Truly Exist? A Recursive Partitioning Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 242-247.	0.9	3
1722	Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. <i>BJU International</i> , 2017, 119, 298-304.	1.3	15
1723	Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 174-180.	1.0	4
1724	Urologists' Current Practices in Screening and Treating Men With a Family History of Prostate Cancer. <i>Urology</i> , 2017, 99, 180-185.	0.5	8
1725	Cancer Biomarker Immunosensing Monitoring Strategies via Graphene Surface-Engineered Materials. , 2017, , 59-81.		1
1726	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017, 37, 296-304.	1.8	29
1727	Early Stage Cancer in Older Adults: Prostate "Avoiding Overtreatment and Undertreatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	1.0	6
1728	Mathematical model for pancreatic cancer progression using non-constant gene mutation rate. , 2017, , .		2
1729	"Researching the Research" in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. <i>Current Urology</i> , 2017, 11, 26-35.	0.4	8
1731	Cancer Screening in Patients with End-Stage Renal Disease: An Individualized Approach. <i>Journal of Onco-Nephrology</i> , 2017, 1, 36-41.	0.3	0

#	ARTICLE	IF	CITATIONS
1732	Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening. Cancer Journal (Sudbury, Mass), 2017, 23, 246-253.	1.0	13
1733	9 Prebiopsy MRI and MRI-Targeted Biopsy. , 2017, , .		1
1734	Spatial-temporal analysis of prostate cancer incidence from the Pennsylvania Cancer Registry, 2000-2011. Geospatial Health, 2017, 12, 611.	0.3	3
1735	Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Canadian Urological Association Journal, 2017, 11, 298-309.	0.3	55
1736	PSA screening for prostate cancer. Revista Da Associa�o M�dica Brasileira, 2017, 63, 722-725.	0.3	8
1737	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. International Journal of Molecular Sciences, 2017, 18, 2023.	1.8	8
1738	Update on Screening for Urological Malignancies. Rambam Maimonides Medical Journal, 2017, 8, e0041.	0.4	7
1739	Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices. Canadian Urological Association Journal, 2017, 11, 396-403.	0.3	10
1740	The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. Biomolecules, 2017, 7, 15.	1.8	92
1741	Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference?. International Journal of Environmental Research and Public Health, 2017, 14, 270.	1.2	40
1742	Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-na�ve patients. Minerva Urology and Nephrology, 2017, 69, 589-595.	1.3	6
1743	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. Tumori, 2017, 103, 292-298.	0.6	1
1744	Next-generation prostate cancer risk calculator for primary care physicians. Canadian Urological Association Journal, 2017, 12, E64-70.	0.3	8
1745	Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance. PLoS ONE, 2017, 12, e0186026.	1.1	6
1747	miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. Frontiers in Bioscience - Landmark, 2017, 22, 212-229.	3.0	14
1748	Metastatic prostate cancer in the modern era of PSA screening. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 416-421.	0.7	1
1749	Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies <i>TANGO2</i> , <i>OR5H14</i> , and <i>CHAD</i> as new prostate cancer susceptibility genes. Oncotarget, 2017, 8, 1495-1507.	0.8	11
1750	EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget, 2017, 8, 49329-49337.	0.8	105

#	ARTICLE	IF	CITATIONS
1751	Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice. <i>Canadian Urological Association Journal</i> , 2017, 12, E53-8.	0.3	8
1752	A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason $\geq 3+4$ Prostate Cancer on Biopsy. <i>Journal of Cancer</i> , 2017, 8, 2554-2560.	1.2	3
1755	Role of mpMRI of the prostate in screening for prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 464-471.	0.6	22
1756	Prostate Problems. , 2018, , 477-490.		1
1757	Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device. <i>Analytical Chemistry</i> , 2018, 90, 3744-3751.	3.2	46
1758	Developing DNA methylation-based diagnostic biomarkers. <i>Journal of Genetics and Genomics</i> , 2018, 45, 87-97.	1.7	41
1759	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 883.	3.8	296
1760	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. <i>EPMA Journal</i> , 2018, 9, 77-102.	3.3	184
1761	Prostate cancer screening: Beliefs and practices of the Brazilian physicians with different specialties. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 508-513.	0.9	2
1762	Less Is More: A Minimalist Approach to Endoscopy. <i>Gastroenterology</i> , 2018, 154, 1993-2003.	0.6	18
1763	Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA $4 \leq 10$ ng/mL. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 461-466.	0.8	9
1764	The Clinical Course of Patients With Prostate-Specific Antigen ≥ 100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening. <i>Urology</i> , 2018, 117, 101-107.	0.5	3
1765	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 310.e7-310.e13.	0.8	19
1766	Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. <i>Scientific Reports</i> , 2018, 8, 5539.	1.6	50
1767	Randomized trials and evidence in medicine: A commentary on Deaton and Cartwright. <i>Social Science and Medicine</i> , 2018, 210, 32-36.	1.8	10
1770	Prostate Cancer Screening. <i>Medical Clinics of North America</i> , 2018, 102, 199-214.	1.1	134
1771	Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. <i>BMJ Open</i> , 2018, 8, e019409.	0.8	8
1772	Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. <i>Cancer</i> , 2018, 124, 1752-1759.	2.0	12

#	ARTICLE	IF	CITATIONS
1773	Safety and Efficacy of Prostatic Artery Chemoembolization for Prostate Cancer—Initial Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 298-305.	0.2	32
1774	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. <i>Radiologic Clinics of North America</i> , 2018, 56, 187-196.	0.9	13
1775	Prostatectomy—based validation of combined urine and plasma test for predicting high grade prostate cancer. <i>Prostate</i> , 2018, 78, 294-299.	1.2	5
1776	Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. <i>Modern Pathology</i> , 2018, 31, 143-155.	2.9	38
1777	What predicts emotional response in men awaiting prostate biopsy?. <i>BMC Urology</i> , 2018, 18, 27.	0.6	12
1778	Benefits and Challenges of Lung Cancer Screening in Older Adults. <i>Clinical Therapeutics</i> , 2018, 40, 526-534.	1.1	20
1779	Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States. <i>Annals of Family Medicine</i> , 2018, 16, 139-144.	0.9	21
1780	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
1781	Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening. <i>Health Care Management Science</i> , 2018, 21, 105-118.	1.5	24
1782	A Survey of the Knowledge of African-American Women About Prostate Cancer Screening. <i>Journal of Cancer Education</i> , 2018, 33, 1115-1119.	0.6	5
1783	News Media Analysis of the United States Preventive Services Task Force and American Urological Association Prostate Cancer Screening Guidelines. <i>Urology Practice</i> , 2018, 5, 24-30.	0.2	2
1784	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. <i>European Urology Focus</i> , 2018, 4, 1002-1004.	1.6	4
1786	The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2763-2786.	1.2	78
1787	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	1.2	23
1788	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	2.3	29
1789	Energy Balance and Prostate Cancer. <i>Energy Balance and Cancer</i> , 2018, , .	0.2	0
1791	Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 947-953.	0.2	47
1792	Prostate cancer prevention with 5-alpha reductase inhibitors. <i>Current Opinion in Urology</i> , 2018, 28, 42-45.	0.9	24

#	ARTICLE	IF	CITATIONS
1793	Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. <i>Cancer</i> , 2018, 124, 507-513.	2.0	6
1794	Germline BRCA mutation in male carriersâ€”ripe for precision oncology?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 48-56.	2.0	13
1795	Metastatic prostate cancer incidence in Australia after amendment to prostateâ€”specific antigen screening guidelines. <i>ANZ Journal of Surgery</i> , 2018, 88, E589-E593.	0.3	7
1796	Prostate cancer diagnosis and characterization with mass spectrometry imaging. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 297-305.	2.0	19
1797	Revisiting Prostate Cancer Screening Practices Among Vermont Primary Care Physicians. <i>Journal of Community Health</i> , 2018, 43, 33-37.	1.9	1
1798	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018, 36, 937-941.	0.8	7
1799	Rastreamento populacional para o cÃ¢ncer de prÃ³stata: mais riscos que benefÃ©cios. <i>Physis</i> , 2018, 28, .	0.1	4
1800	The prostate cancer focal therapy. <i>Gland Surgery</i> , 2018, 7, 89-102.	0.5	15
1801	Screening for prostate cancer: are organized screening programs necessary?. <i>Translational Andrology and Urology</i> , 2018, 7, 4-11.	0.6	11
1802	LXRs, SHP, and FXR in Prostate Cancer: Enemies or MÃ©nage Ã Quatre With AR?. <i>Nuclear Receptor Signaling</i> , 2018, 15, 155076291880107.	1.0	9
1803	Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a high-volume center experience. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 588-593.	3.9	5
1804	Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 495-502.	0.4	15
1805	Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1). <i>Annals of Internal Medicine</i> , 2018, 168, 609.	2.0	4
1806	Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1). <i>Annals of Internal Medicine</i> , 2018, 168, 610.	2.0	10
1807	Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 185-199.	0.6	2
1808	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 230.	0.8	9
1810	Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. <i>Cell Cycle</i> , 2018, 17, 2802-2818.	1.3	51
1811	Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. <i>Frontiers in Oncology</i> , 2018, 8, 630.	1.3	72

#	ARTICLE	IF	CITATIONS
1812	Introduction to Prostate Cancer. , 2018, , 567-571.		0
1813	Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer. Oncotarget, 2018, 9, 32534-32550.	0.8	21
1814	The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature. Frontiers in Oncology, 2018, 8, 377.	1.3	18
1815	Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target. Current Urology, 2018, 12, 13-19.	0.4	4
1816	Treater to Target: A Urologist's Personal Experience with Prostate Cancer. , 2018, , 149-159.		0
1817	Prostate-specific antigen-based screening in Afro-Caribbean men: a survey of members of the Caribbean Urological Association. Ecancermedicalscience, 2018, 12, 842.	0.6	4
1818	Evaluation of Prostate Needle Biopsies. Advances in Experimental Medicine and Biology, 2018, 1096, 69-86.	0.8	1
1819	Top 20 POEMs of the Past 20 Years: A Survey of Practice-Changing Research for Family Physicians. Annals of Family Medicine, 2018, 16, 436-439.	0.9	3
1820	Der Ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis. Oncology Research and Treatment, 2018, 41, 2-26.	0.8	2
1821	Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 USPSTF PSA screening recommendations. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 697-703.	0.7	1
1822	The Relationship of Health Insurance and Mortality. Annals of Internal Medicine, 2018, 168, 604.	2.0	0
1823	The Relationship of Health Insurance and Mortality. Annals of Internal Medicine, 2018, 168, 605.	2.0	1
1824	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2018, 168, 606.	2.0	1
1825	Genetics and biology of prostate cancer. Genes and Development, 2018, 32, 1105-1140.	2.7	434
1826	MPCaD: a multi-scale radiomics-driven framework for automated prostate cancer localization and detection. BMC Medical Imaging, 2018, 18, 16.	1.4	43
1827	Increased levels of serum miR-148a-3p are associated with prostate cancer. Apmis, 2018, 126, 722-731.	0.9	32
1828	Study on Correlation between Serum Prostate Specific Antigen and Various Prostatic Pathology. Nepalese Medical Journal, 2018, 1, 70-73.	0.0	1
1829	The pendulum swings back: Screening for prostate cancer in 2018. Cancer, 2018, 124, 2690-2692.	2.0	1

#	ARTICLE	IF	CITATIONS
1830	New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients. <i>Urology</i> , 2018, 118, 119-126.	0.5	13
1832	PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. <i>Cancer</i> , 2018, 124, 2733-2739.	2.0	49
1833	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 297-316.	157.7	433
1834	Hyaluronic acid and hyaluronidase as possible novel urine biomarkers for the diagnosis of prostate cancer. <i>Medical Oncology</i> , 2018, 35, 97.	1.2	13
1835	Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population. <i>Health Equity</i> , 2018, 2, 55-61.	0.8	10
1837	Tissue proteomics studies in the investigation of prostate cancer. <i>Expert Review of Proteomics</i> , 2018, 15, 593-611.	1.3	8
1838	Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 366.e1-366.e9.	0.8	15
1839	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
1840	Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer. <i>Cancers</i> , 2018, 10, 249.	1.7	88
1841	Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer risk stratification. <i>Oncology Letters</i> , 2018, 16, 1357-1365.	0.8	20
1842	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 605.	2.0	0
1843	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 606.	2.0	0
1844	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 608.	2.0	1
1845	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 608.	2.0	16
1847	A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. <i>Cancer Informatics</i> , 2018, 17, 117693511878626.	0.9	3
1848	Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use. <i>Journal of the National Medical Association</i> , 2018, 110, 491-500.	0.6	6
1849	Current guidelines for prostate cancer screening: A systematic review and minimal core proposal. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 290-296.	0.3	5
1851	Screening for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1901.	3.8	876

#	ARTICLE	IF	CITATIONS
1852	Prostate-Specific Antigen-Based Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 1914.	3.8	367
1853	Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer, 2018, 18, 84.	1.1	30
1854	Evaluation and Treatment for Older Men with Elevated PSA. , 2018, , 21-41.		0
1855	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2018, 168, 607.	2.0	1
1856	Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. BMC Urology, 2018, 18, 69.	0.6	7
1857	RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine, 2018, 32, 234-244.	2.7	60
1858	A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 845-857.	1.1	118
1859	Evaluation of a Computer-Based Decision Aid for Promoting Informed Prostate Cancer Screening Decisions Among African American Men: iDecide. American Journal of Health Promotion, 2019, 33, 267-278.	0.9	35
1860	How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017. European Urology, 2019, 75, 25-31.	0.9	8
1861	Cost analysis of prostate cancer detection including the prostate health index (phi). World Journal of Urology, 2019, 37, 481-487.	1.2	11
1862	Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy. Cancers, 2019, 11, 1165.	1.7	10
1863	Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies. PLoS ONE, 2019, 14, e0221051.	1.1	18
1864	Screening of Prostate Cancer. , 2019, , 97-108.		0
1865	Patterns of prostate-specific antigen testing by remoteness of residence and socioeconomic status: An Australian population-based study. Australian Journal of Rural Health, 2019, 27, 216-223.	0.7	9
1866	A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 478-485.	0.7	3
1867	Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer Research, 2019, 79, 4592-4598.	0.4	16
1868	New Insights into the Epidemiology of Prostate Cancer in Ontario. Cancer Investigation, 2019, 37, 513-523.	0.6	0
1871	Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives. International Journal of Urology, 2019, 26, 1099-1105.	0.5	2

#	ARTICLE	IF	CITATIONS
1872	Long non-coding RNAs in prostate cancer: Functional roles and clinical implications. <i>Cancer Letters</i> , 2019, 464, 37-55.	3.2	56
1873	Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	28
1874	Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. <i>Cancers</i> , 2019, 11, 1449.	1.7	73
1875	Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 801.	1.3	205
1876	Simultaneous multiplexed detection of exosomal microRNAs and surface proteins for prostate cancer diagnosis. <i>Biosensors and Bioelectronics</i> , 2019, 146, 111749.	5.3	104
1877	Obstacles in prostate cancer screening: Current issues and future solutions. <i>Journal of Clinical Urology</i> , 2019, 12, 111-116.	0.1	0
1878	5 α -Reductase Inhibitor Use in Patients With Prostate Cancerâ€”Reply. <i>JAMA Internal Medicine</i> , 2019, 179, 1440.	2.6	0
1879	5 α -Reductase Inhibitor Use in Patients With Prostate Cancer. <i>JAMA Internal Medicine</i> , 2019, 179, 1440.	2.6	1
1880	Genomics of Prostate Cancer: What Nurses Need to Know. <i>Seminars in Oncology Nursing</i> , 2019, 35, 79-92.	0.7	4
1881	Behavioral economics and health-care markets. <i>Handbook of Behavioral Economics</i> , 2019, 2, 459-502.	3.7	21
1882	Enzymatic radiosynthesis of a ¹⁸ F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA). <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 1480-1486.	1.5	12
1883	<p>Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3079-3097.	0.9	12
1884	Prostate cancer screening: guidelines review and laboratory issues. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1474-1487.	1.4	31
1885	<p>The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: a prospective caseâ€“control cohort study in an Iranian population</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4549-4556.	0.9	11
1886	Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) â€“ A retrospective study. <i>PLoS ONE</i> , 2019, 14, e0217879.	1.1	2
1887	Epidemiology of Prostate Cancer. <i>World Journal of Oncology</i> , 2019, 10, 63-89.	0.6	1,503
1888	Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001â€“2010. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1331-1338.	1.1	10
1889	Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening. <i>International Journal of Urology</i> , 2019, 26, 956-970.	0.5	43

#	ARTICLE	IF	CITATIONS
1890	ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2802.	1.8	18
1891	Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 50-60.	1.8	4
1892	Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. <i>Prostate</i> , 2019, 79, 1099-1105.	1.2	18
1893	How to choose proper local treatment in men aged ≥ 75 years with cT2 localized prostate cancer?. <i>Cancer Medicine</i> , 2019, 8, 3370-3378.	1.3	4
1895	Kallikrein-related peptidase 3 common genetic variant and the risk of prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 14822-14830.	1.2	4
1896	A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1813.	1.8	96
1897	Overdiagnosis and overimaging: an ethical issue for radiological protection. <i>Radiologia Medica</i> , 2019, 124, 714-720.	4.7	26
1898	Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential. <i>Frontiers in Endocrinology</i> , 2019, 10, 65.	1.5	10
1899	<p><p>Research status and progress of the RNA or protein biomarkers for prostate cancer</p><p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2123-2136.	1.0	9
1900	Are Men Making Informed Decisions According to the Prostate-Specific Antigen Test Guidelines? Analysis of the 2015 Behavioral Risk Factor Surveillance System. <i>American Journal of Men's Health</i> , 2019, 13, 155798831983484.	0.7	12
1901	Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 184-210.	157.7	448
1902	epiCaPtire: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 2019, 1-18.	1.5	27
1903	Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. <i>Nature Reviews Urology</i> , 2019, 16, 302-317.	1.9	86
1904	Analysis of annexin 7 gene of malignant prostatic hyperplasia-induced male wistar rats in the presence of <i>Annona muricata</i> . <i>Journal of Taibah University for Science</i> , 2019, 13, 460-467.	1.1	2
1905	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15
1906	Cancer Screening. , 2019, , 35-67.		0
1907	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019, 76, 43-51.	0.9	359
1908	Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions. <i>European Journal of Radiology</i> , 2019, 114, 38-44.	1.2	42

#	ARTICLE	IF	CITATIONS
1909	Prostate care and prostate cancer from the perspectives of undiagnosed men: a systematic review of qualitative research. <i>BMJ Open</i> , 2019, 9, e022842.	0.8	8
1910	Australian ultrasound-guided biopsy trends: a 17-year analysis of national data. <i>Prostate International</i> , 2019, 7, 150-155.	1.2	4
1911	High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. <i>Brachytherapy</i> , 2019, 18, 793-799.	0.2	8
1912	Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men. <i>JAMA Oncology</i> , 2019, 5, 60.	3.4	40
1913	Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer. <i>Revista Espanola De Patologia</i> , 2019, 52, 20-26.	0.6	3
1914	A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 50-79.	157.7	84
1915	Determination of prostate cancer biomarker acid phosphatase at a copper phthalocyanine-modified screen printed gold transducer. <i>Analytica Chimica Acta</i> , 2019, 1057, 98-105.	2.6	21
1916	Prostate Cancer Research at the Crossroads. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a036277.	2.9	3
1917	Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy. <i>World Journal of Urology</i> , 2019, 37, 1321-1328.	1.2	1
1918	Nanocomposite materials for prosthetic devices. , 2019, , 127-144.		10
1919	Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer. <i>JAMA Oncology</i> , 2019, 5, 556.	3.4	24
1920	Exnovation of Low Value Care: A Decade of Prostate-specific Antigen Screening Practices. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 29-36.	1.3	9
1921	Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. <i>BJU International</i> , 2019, 123, 854-860.	1.3	73
1922	The Effect of Educational Program Based on PRECEDE Model in Promoting Prostate Cancer Screening in a Sample of Iranian Men. <i>Journal of Cancer Education</i> , 2019, 34, 161-172.	0.6	23
1923	Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. <i>Aging Male</i> , 2020, 23, 81-92.	0.9	58
1924	Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20 ng/ml?. <i>Aging Male</i> , 2020, 23, 860-864.	0.9	4
1925	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. <i>European Urology Focus</i> , 2020, 6, 273-279.	1.6	8
1926	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 640-647.	2.6	15

#	ARTICLE	IF	CITATIONS
1927	Decision models for distinguishing between clinically insignificant and significant tumors in prostate cancer biopsies: an application of Bayesâ€™ Theorem to reduce costs and improve outcomes. <i>Health Care Management Science</i> , 2020, 23, 102-116.	1.5	2
1928	Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 565-591.	1.2	12
1929	SFFSâ€™SVM based prostate carcinoma diagnosis in DCE-MRI via ACM segmentation. <i>Multidimensional Systems and Signal Processing</i> , 2020, 31, 689-710.	1.7	3
1930	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. <i>Nature Reviews Urology</i> , 2020, 17, 41-61.	1.9	207
1931	Fighting diagnostic and therapeutic nihilism in the elderly with cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1324-1332.	0.5	7
1932	Prostate cancer and the role of biomarkers. <i>Abdominal Radiology</i> , 2020, 45, 2120-2132.	1.0	13
1933	Biomarkers for prostate cancer: prostate-specific antigen and beyond. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 326-339.	1.4	123
1934	Broadâ€™and narrowâ€™sense validity performance of three polygenic risk score methods for prostate cancer risk assessment. <i>Prostate</i> , 2020, 80, 83-87.	1.2	8
1935	Longâ€™term consequences of the USPSTF Grade D recommendation for prostateâ€™specific antigen screening. <i>Cancer</i> , 2020, 126, 694-696.	2.0	9
1936	Modeling the overdetection of screenâ€™identified cancers in populationâ€™based cancer screening with the Coxian phaseâ€™type Markov process. <i>Statistics in Medicine</i> , 2020, 39, 660-673.	0.8	6
1937	Towards Wiser Use and Interpretation of <i>P</i> Values. <i>Journal of Sexual Medicine</i> , 2020, 17, 1-3.	0.3	3
1938	Progress in cancer biomarkers monitoring strategies using graphene modified support materials. <i>Talanta</i> , 2020, 210, 120669.	2.9	38
1939	Statistical issues and methods in designing and analyzing survival studies. <i>Cancer Reports</i> , 2020, 3, e1176.	0.6	5
1940	Conceptual review of key themes in treating prostate cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2020, 11, 893-898.	0.5	1
1941	Economic burden of illness associated with localized prostate cancer in the United States. <i>Future Oncology</i> , 2020, 16, 4265-4277.	1.1	14
1942	Screening and Early Detection. , 2020, , 375-398.e7.		1
1943	Optimal Starting Age and Baseline Level for Repeat Tests: Economic Concerns of PSA Screening for Chinese Men â€™ 10-Year Experience of a Single Center. <i>Urologia Internationalis</i> , 2020, 104, 230-238.	0.6	7
1944	Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study. <i>International Journal of Clinical Practice</i> , 2020, 74, e13447.	0.8	4

#	ARTICLE	IF	CITATIONS
1945	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.	2.0	64
1946	Age dependence of modern clinical risk groups for localized prostate cancer—A population-based study. <i>Cancer</i> , 2020, 126, 1691-1699.	2.0	25
1947	Initial experience with SelectMDx® in the diagnosis of prostate cancer in a real-world evidence clinical practice setting. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 400-407.	0.2	0
1948	Cancer control in Ghana: A narrative review in global context. <i>Heliyon</i> , 2020, 6, e04564.	1.4	10
1949	Non-invasive prostate cancer screening using chemometric processing of macro and trace element concentration profiles in urine. <i>Microchemical Journal</i> , 2020, 159, 105464.	2.3	4
1950	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020, 11, 3905.	5.8	28
1951	<p>Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5667-5676.	0.9	15
1952	Liquid Biopsy to Detect DNA/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction. <i>Frontiers in Oncology</i> , 2020, 10, 778.	1.3	10
1953	Prostate cancer screening and treatment: where have we come from and where are we going?. <i>BJU International</i> , 2020, 126, 218-224.	1.3	39
1954	The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0237332.	1.1	9
1955	Cancer Screening in Older Adults. <i>Medical Clinics of North America</i> , 2020, 104, 989-1006.	1.1	7
1956	Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2454-2462.	1.1	12
1958	Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma. <i>Journal of Laboratory Physicians</i> , 2020, 12, 44-48.	0.4	3
1959	Multiparametric MRI of Prostate Cancer: Recent Advances. <i>Current Radiology Reports</i> , 2020, 8, 1.	0.4	3
1960	Advances in the diagnostic options for prostate cancer. <i>Postgraduate Medicine</i> , 2020, 132, 52-62.	0.9	1
1961	Cancer Screening Among Older Adults: a Geriatrician's Perspective on Breast, Cervical, Colon, Prostate, and Lung Cancer Screening. <i>Current Oncology Reports</i> , 2020, 22, 108.	1.8	16
1962	Effects of Radiotherapy or Radical Prostatectomy on the Risk of Long-Term Heart-Specific Death in Patients With Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 592746.	1.3	4
1963	General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands. <i>BMC Family Practice</i> , 2020, 21, 270.	2.9	5

#	ARTICLE	IF	CITATIONS
1964	Public health nudges: weighing individual liberty and population health benefits. <i>Journal of Medical Ethics</i> , 2020, 47, medethics-2020-106077.	1.0	1
1965	Current Knowledge and Opinions of Medical Trainees Regarding PSA Screening. <i>Journal of Cancer Education</i> , 2020, , 1.	0.6	1
1966	EDITORIAL COMMENT. <i>Urology</i> , 2020, 145, 195-196.	0.5	0
1967	Screening Tests. , 2020, , 250-279.		0
1968	Is there a non-linear relationship between dietary protein intake and prostate-specific antigen: proof from the national health and nutrition examination survey (2003â€”2010). <i>Lipids in Health and Disease</i> , 2020, 19, 82.	1.2	7
1969	Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	0.9	18
1970	Does screening for prostate cancer improve cancerâ€”specific mortality in Asian men? Realâ€”world data in Yokosuka City 15 years after introducing PSAâ€”based population screening. <i>Prostate</i> , 2020, 80, 824-830.	1.2	11
1971	Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. <i>Translational Andrology and Urology</i> , 2020, 9, 196-209.	0.6	12
1972	Cancer Screening in Patients Undergoing Maintenance Dialysis: Who, What, and When. <i>American Journal of Kidney Diseases</i> , 2020, 76, 558-566.	2.1	9
1973	Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. <i>British Journal of Cancer</i> , 2020, 123, 487-494.	2.9	17
1974	Predictors of prostateâ€”specific antigen testing in men aged â‰¥55Â”years: A crossâ€”sectional study based on patientâ€”reported outcomes. <i>International Journal of Urology</i> , 2020, 27, 711-718.	0.5	2
1975	Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression. <i>BMC Cancer</i> , 2020, 20, 555.	1.1	3
1976	Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants. <i>Clinical Breast Cancer</i> , 2020, 20, 300-306.	1.1	0
1977	Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review. <i>Annals of Medicine and Surgery</i> , 2020, 56, 110-115.	0.5	17
1978	Hacia un cribado personalizado del cÃ¡ncer de prÃ³stata. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	3
1979	Genomics to personalize care of prostate cancer. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 106-108.	0.5	1
1980	Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 636.e13-636.e19.	0.8	2
1981	The golden rule: Do not do to others what you do not want done to yourself. <i>Cancer</i> , 2020, 126, 2319-2320.	2.0	2

#	ARTICLE	IF	CITATIONS
1982	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	2.0	29
1983	Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years. JAMA Network Open, 2020, 3, e1919284.	2.8	33
1985	A discussion on controversies and ethical dilemmas in prostate cancer screening. Journal of Medical Ethics, 2021, 47, 152-158.	1.0	11
1986	Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey. Journal of Community Health, 2021, 46, 389-398.	1.9	5
1987	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Journal of the National Cancer Institute, 2021, 113, 719-726.	3.0	45
1989	Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry. Prostate International, 2021, 9, 12-17.	1.2	10
1991	Value of MRI texture analysis for predicting high-grade prostate cancer. Clinical Imaging, 2021, 72, 168-174.	0.8	7
1992	Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis. Urology, 2021, 148, 1-3.	0.5	1
1993	Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). Urology, 2021, 149, 110-116.	0.5	4
1994	Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network. Journal of General Internal Medicine, 2021, 36, 92-99.	1.3	10
1995	Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. European Urology Focus, 2021, 7, 86-94.	1.6	28
1996	Overdiagnosis in urologic cancer. World Journal of Urology, 2022, 40, 1-8.	1.2	14
1997	A Machine Learning-Driven Approach to Predict the Outcome of Prostate Biopsy: Identifying Cancer, Clinically Significant Disease, and Unfavorable Pathological Features on Prostate Biopsy. Transactions on Computational Science and Computational Intelligence, 2021, , 591-600.	0.3	0
1998	The Role of E-Health Interventions in Improving Clinical Outcomes and Overall Health for Prostate Cancer Patients. Advances in Medical Technologies and Clinical Practice Book Series, 2021, , 144-171.	0.3	0
1999	Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JAMA Network Open, 2021, 4, e2032072.	2.8	18
2000	The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy. Investigative and Clinical Urology, 2021, 62, 438-446.	1.0	0
2001	Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy. World Journal of Surgical Oncology, 2021, 19, 5.	0.8	3
2002	Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups. Journal of Translational Medicine, 2021, 19, 46.	1.8	11

#	ARTICLE	IF	CITATIONS
2003	Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study. <i>BMC Urology</i> , 2021, 21, 20.	0.6	1
2005	Prostate cancer follow-up costs in Germany from 2000 to 2015. <i>Journal of Cancer Survivorship</i> , 2022, 16, 86-94.	1.5	5
2006	Relating prostate-specific antigen leakage with vascular tumor growth in a mathematical model of prostate cancer response to androgen deprivation. <i>Computational and Systems Oncology</i> , 2021, 1, e1014.	1.1	7
2007	Carcinoma intraductal de próstata concomitante y respuesta al tratamiento hormonal en el carcinoma de próstata metastásico. <i>Actas Urológicas Españolas</i> , 2021, 45, 455-460.	0.3	4
2008	Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer. <i>Cancers</i> , 2021, 13, 1273.	1.7	4
2009	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021, 22, 173.	0.7	4
2010	Au-Ag assembled on silica nanoprobe for visual semiquantitative detection of prostate-specific antigen. <i>Journal of Nanobiotechnology</i> , 2021, 19, 73.	4.2	23
2012	Health Checkup of Urological Disease. <i>Health Evaluation and Promotion</i> , 2021, 48, 319-324.	0.0	0
2013	Knowledge of prostate cancer presentation, etiology, and screening practices among women: a mixed-methods systematic review. <i>Systematic Reviews</i> , 2021, 10, 138.	2.5	5
2014	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1336-1342.	3.0	22
2015	Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. <i>Frontiers in Oncology</i> , 2021, 11, 681006.	1.3	4
2016	Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. <i>European Urology Open Science</i> , 2021, 27, 77-87.	0.2	1
2017	Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. <i>Cancers</i> , 2021, 13, 3064.	1.7	8
2018	Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey. <i>Frontiers in Oncology</i> , 2021, 11, 691197.	1.3	4
2019	Prostate Cancer Screening in Brazil: a single center experience in the public health system. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 558-565.	0.7	6
2020	Silver-Assembled Silica Nanoparticles in Lateral Flow Immunoassay for Visual Inspection of Prostate-Specific Antigen. <i>Sensors</i> , 2021, 21, 4099.	2.1	11
2021	Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 455-460.	0.2	1
2022	Impact of 2012 Prostate Cancer Screening Statement. <i>Journal of General Internal Medicine</i> , 2021, 36, 2854-2855.	1.3	0

#	ARTICLE	IF	CITATIONS
2024	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 3570.	1.7	9
2025	Intelligent Computer-Aided Prostate Cancer Diagnosis Systems: State-of-the-Art and Future Directions. <i>Mathematical Problems in Engineering</i> , 2021, 2021, 1-17.	0.6	1
2026	Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan. <i>Prostate</i> , 2021, 81, 1172-1178.	1.2	2
2027	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2022, 5, 18-29.	2.6	31
2028	Genetically Informed Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2021, 48, 373-386.	0.8	1
2029	Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. <i>Current Oncology Reports</i> , 2021, 23, 130.	1.8	4
2030	Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. <i>American Journal of Human Biology</i> , 2022, 34, e23665.	0.8	4
2031	Metabolomics, metabolic flux analysis and cancer pharmacology. , 2021, 224, 107827.		44
2032	Feasibility of dietary folic acid reduction intervention for men on active surveillance for prostate cancer. <i>Clinical Nutrition ESPEN</i> , 2021, 44, 270-275.	0.5	3
2033	Are outpatient transperineal prostate biopsies without antibiotic prophylaxis equivalent to standard transrectal biopsies for patient safety and cancer detection rates?A retrospective cohort study in 222 patients. <i>Patient Safety in Surgery</i> , 2021, 15, 28.	1.1	2
2034	Pathology grade influences competing mortality risks in elderly men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 493.e1-493.e7.	0.8	0
2035	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 602-617.	0.8	3
2036	Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening. <i>Urology</i> , 2021, 155, 62-69.	0.5	6
2037	Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCR. <i>Cancers</i> , 2021, 13, 4459.	1.7	5
2038	Cancer incidence in World Trade Center-exposed and non-exposed male firefighters, as compared with the US adult male population: 2001-2016. <i>Occupational and Environmental Medicine</i> , 2021, 78, 707-714.	1.3	11
2039	The Pursuit of Health Equity and Equality in Urologic Oncology: Where We Have Been and Where We Are Going. <i>European Urology Focus</i> , 2021, 7, 929-936.	1.6	1
2040	A Systematic Review of Artificial Intelligence Techniques in Cancer Prediction and Diagnosis. <i>Archives of Computational Methods in Engineering</i> , 2022, 29, 2043-2070.	6.0	68
2041	Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1211-1220.	0.4	1

#	ARTICLE	IF	CITATIONS
2042	PD50-02â€fPROSTATE SPECIFIC ANTIGEN DYNAMICS AND PROSTATE CANCER RISK: A POPULATION-BASED STUDY. Journal of Urology, 2021, 206, .	0.2	0
2043	MP30-02â€fAN AI DRIVEN APPROACH TO PREDICT THE OUTCOME OF PROSTATE BIOPSY: IDENTIFYING CANCER, CLINICALLY SIGNIFICANT DISEASE, AND UNFAVORABLE PATHOLOGICAL FEATURES ON PROSTATE BIOPSY. Journal of Urology, 2021, 206, .	0.2	0
2044	Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis. Value in Health, 2022, 25, 133-146.	0.1	8
2045	Synthetic Retinoids as Potential Therapeutics in Prostate Cancerâ€”An Update of the Last Decade of Research: A Review. International Journal of Molecular Sciences, 2021, 22, 10537.	1.8	3
2046	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open, 2021, 11, e048144.	0.8	10
2047	Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan. International Journal of Clinical Oncology, 2021, 26, 2303-2309.	1.0	0
2048	Should men undergo MRI before prostate biopsy â€“ CON. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 92-95.	0.8	1
2049	Disparities in prostate cancer diagnosis, treatment, and survival among men with disabilities: Retrospective cohort study in South Korea. Disability and Health Journal, 2021, 14, 101125.	1.6	10
2050	Targeting LIN28: a new hope in prostate cancer theranostics. Future Oncology, 2021, 17, 3873-3880.	1.1	6
2051	Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil. Value in Health Regional Issues, 2021, 26, 89-97.	0.5	1
2052	Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study. Investigative and Clinical Urology, 2021, 62, 282.	1.0	5
2053	Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?. Therapeutic Advances in Urology, 2021, 13, 175628722199718.	0.9	14
2054	Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. Archives of Internal Medicine, 2010, 170, 1390.	4.3	70
2056	Behavioral Medicine and theÂBenefits of Healthcare: A Critical Appraisal and theÂNeed for Exnovation. , 2018, , 1069-1086.		1
2057	Psychosocial Outcomes of Screening for Cancer and Pre-invasive Disease. , 2011, , 245-268.		2
2059	Nomograms in Prostate Cancer. , 2013, , 581-592.		1
2060	Transparent Communication of Health Risks. , 2013, , .		22
2061	Do International Trends in Cancer Incidence and Mortality Reflect Expectations from Cancer Screening?. Statistics in the Health Sciences, 2013, , 299-313.	0.2	1

#	ARTICLE	IF	CITATIONS
2062	Cryoablation. , 2013, , 345-353.		1
2063	Active Surveillance and Focal Therapy: A European Perspective. , 2013, , 37-52.		1
2064	Prostate Cancer Screening: Navigating the Controversy. , 2013, , 11-26.		1
2065	Prostate Cancer Prevention. , 2019, , 607-628.		1
2066	Cancer Health Disparities. , 2019, , 199-246.		2
2067	Multi-Image Texture Analysis in Classification of Prostatic Tissues from MRI. Preliminary Results. Advances in Intelligent Systems and Computing, 2014, , 139-150.	0.5	8
2068	A Multi-Parametric Diffusion Magnetic Resonance Imaging Texture Feature Model for Prostate Cancer Analysis. Mathematics and Visualization, 2014, , 79-88.	0.4	13
2070	Principles for Developing Digital Health Interventions for Prostate Cancer: A Community-Based Design Approach with African American Men. Lecture Notes in Computer Science, 2015, , 134-145.	1.0	3
2071	Cancer Overdiagnosis and Overtreatment. Current Clinical Urology, 2018, , 1-8.	0.0	2
2072	Evidence Negating the Healthy Worker Effect. , 2010, , 93-103.		2
2073	A Unifying Framework for Correspondence-Less Shape Alignment and Its Medical Applications. Communications in Computer and Information Science, 2013, , 40-52.	0.4	2
2074	Cancer Health Disparities. , 2014, , 151-193.		9
2075	Biomarker Discovery in Biological Fluids. , 2011, , 291-326.		4
2076	Cancer Screening in the U.S. and Europe: Policies, Practices, and Trends in Cancer Incidence and Mortality. , 2013, , 125-154.		2
2078	Endocrinology of the Prostate. , 2010, , 2592-2609.		2
2079	Cancer of the Prostate. , 2010, , 925-986.		2
2080	Epidemiology, Etiology, and Prevention of Prostate Cancer. , 2012, , 2704-2725.e7.		12
2081	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2

#	ARTICLE	IF	CITATIONS
2082	Testicular Disorders. , 2011, , 688-777.		15
2084	Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. Urology Practice, 2019, 6, 256-261.	0.2	5
2086	Prostate cancer: an emerging threat to the health of aging men in Asia. Asian Journal of Andrology, 2011, 13, 574-578.	0.8	69
2087	Determinants of male health: the interaction of biological and social factors. Asian Journal of Andrology, 2010, 12, 291-297.	0.8	15
2088	What we have learned from randomized trials of prostate cancer screening. Asian Journal of Andrology, 2011, 13, 369-373.	0.8	5
2089	Randomized studies of PSA screening: an opinion. Asian Journal of Andrology, 2011, 13, 364-365.	0.8	3
2090	The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian Journal of Andrology, 2012, 14, 310-315.	0.8	112
2091	Formalized prediction of clinically significant prostate cancer: is it possible?. Asian Journal of Andrology, 2012, 14, 349-354.	0.8	19
2092	Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian Journal of Andrology, 2012, 14, 355-360.	0.8	23
2093	Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian Journal of Andrology, 2012, 14, 361-364.	0.8	7
2094	Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2011, 13, 683-689.	0.8	7
2095	A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian Journal of Andrology, 2013, 15, 129-133.	0.8	35
2096	Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer. Asian Journal of Andrology, 2013, 15, 218-220.	0.8	3
2097	Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?. Asian Journal of Andrology, 2012, 14, 522-524.	0.8	5
2098	Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis. Asian Journal of Andrology, 2013, 15, 323-327.	0.8	6
2099	PSA screening for prostate cancer: why so much controversy?. Asian Journal of Andrology, 2013, 15, 603-607.	0.8	5
2100	Prostate cancer testing: a snapshot of the attitudes and practice of Australian general practitioners. Australian Journal of Primary Health, 2015, 21, 111.	0.4	5
2102	Simple Heuristics in a Social Game. , 2012, , 39-66.		3

#	ARTICLE	IF	CITATIONS
2103	Trust-Your-Doctor: A Simple Heuristic in Need of a Proper Social Environment. , 2012, , 67-102.		6
2104	The Is and Ought of Sharing: The Equality Heuristic Across the Lifespan. , 2012, , 171-196.		4
2105	When Will We Meet Again? Regularities of Social Connectivity and Their Reflections in Memory and Decision Making. , 2012, , 199-224.		6
2106	Fast Acceptance by Common Experience: Augmenting Schelling's Neighborhood Segregation Model With FACE-Recognition. , 2012, , 225-258.		1
2107	The "Less-Is-More" Effect in Group Decision Making. , 2012, , 293-318.		1
2108	Social Learning: A Route to Good Cue Orders. , 2012, , 343-354.		2
2109	The Evolutionary Rationality of Social Learning. , 2012, , 381-408.		4
2110	The Lives of Others: Social Rationality in Animals. , 2012, , 409-432.		3
2111	The Heart Has Its Reasons: Social Rationality in Mate Choice. , 2012, , 433-458.		1
2112	Can Simple Heuristics Explain Moral Inconsistencies?. , 2012, , 459-486.		1
2113	Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL. International Journal of Urology, 2017, 24, 602-609.	0.5	6
2114	Prostate specific antigen for detecting early prostate cancer. BMJ: British Medical Journal, 2009, 339, b3572-b3572.	2.4	6
2115	Screening for prostate cancer remains controversial. BMJ: British Medical Journal, 2009, 339, b3601-b3601.	2.4	40
2116	Screening for prostate cancer. BMJ: British Medical Journal, 2010, 341, c4538-c4538.	2.4	7
2117	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. BMJ Open, 2017, 7, e017729.	0.8	27
2118	Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight, 2018, 3, .	2.3	71
2119	Screening of Target Genes and Regulatory Function of miRNAs as Prognostic Indicators for Prostate Cancer. Medical Science Monitor, 2015, 21, 3748-3759.	0.5	29
2120	Declining Death Rates Reflect Progress against Cancer. PLoS ONE, 2010, 5, e9584.	1.1	194

#	ARTICLE	IF	CITATIONS
2121	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. PLoS ONE, 2011, 6, e21366.	1.1	47
2122	Regular Health Checks: Cross-Sectional Survey. PLoS ONE, 2012, 7, e33694.	1.1	8
2123	Averaged Differential Expression for the Discovery of Biomarkers in the Blood of Patients with Prostate Cancer. PLoS ONE, 2012, 7, e34875.	1.1	12
2124	Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction. PLoS ONE, 2012, 7, e39236.	1.1	11
2125	Cell-Free Circulating Plasma hTERT mRNA Is a Useful Marker for Prostate Cancer Diagnosis and Is Associated with Poor Prognosis Tumor Characteristics. PLoS ONE, 2012, 7, e43470.	1.1	74
2126	Reproducibility, Performance, and Clinical Utility of a Genetic Risk Prediction Model for Prostate Cancer in Japanese. PLoS ONE, 2012, 7, e46454.	1.1	30
2127	MicroRNA Profiling in Prostate Cancer - The Diagnostic Potential of Urinary miR-205 and miR-214. PLoS ONE, 2013, 8, e76994.	1.1	149
2128	A Novel Three Serum Phospholipid Panel Differentiates Normal Individuals from Those with Prostate Cancer. PLoS ONE, 2014, 9, e88841.	1.1	28
2129	Involving a Citizensâ€™™ Jury in Decisions on Individual Screening for Prostate Cancer. PLoS ONE, 2016, 11, e0143176.	1.1	10
2130	Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort. PLoS ONE, 2017, 12, e0168917.	1.1	7
2131	Can facts trump unconditional trust? Evidence-based information halves the influence of physiciansâ€™™ non-evidence-based cancer screening recommendations. PLoS ONE, 2017, 12, e0183024.	1.1	20
2132	Evolving Recommendations on Prostate Cancer Screening. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e80-e87.	1.8	6
2133	Towards personalized prostate cancer screening. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	1
2134	Prostate cancer screening among elderly men in Brazil: should we diagnose or not?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 34-41.	0.7	4
2135	New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough. Einstein (Sao Paulo, Brazil), 2017, 15, 7-10.	0.3	3
2137	Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 55.	0.0	6
2138	Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study. Sultan Qaboos University Medical Journal, 2018, 17, 424.	0.3	6
2139	Limited improvement in prostate cancer mortality-to-incidence ratios in countries with high health care expenditures. Aging, 2020, 12, 21308-21315.	1.4	12

#	ARTICLE	IF	CITATIONS
2140	Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms. <i>Oncotarget</i> , 2016, 7, 48038-48049.	0.8	13
2141	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. <i>Oncotarget</i> , 2016, 7, 70669-70684.	0.8	21
2142	The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. <i>Oncotarget</i> , 2016, 7, 82783-82797.	0.8	30
2143	NUSAP1 promotes invasion and metastasis of prostate cancer. <i>Oncotarget</i> , 2017, 8, 29935-29950.	0.8	55
2144	Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. <i>Oncotarget</i> , 2017, 8, 76987-76999.	0.8	14
2145	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. <i>Oncotarget</i> , 2018, 9, 6550-6561.	0.8	16
2146	The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. <i>Oncotarget</i> , 2019, 10, 6124-6137.	0.8	15
2147	Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. <i>Oncotarget</i> , 2015, 6, 40611-40621.	0.8	17
2148	Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. <i>Translational Andrology and Urology</i> , 2018, 7, 98-105.	0.6	24
2149	How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the U.S. Guideline Screening Initiation Ages. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
2150	Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer. <i>Current Medical Imaging</i> , 2019, 15, 589-594.	0.4	5
2151	Contrasting Assessed and Perceived Risk: A Case Study of Two Rapidly Increasing Cancers in Taiwan. <i>The Open Epidemiology Journal</i> , 2011, 4, 78-93.	1.0	1
2152	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
2153	Supporting Informed Decision Making for Prostate Specific Antigen (PSA) Testing on the Web: An Online Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2010, 12, e27.	2.1	69
2154	Supporting Informed Decision Making Online in 20 Minutes: An Observational Web-log Study of a PSA Test Decision Aid. <i>Journal of Medical Internet Research</i> , 2010, 12, e15.	2.1	27
2155	Cancer incidence, mortality and survival trends in Canada, 1970â€“2007. <i>Chronic Diseases and Injuries in Canada</i> , 2013, 33, 69-80.	1.4	53
2156	Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-490.	1.3	79
2157	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	1.3	70

#	ARTICLE	IF	CITATIONS
2158	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
2159	PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer. <i>Cancers</i> , 2020, 12, 398.	1.7	17
2160	Presenting Stage and Risk Group in Men Dying of Prostate Cancer. <i>Current Oncology</i> , 2020, 27, 547-551.	0.9	2
2161	The Use of Biomarkers in Prostate Cancer Screening and Treatment. <i>Reviews in Urology</i> , 2017, 19, 221-234.	0.9	51
2163	A partial differential equation model of metastasized prostatic cancer. <i>Mathematical Biosciences and Engineering</i> , 2013, 10, 591-608.	1.0	4
2164	The new data on prostate cancer screening: What should we do now?. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 446-448.	0.6	5
2165	Men's health 2018: BPH, prostate cancer, erectile dysfunction, supplements. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 871-880.	0.6	5
2166	PSA-måling og prostatakraft " overdiagnostisering og overbehandling?. <i>Tidsskrift for Den Norske Lægeforening</i> , 2013, 133, 1711-1716.	0.2	14
2167	Age appropriate screening for cancer. <i>Journal of Postgraduate Medicine</i> , 2014, 60, 318-321.	0.2	5
2168	Androgens and prostate disease. <i>Asian Journal of Andrology</i> , 2014, 16, 248.	0.8	17
2169	Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. <i>Asian Journal of Andrology</i> , 2015, 17, 475.	0.8	47
2170	Heart healthy equals prostate healthy and statins, aspirin, and/or metformin are the ideal recommendations for prostate cancer prevention. <i>Asian Journal of Andrology</i> , 2014, 17, 783-91.	0.8	7
2171	Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. <i>Asian Journal of Andrology</i> , 2016, 18, 633.	0.8	10
2172	The end of the road for prostate specific antigen testing?. <i>Nigerian Journal of Clinical Practice</i> , 2013, 16, 407.	0.2	2
2173	Prostate cancer for the internist. <i>North American Journal of Medical Sciences</i> , 2015, 7, 429.	1.7	14
2174	Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?. <i>Asian Journal of Andrology</i> , 2019, 21, 37.	0.8	8
2175	Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study. <i>Cancer Research and Treatment</i> , 2016, 48, 899-906.	1.3	30
2176	Radioresistance and Cancer Stem Cells: Survival of the Fittest. <i>Journal of Carcinogenesis & Mutagenesis</i> , 0, s1, .	0.3	10

#	ARTICLE	IF	CITATIONS
2177	Prostate cancer screening: A primary care survey. <i>Health</i> , 2010, 02, 1179-1183.	0.1	2
2178	Correlation of PSA Density to Prostate Cancer Based on Prostate Volume by 3.0 T MRI. <i>Open Journal of Urology</i> , 2011, 01, 28-36.	0.0	4
2179	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. <i>Balkan Medical Journal</i> , 2017, 34, 388-396.	0.3	5
2180	REVIEW ARTICLES PSA mass screening: is there enough evidence?. <i>Central European Journal of Urology</i> , 2012, 65, 04-06.	0.2	4
2181	Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 43-52.	0.9	12
2182	Does the reflexive measurement of free PSA have a role in a tertiary cancer centre. <i>Canadian Urological Association Journal</i> , 2010, 4, 317-320.	0.3	3
2183	Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. <i>Canadian Urological Association Journal</i> , 2012, 6, 367-373.	0.3	36
2184	The cost implications of informed decision-making: a mathematical simulation model of the potential financial effects of a web-based prostate specific antigen decision aid. <i>European Journal for Person Centered Healthcare</i> , 2013, 1, 193.	0.3	1
2185	Molecular Diagnostics in Urologic Malignancies: A Work in Progress. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 610-621.	1.2	24
2186	PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 795-803.	2.3	17
2187	Impact of PSA and DRE on Histologic Findings at Prostate Biopsy in Turkish Men Over 75 Years of Age. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6085-6088.	0.5	10
2188	Clinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On. <i>Annals of Internal Medicine</i> , 2009, 150, 647.	2.0	3
2189	PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2021, 48, e20212965.	0.3	0
2190	Characteristics of Scientific Evidence Informing Changed U.S. Preventive Services Task Force Insufficient Evidence Statements. <i>American Journal of Preventive Medicine</i> , 2021, , .	1.6	2
2191	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	5.1	48
2192	Ethnic and regional differences in the temporal trends of prostate cancer incidence and mortality in New Zealand. <i>ANZ Journal of Surgery</i> , 2021, , .	0.3	0
2193	Cholesterol-Based Nanovesicles Enhance the In Vitro Cytotoxicity, Ex Vivo Intestinal Absorption, and In Vivo Bioavailability of Flutamide. <i>Pharmaceutics</i> , 2021, 13, 1741.	2.0	5
2194	Bioinformatics Prediction and Analysis of MicroRNAs and Their Targets as Biomarkers for Prostate Cancer: A Preliminary Study. <i>Molecular Biotechnology</i> , 2022, 64, 401-412.	1.3	5

#	ARTICLE	IF	CITATIONS
2195	The Efficacy Implementation Ratio: A Conceptual Model for Understanding the Impact of Implementation Strategies Using Health Outcomes. <i>Global Implementation Research and Applications</i> , 2021, 1, 258.	0.4	0
2196	Gland context networks: a novel approach for improving prostate cancer identification. <i>Computerized Medical Imaging and Graphics</i> , 2021, 94, 101999.	3.5	0
2197	Prostate Cancer: Confessions of a Wishful Waiter. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2200	Update on the management of prostate cancer with goserelin acetate: patient perspectives. <i>Cancer Management and Research</i> , 2009, 1, 99.	0.9	0
2202	Circulating Tumor-Related DNA Alterations as Prostate Cancer Biomarkers. , 2010, , 21-27.		0
2203	What Are Some New Developments in Prostate Cancer Diagnosis?. <i>Journal of the Korean Medical Association</i> , 2010, 53, 107.	0.1	0
2206	Chemoprevention of Prostate Cancer. <i>Journal of the Nihon University Medical Association</i> , 2010, 69, 75-81.	0.0	0
2207	Controversies in Prostate Cancer. , 2010, , 229-250.		2
2208	Biología molecular en el cáncer de próstata. <i>Archivos Espanoles De Urologia</i> , 2010, 63, .	0.1	0
2209	¿Cuántos cánceres precoces de próstata es necesario detectar para prevenir un fallecimiento?. <i>Archivos Espanoles De Urologia</i> , 2010, 63, .	0.1	0
2211	Biomarkers for Detection of Intra-epithelial Neoplasia. , 2011, , 151-166.		0
2212	Population based screening - the difficulty of how to do more good than harm and how to achieve that. <i>Swiss Medical Weekly</i> , 2010, 140, w13061.	0.8	11
2213	Health Maintenance and Prevention. , 2011, , 145-157.		0
2214	MicroRNAs in Prostate Cancer: A Possible Role as Novel Biomarkers and Therapeutic Targets?. , 2011, , 145-162.		0
2215	Erkrankungen der Nieren und Harnwege. , 2011, , 529-606.		0
2218	Predicting Robotic Utilization in Urologic Disease: An Epidemiology-Based Model. , 2011, , 205-216.		0
2219	Prostate Cancer Epidemiology. , 2011, , 3025-3030.		0
2220	An integrative approach to prostate cancer. , 2011, , 701-716.		0

#	ARTICLE	IF	CITATIONS
2221	PSA screening: Is it necessary in Japan?. Health Evaluation and Promotion, 2011, 38, 789-793.	0.0	0
2223	Molecular Biology of Prostate Cancer and Emerging Diagnostic and Prognostic Biomarkers. , 2012, , 157-167.		0
2224	Mercury by the Numbers. , 2011, , 51-70.		0
2225	Uncertainty, Variability, and Resource Allocation in the Health Care Decision Process. , 2011, , .		0
2226	Patient selection essential in optimizing the benefit of radical prostatectomy for patients with organ-confined prostate cancer. Asian Journal of Andrology, 2011, 13, 789-790.	0.8	1
2228	Future of Prostate Biopsy: Who Will Get It and How?. , 0, , .		0
2229	Radical Prostatectomy in High Risk Prostate Cancer. , 0, , .		0
2230	Future Aspects of Prostate Biopsy – The Use of Primary Circulating Prostate Cells to Select Patients for Prostate Biopsy: Evidence, Utility and Cost-Benefit. , 0, , .		0
2231	How Will Health Care Reform Affect the Medically Underserved and the Safety Net Hospitals That Care for Them?. , 2011, , 73-92.		0
2233	Twenty Years and Counting: Is PSA Still Useful in 2010?. , 2012, , 13-24.		0
2234	Expectant Management of Prostate Cancer. , 2012, , 2789-2800.e2.		2
2235	Urinary Tract Disorders. , 2012, , 899-927.		1
2236	Individual and Mass Screening. , 2012, , 25-37.		0
2237	Screening and Early Detection for Genitourinary Cancer. , 2012, , 27-42.		0
2238	Early Detection, Diagnosis, and Staging of Prostate Cancer. , 2012, , 2763-2770.e7.		2
2239	Predicting High-Risk Disease Using Tissue Biomarkers. , 2012, , 23-34.		0
2240	Public Knowledge of Benefits of Breast and Prostate Cancer Screening. , 2012, , 67-78.		0
2241	Tumor Markers. , 2012, , 617-667.		1

#	ARTICLE	IF	CITATIONS
2242	Recent Developments in Prostate Cancer Screening Guidelines. Journal of Cancer Science & Therapy, 2012, 01, .	1.7	0
2245	Urologists's™ Opinion on Active Surveillance: USA Versus the Netherlands. , 2012, , 157-168.		0
2246	I rischi di una diagnostica senza limiti. , 2012, , 27-36.		0
2247	The Utility of Nomograms in Routine Clinical Practice. , 2012, , 201-213.		0
2248	The Future of Active Surveillance. , 2012, , 187-199.		0
2250	Uncertain Enthusiasm: PSA Screening, Proton Therapy and Prostate Cancer. , 2012, , 186-203.		0
2252	Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment. , 2012, , 299-326.		1
2253	Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications. , 2012, , 25-49.		0
2254	Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.. Journal of Clinical Oncology, 2012, 30, 5-5.	0.8	0
2256	The Case for Prostate Cancer Risk Reduction by 5-Alpha Reductase Inhibitors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 92-95.	1.8	0
2259	Prostate Cancer: Predictive Markers in Clinical Development. , 2013, , 69-103.		0
2260	Update in Hematology and Medical Oncology: Evidence Published in 2011. Annals of Internal Medicine, 2012, 157, 276.	2.0	0
2261	Prostate Cancer Screening or Early Diagnosis in Senior Adults?. , 2013, , 65-75.		0
2262	Urologic Oncology. , 2013, , 95-123.		0
2263	PSA Dynamics. , 2013, , 41-49.		0
2265	Is the PSA Era Over?. , 2013, , 27-39.		0
2267	Future Directions in Prostate Cancer Diagnosis. , 2013, , 363-372.		0
2268	Transrectal Saturation Biopsy. , 2013, , 285-308.		0

#	ARTICLE	IF	CITATIONS
2269	The Advice of Others: When and How We Benefit From It. , 2012, , 355-378.		0
2270	The Mind as an Intuitive Pollster: Frugal Search in Social Spaces. , 2012, , 261-292.		3
2271	Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy. , 2013, , 17-36.		0
2272	Simple Heuristics and Information Sharing in Groups. , 2012, , 319-342.		1
2273	Why Simple Heuristics Make Life Both Easier and Harder: A Socialâ€“Psychological Perspective. , 2012, , 487-516.		1
2274	Cooperate with Equals: A Simple Heuristic for Social Exchange. , 2012, , 135-170.		0
2277	Update on Diagnostic Criteria, on Biopsy and Surgical Specimen: Preinvasive Lesions, from Epithelial Cell Hyperplasia to Carcinoma In Situ and Invasive Carcinoma â€“ First-Line Immuno-Phenotyping of Prostate Diseases. , 2013, , 3-42.		0
2281	Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Translational Medicine (Sunnyvale, Calif), 2013, 01, 005.	0.4	5
2282	Prostate cancer patientâ€™s survival in Lithuania. Acta Medica Lituanica, 2013, 19, 439-444.	0.2	0
2283	The Role of miR-21, an Androgen-Regulated MicroRNA, in Prostate Cancer. , 2013, , 285-305.		1
2284	PSA. , 2013, , 1-8.		0
2285	Prostate Disease. , 2013, , 686-691.		0
2286	Management and Prevention of Urological Diseases in Men. , 2013, , 391-404.		0
2288	The role of prostate-specific antigen (PSA) testing in screening for prostate cancer. University of Western Ontario Medical Journal, 2013, 82, 17-18.	0.1	1
2289	The role of surgery as active treatment for high risk localized prostate cancer seen from an epidemiological perspective. OA Epidemiology, 2013, 1, .	0.2	0
2290	Introduction to Prostate Cancer. , 2014, , 553-557.		0
2291	PET/CT for Interventional Use. , 2014, , 225-232.		2
2293	The Dilemma of Early Diagnosis for a Clinically Relevant Prostate Cancer: The Role of Urologist. , 2014, , 43-55.		0

#	ARTICLE	IF	CITATIONS
2294	Cribado poblacional y detección precoz. , 2014, , 7-8.		0
2295	Prostate Cancer Biomarkersâ€“ A Bench to Bedside Perspective. Cancer Science & Research Open Access, 2014, 1, .	1.4	0
2296	Prostate Cancer in Older Adults. , 2014, , 273-288.		0
2297	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1
2298	The issues related to PSA screening and the countermeasure for spreading of PSA screening. Health Evaluation and Promotion, 2014, 41, 308-314.	0.0	0
2299	Prostatakarzinom. , 2014, , 513-676.		0
2300	Prevention and Early Detection of Urologic Cancers: A Mini-Review. , 2014, S, .		0
2301	Storage Lower Urinary Tract Symptoms: Evaluation and Investigations. , 2014, , 65-72.		0
2302	Technology and the Digitization of Health Care. AACN Advanced Critical Care, 2014, 25, 15-17.	0.6	0
2303	The Oncological Outcome of HIFU for the Treatment of Localized Prostate Cancer. Journal of Cancer Research Updates, 0, , .	0.3	0
2304	Annual Exam. , 2015, , 147-159.		0
2305	Multiparametric Magnetic Resonance Imaging for Prostate Cancer. , 2015, , 141-166.		0
2307	Epidemiology, Screening, Pathology and Pathogenesis. , 2015, , 677-695.		0
2308	For early diagnosis of prostate cancer in the Voronezh region. Journal of New Medical Technologies, 2014, 8, 0-0.	0.0	0
2311	Prostate Cancer Diagnostic and Evaluation in Gaza-Strip, Palestine. Health, 2015, 07, 1552-1559.	0.1	0
2312	The Ethical Dilemma Surrounding Prostate Specific Antigen (PSA) Screening. Journal of Clinical Research & Bioethics, 2015, 06, .	0.2	1
2313	Prostatakarzinom. , 2015, , 1-6.		0
2314	Prostate Cancer Epidemiology. , 2015, , 1-6.		1

#	ARTICLE	IF	CITATIONS
2315	Comparative Effectiveness Research in Urologic Cancers. <i>Cancer Treatment and Research</i> , 2015, 164, 221-235.	0.2	0
2316	Role of PCA3 test in clinical decision making for prostate cancer diagnosis. <i>World Journal of Clinical Urology</i> , 2015, 4, 68.	0.0	0
2317	Prostate Cancer Screening in the Fit Chilean Elderly: a Head to Head Comparison of Total Serum PSA versus Age Adjusted PSA versus Primary Circulating Prostate Cells to Detect Prostate Cancer at Initial Biopsy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 601-606.	0.5	2
2318	AvaliaÃ§Ã£o dos conhecimentos dos utentes de uma USF do Grande Porto sobre o rastreio do cancro da prÃ³stata. <i>Revista Portuguesa De CiÃªncia Geral</i> , 2015, 31, 94-102.	0.1	1
2319	Is PSA Still the Best Marker in Diagnosis and Monitoring of Prostate Cancer?. <i>Electronic Journal of General Medicine</i> , 2015, 12, .	0.3	0
2320	Natural Prevention of Prostatitis [Prostate Inflammation] For 24 Male Subjects Over 6 Months. <i>MOJ Clinical & Medical Case Reports</i> , 2015, 2, .	0.0	0
2322	Tumor markers currently utilized in cancer care. <i>Materials and Methods</i> , 0, 5, .	0.0	3
2324	PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES. <i>IssledovaniÄ I Praktika V Medicine</i> , 2015, 2, 76-81.	0.1	1
2325	Finasteride in prevention of prostate cancer progration. <i>Health of Man</i> , 2015, .	0.1	0
2327	Legal Implications of Prostate Cancer Screening. , 2016, , 613-619.		0
2328	Heart Healthy = Prostate Healthy and S.A.M. are the Ideal â€œNaturalâ€ Recommendations for Prostate Cancer. , 2016, , 169-181.		0
2329	Population Screening for Prostate Cancer and Early Detection. , 2016, , 3-12.		0
2330	New Developments in the Use of Biomarkers in Translational Medicine. , 2016, , 1-33.		0
2331	Procedure for transperineal mapping biopsy in the diagnosis of prostate cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2016, 5, 12.	0.0	0
2332	Clinical Stage Evaluation at Diagnosis of Prostate Cancer at Urology- Andrology Clinic CNHU-HKM Cotonou. <i>Journal of Medical & Surgical Pathology</i> , 2016, 01, .	0.2	0
2333	Template Mapping Biopsies: An Overview of Technique and Results. , 2016, , 111-123.		0
2334	Prostate Cancer Screening. , 2016, , 173-185.		0
2335	Urologic Oncology. , 2016, , 77-107.		0

#	ARTICLE	IF	CITATIONS
2336	Prostate Cancer Epidemiology. , 2016, , 3746-3752.		1
2337	AB190. Could magnetic resonance imaging help identify the presence of prostate cancer before initial biopsy? The development of nomogram predicting the outcomes of prostate biopsy in the Chinese population. Translational Andrology and Urology, 2016, 5, AB190-AB190.	0.6	0
2338	Healthcare: How Did We Get Here and Where Are We Going?. , 2016, , 25-40.		0
2339	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2017, , 1-11.		0
2340	5-Alpha-Reductase Inhibition as a Secondary Preventive Strategy. Current Clinical Urology, 2017, , 399-405.	0.0	0
2341	Psychosocial, Ethical, and Legal Implications for Mutation Carriers. , 2017, , 205-234.		1
2342	In-Bore Magnetic Resonance Imaging-Targeted Prostate Biopsy. Current Clinical Urology, 2017, , 205-218.	0.0	1
2343	Screening of Prostate Cancer. , 2017, , 1-12.		0
2345	Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen. Anticancer Research, 2017, 37, 3163-3167.	0.5	6
2346	Chapter 31: Radioactive Gold Nanoparticles in Cancer Therapy: Therapeutic Efficacy Studies of ¹⁹⁸ AuNP Nanoconstruct in Prostate Tumor-bearing Mice. , 2017, , 753-774.		0
2348	Triggers for Intervention. Current Clinical Urology, 2018, , 83-94.	0.0	0
2349	Prostatakrebsdiagnostik: Die MRT-Ultraschall-Fusionsbiopsie. WissenKompakt Medizin, 2018, , 1-10.	0.0	0
2350	RASTREIO DO CÂNCER DE PRÓSTATA: REVISÃO SISTEMÁTICA DA LITERATURA SOBRE AS PERSPECTIVAS MUNDIAIS. Revista De Atenção À Saúde, 2018, 16, .	0.0	0
2352	Prostata-specifices Antigen. , 2018, , 1-2.		0
2353	Screening for Chronic Disease. , 2018, , 163-173.		1
2354	Role of nm23H1 in predicting metastases in prostatic carcinoma. Indian Journal of Pathology and Microbiology, 2018, 61, 70.	0.1	1
2355	PSA Screening for Prostate Cancer in Men under the Age of 65: A Review of Current Practice. Open Journal of Urology, 2018, 08, 135-160.	0.0	0
2356	Methods and Data Collection. , 2018, , 23-35.		0

#	ARTICLE	IF	CITATIONS
2357	Western Algerian Propolis Alcohol Extract Effects Against Disruption of Testes Function Induced by Cadmium-sulfate in Male Rats. <i>Asian Journal of Biological Sciences</i> , 2018, 12, 24-30.	0.2	0
2359	Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management. <i>Springer Theses</i> , 2019, , 1-29.	0.0	0
2360	Prostata-spezifisches Antigen. <i>Springer Reference Medizin</i> , 2019, , 1968-1970.	0.0	0
2361	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2019, , 179-190.		0
2362	Epidemiology and Prevention. <i>Principles of Specialty Nursing</i> , 2019, , 19-37.	0.2	0
2363	Cancer Epidemiology and Screening. , 2019, , 3-15.		0
2364	Urological neoplasia. , 2019, , 252-406.		1
2367	Beschleunigte medizinische Forschung. , 2020, , 125-148.		0
2369	Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 192-199.	1.1	18
2370	Multiparametric MRI in the management of prostate cancer: an update—a narrative review. <i>Gland Surgery</i> , 2020, 9, 2321-2330.	0.5	6
2371	Prostate Cancer: People Transforming A Diagnosis, A Diagnosis Transforming People. <i>Science, Technology and Society</i> , 2021, 26, 41-63.	1.1	0
2372	Prostat Kanseri Tanımsında Tünel/Disfonksiyon Dengesi PSA'ya Ek Bir Serum Belirteci Olarak Gözlenir mi?. <i>Acta Medica Alanya</i> , 2019, 3, 231-235.	0.2	0
2373	Prostate-Specific Antigen (PSA). , 2020, , 1753-1754.		0
2374	Prostate cancer. Epidemiology, risk factors and early detection. <i>Profilakticheskaya Meditsina</i> , 2020, 23, 149.	0.2	4
2375	Cancers urologiques. , 2020, , 147-158.e8.		0
2376	Cusp Catastrophe Regression Analysis of Testosterone in Bifurcating the Age-Related Changes in PSA, a Biomarker for Prostate Cancer. <i>ICSA Book Series in Statistics</i> , 2020, , 363-381.	0.0	1
2378	Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Progres En Urologie</i> , 2020, 30, 252-260.	0.3	2
2379	Experiencia inicial del uso de SelectMDx® en el diagnóstico de cáncer de próstata en un entorno de práctica clínica habitual «real-world evidence». <i>Actas Urológicas Españolas</i> , 2020, 44, 400-407.	0.3	1

#	ARTICLE	IF	CITATIONS
2381	Prostatakarzinom. , 2014, , 513-676.		0
2383	Prostate Cancer Screening Recommendations for General and Specific Populations in the Western Nations. European Medical Journal (Chelmsford, England), 0, , .	3.0	0
2385	Relevance of nationwide prostate specific antigen screening test for prostate cancer. Journal of the Korean Medical Association, 2020, 63, 652-658.	0.1	0
2386	Translating Laboratory Tests into Clinical Practice: A Conceptual Framework. Hamostaseologie, 2020, 40, 420-429.	0.9	4
2387	The burden of prostate cancer in Canada. Canadian Urological Association Journal, 2009, 3, S92-S100.	0.3	27
2389	Predictive models for newly diagnosed prostate cancer patients. Reviews in Urology, 2009, 11, 117-26.	0.9	21
2390	Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Reviews in Urology, 2009, 11, 127-33.	0.9	50
2391	Randomized trials of prostate cancer screening. Reviews in Urology, 2009, 11, 179-80.	0.9	2
2392	The impact of prostate cancer and hormonal therapy on bone. Reviews in Urology, 2009, 11, 185-9.	0.9	4
2393	What is the true mortality benefit of prostate-specific antigen screening?. Reviews in Urology, 2010, 12, 66-7.	0.9	0
2396	Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006. Preventing Chronic Disease, 2011, 8, A114.	1.7	10
2397	PURLs: PSA testing: when it's useful, when it's not. Journal of Family Practice, 2011, 60, 357-60.	0.2	13
2398	Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. Molecular and Cellular Pharmacology, 2011, 3, 115-124.	1.7	16
2399	First, do no harm. Canadian Family Physician, 2012, 58, 915.	0.1	0
2400	Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance. Canadian Family Physician, 2012, 58, e502-7.	0.1	4
2401	Prostate cancer screening trends in a large, integrated health care system. , 2012, 16, 4-9.		3
2402	LHRH Agonists for the Treatment of Prostate Cancer: 2012. Reviews in Urology, 2012, 14, 1-12.	0.9	34
2403	Prostate cancer survival in Trinidad: Is PSA a prognostic factor?. Canadian Urological Association Journal, 2012, 6, E249-55.	0.3	6

#	ARTICLE	IF	CITATIONS
2404	Update of randomized trials for prostate cancer screening. <i>Reviews in Urology</i> , 2013, 15, 37-9.	0.9	0
2405	Developing a conceptual map of patient information needs in prostate cancer screening. , 2012, 2012, 273.		0
2406	Treatment options for localized prostate cancer. <i>Canadian Family Physician</i> , 2013, 59, 1269-74.	0.1	37
2407	New Prognostic Markers: The Pathway from Research to Clinical Practice. , 2009, 8, 7-13.		0
2408	Prostate biopsy for elevated prostate specific antigen (PSA)--Indian perspective. <i>Indian Journal of Medical Research</i> , 2014, 139, 802-3.	0.4	0
2409	Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. <i>Indian Journal of Medical Research</i> , 2014, 139, 851-6.	0.4	10
2410	Active surveillance in men with low-risk prostate cancer: current and future challenges. <i>American Journal of Clinical and Experimental Urology</i> , 2013, 1, 72-82.	0.4	3
2412	Prostate Cancer Knowledge and Decision Making Among African-American Men and Women in the Southeastern United States. <i>International Journal of Men's Health</i> , 2015, 14, 55-70.	0.4	23
2413	On pancreatic cancer screening by magnetic resonance imaging with the recent evidence by Del Chiaro and colleagues. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 417-22.	0.7	1
2414	Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2015, 15, 1-64.	3.0	20
2415	Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision. <i>Reviews in Urology</i> , 2015, 17, 171-7.	0.9	22
2416	Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less. <i>Iranian Journal of Public Health</i> , 2015, 44, 1466-72.	0.3	3
2417	Update on age-appropriate preventive measures and screening for Canadian primary care providers. <i>Canadian Family Physician</i> , 2016, 62, 131-8.	0.1	18
2418	Use of Biomarkers in Screening for Cancer. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2010, 21, 1-12.	0.7	5
2419	LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 5141-5150.	0.0	36
2420	Population-based Prostate Cancer Screening in Kazakhstan. <i>Iranian Journal of Public Health</i> , 2017, 46, 917-922.	0.3	5
2421	Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. <i>Reviews in Urology</i> , 2017, 19, 77-88.	0.9	8
2423	A Ten-Year Study of Prostate Cancer: A Southern Iranian Experience. <i>Iranian Journal of Medical Sciences</i> , 2018, 43, 372-379.	0.3	1

#	ARTICLE	IF	CITATIONS
2424	Prostate Cancer: Update on Early Detection and New Biomarkers. Missouri Medicine, 2018, 115, 132-134.	0.3	2
2425	Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines. Reviews in Urology, 2018, 20, 77-83.	0.9	4
2426	Don't test – don't treat: the new paradigm for the treatment of prostate cancer?. Missouri Medicine, 2011, 108, 409-12.	0.3	1
2427	Prostate cancer diagnosis. Missouri Medicine, 2010, 107, 107-12.	0.3	7
2428	Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation. Reviews in Urology, 2018, 20, 125-130.	0.9	3
2429	Help patients navigate the system. Canadian Family Physician, 2019, 65, 8.	0.1	0
2430	Impact of 1 α -adrenoceptor antagonists on prostate cancer development, progression and prevention. American Journal of Clinical and Experimental Urology, 2019, 7, 46-60.	0.4	5
2431	Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men. Reviews in Urology, 2019, 21, 1-7.	0.9	4
2432	Physicians' attitudes about shared decision making for prostate cancer screening. Family Medicine, 2011, 43, 260-6.	0.3	22
2433	What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review. Acta Biomedica, 2019, 90, 423-426.	0.2	7
2434	A Trend Toward Aggressive Prostate Cancer. Reviews in Urology, 2020, 22, 102-109.	0.9	2
2435	Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice. Reviews in Urology, 2020, 22, 152-158.	0.9	0
2436	Hypoechoic lesions on Transrectal Ultrasound and its correlation to Gleason grade in the diagnosis of Clinically Significant Prostate Cancer: A Prospective Study. South Asian Journal of Cancer, 2021, 10, 155-160.	0.2	2
2437	Lung cancer screening: An unending tale. Journal of Cancer Research and Therapeutics, 2021, 17, 1289.	0.3	3
2439	Role of MRI in Prostate Cancer Assessment. , 2021, , 81-94.		0
2440	Photothermal therapeutic potency of plasmonic silver nanoparticles for apoptosis and anti-angiogenesis in testosterone induced benign prostate hyperplasia in rats. Life Sciences, 2022, 291, 120240.	2.0	14
2441	Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis. Cancer Epidemiology, 2022, 77, 102093.	0.8	13
2442	Prostate Cancer Screening Trends in a Large, Integrated Health Care System. , 2012, 16, .		6

#	ARTICLE	IF	CITATIONS
2443	Socioeconomic Gradients in Prostate Cancer Incidence Among Canadian Males: A Trend Analysis From 1992 to 2010. <i>Cancer Control</i> , 2021, 28, 107327482110552.	0.7	6
2444	Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study. <i>European Radiology</i> , 2022, 32, 2330-2339.	2.3	11
2445	Preventing Digital Overdiagnosis. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 525.	3.8	15
2447	The national-wide incidence of prostate-specific antigen testing trend for a decade in Korea by age group. <i>Investigative and Clinical Urology</i> , 2022, 63, 184.	1.0	4
2448	Effect of Perceived Self-Vulnerability on Prostate Cancer Screening Uptake and Associated Factors: A Cross-Sectional Study of Public Health Facilities in Western Kenya. <i>Annals of Global Health</i> , 2022, 88, 12.	0.8	2
2449	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. <i>Cancers</i> , 2022, 14, 1004.	1.7	3
2450	Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways. <i>Anti-Cancer Drugs</i> , 2022, 33, 384-388.	0.7	4
2451	The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone. <i>International Urology and Nephrology</i> , 2022, 54, 749-756.	0.6	5
2452	De-implementing low-value care in cancer care delivery: a systematic review. <i>Implementation Science</i> , 2022, 17, 24.	2.5	13
2453	UPDATE “ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2021, 16, E184-96.	0.3	12
2454	Retrospective analysis to describe trends in first-ever prostate-specific antigen (PSA) testing for primary healthcare facilities in the Gauteng Province, South Africa, between 2006 and 2016. <i>BMJ Open</i> , 2022, 12, e050646.	0.8	0
2455	Grade Migration of Prostate Cancer in the United States During the Last Decade. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1012-1019.	3.0	13
2456	Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. <i>Frontiers in Oncology</i> , 2022, 12, 864111.	1.3	4
2457	Significance of PSA Screening in Niigata, Japan: Survey of Actual Status of New Cases of Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 859-866.	0.6	0
2458	Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 592-599.	3.0	5
2459	Current state of prostate-specific membrane antigen PET/CT imaging“targeted biopsy techniques for detection of clinically significant prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 776-780.	0.9	10
2460	Damaged Masculinity: How Honor Endorsement Can Influence Prostate Cancer Screening Decision-Making and Prostate Cancer Mortality Rates. <i>Personality and Social Psychology Bulletin</i> , 2023, 49, 296-308.	1.9	5
2464	Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana Prostate Cancer Project (PCaP). <i>Cancer Causes and Control</i> , 2022, , .	0.8	1

#	ARTICLE	IF	CITATIONS
2465	Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials. <i>BMC Urology</i> , 2022, 22, 45.	0.6	3
2467	Optimization of Biomarker-Based Prostate Cancer Screening Policies. , 2022, , 141-158.		0
2469	A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. <i>Molecules</i> , 2022, 27, 2617.	1.7	15
2470	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1139-1145.	1.1	7
2475	Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. <i>Tumori</i> , 2012, 98, 722-7.	0.6	3
2476	Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics. <i>Tumori</i> , 2011, 97, 149-55.	0.6	4
2477	Screening and early diagnosis of prostate cancer: an update. <i>Acta Clinica Belgica</i> , 2012, 67, 270-5.	0.5	12
2482	Causes of Death after Prostate Cancer Diagnosis: A Population-Based Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-12.	1.9	15
2483	Real-world use of MRI for risk stratification prior to prostate biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 353-359.	2.0	8
2486	Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats. <i>Research and Reports in Urology</i> , 0, Volume 14, 225-239.	0.6	3
2487	How Much Information Do Icelandic Men Receive on Pros and Cons of Prostate-Specific Antigen Testing Prior to Undergoing Testing?. <i>American Journal of Men's Health</i> , 2022, 16, 155798832210978.	0.7	1
2488	Concordance of MRI-Guided Fusion and Systematic 12-Core Prostate Biopsy for the Detection of Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2489	The state of PSA counseling in male-to-female transgender patients in the U.S.. <i>Prostate</i> , 0, , .	1.2	3
2490	Podemos usar a expressÃo de Ki67 para prever a agressividade do cÃncer de prÃstata?. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 0, 49, .	0.3	0
2491	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.		2
2492	Can we use Ki67 expression to predict prostate cancer aggressiveness?. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 0, 49, .	0.3	5
2494	Prostate cancer screening - is it time to change approach?. <i>Central European Journal of Public Health</i> , 2022, 30, S11-S15.	0.4	2
2495	Pan-cancer screening by circulating tumor DNA (ctDNA)Â€ recent breakthroughs and chronic pitfalls. <i>Laboratoriums Medizin</i> , 2022, 46, 247-253.	0.1	6

#	ARTICLE	IF	CITATIONS
2496	Perceptions et connaissances concernant la décision de réaliser le dépistage du cancer de la prostate. <i>Sante Publique</i> , 2022, Vol. 34, 107-118.	0.0	1
2497	<i>Cancer Epidemiology, Prevention, and Survivorship.</i> , 2023, , 3-14.		1
2498	The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	1
2499	Accommodating population differences when validating risk prediction models. <i>Statistics in Medicine</i> , 0, , .	0.8	2
2502	Should Contemporary Western Guidelines Based on Studies Conducted in the 2000s Be Adopted for the Prostate-Specific Antigen Screening Policy for Asian Men in the 2020s?. <i>World Journal of Men's Health</i> , 2022, 40, 543.	1.7	4
2503	STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) and Their Clinical Implications for Prostate Cancer. <i>Cancers</i> , 2022, 14, 4034.	1.7	13
2504	Variability of body mass index and risks of prostate, lung, colon, and ovarian cancers. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
2505	Cancer overdiagnosis: A challenge in the era of screening. <i>Journal of the National Cancer Center</i> , 2022, 2, 235-242.	3.0	14
2506	Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. <i>Nature Reviews Urology</i> , 2022, 19, 562-572.	1.9	55
2507	Overdiagnosis no contexto do câncer. <i>Research, Society and Development</i> , 2022, 11, e98111234071.	0.0	0
2508	Socioeconomic inequalities in prostate cancer screening in low- and middle-income countries: An analysis of the demographic and health surveys between 2010 and 2019. <i>Journal of Cancer Policy</i> , 2022, 34, 100360.	0.6	4
2509	Usefulness of PSA in prostate cancer screening in the perspective of personalized medicine. <i>Revista De Medicina De Laboratorio</i> , 2022, , .	0.0	0
2510	De beslissing tot endodontische (her)behandeling. , 2022, , 485-507.		0
2511	Prostate cancer screening: Continued controversies and novel biomarker advancements. <i>Current Urology</i> , 2022, 16, 197-206.	0.4	2
2512	Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at 55 years of age: a 25-year follow-up of 60,000 men. <i>International Urology and Nephrology</i> , 2023, 55, 295-300.	0.1	3
2513	Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. <i>Cell Reports Physical Science</i> , 2022, 3, 101062.	2.8	12
2514	Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial. <i>International Journal of Cancer</i> , 2023, 152, 854-864.	2.3	12
2515	The most effective but largely ignored target for prostate cancer early detection and intervention. <i>Journal of Cancer</i> , 2022, 13, 3463-3475.	1.2	2

#	ARTICLE	IF	CITATIONS
2516	A flexible parametric approach for analyzing arbitrarily censored data that are potentially subject to left truncation under the proportional hazards model. <i>Lifetime Data Analysis</i> , 2023, 29, 188-212.	0.4	5
2517	Magnetically Engineered Conductivity of Soft Liquid Metal Composites for Robotic, Wearable Electronic, and Medical Applications. <i>Advanced Intelligent Systems</i> , 2022, 4, .	3.3	10
2518	PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. <i>Diagnostics</i> , 2022, 12, 2594.	1.3	21
2521	The use of PSA testing over more than 20 years: A population-based study in North-Eastern Italy. <i>Tumori</i> , 2023, 109, 406-412.	0.6	1
2522	Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. <i>JAMA Oncology</i> , 2022, 8, 1747.	3.4	11
2526	Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. <i>BMJ Open</i> , 2022, 12, e059482.	0.8	8
2528	Narrative reviewâ€”focal therapy: are we ready to change the prostate cancer treatment paradigm?. <i>Annals of Translational Medicine</i> , 2023, 11, 24-24.	0.7	1
2529	Super-Extended Robot Assisted Radical Prostatectomy in Locally Advanced Prostate Cancer. , 2022, , 351-358.		0
2530	Clinical Issues for Prostate-Specific Antigen Screening: A Narrative Review. <i>European Medical Journal Oncology</i> , 0, , 102-108.	0.0	0
2531	Populationâ€”based prostateâ€”specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan. <i>Molecular and Clinical Oncology</i> , 2022, 18, .	0.4	1
2532	Cancer de la prostate, une maladie hÃ©tÃ©rogÃ©ne. <i>Option/Bio</i> , 2022, 33, 26-27.	0.0	0
2533	Lateral flow assays for detection of disease biomarkers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 225, 115206.	1.4	9
2534	Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. <i>New England Journal of Medicine</i> , 2022, 387, 2126-2137.	13.9	99
2535	Urinary exosomal prostateâ€”specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles. <i>International Journal of Cancer</i> , 2023, 152, 1719-1727.	2.3	6
2536	Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. <i>European Urology</i> , 2023, 83, 241-248.	0.9	16
2537	High expression of KNL1 in prostate adenocarcinoma is associated with poor prognosis and immune infiltration. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2538	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. <i>Nature Reviews Urology</i> , 2023, 20, 205-216.	1.9	10
2539	Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels of S100A4 as a Detector in Plasma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 547.	1.8	0

#	ARTICLE	IF	CITATIONS
2540	Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. <i>Cancers</i> , 2023, 15, 821.	1.7	2
2541	Biomarkers of Aggressive Prostate Cancer at Diagnosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2185.	1.8	12
2542	Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data. <i>Investigative and Clinical Urology</i> , 2023, 64, 140.	1.0	2
2543	Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. <i>Cancer Epidemiology</i> , 2023, 84, 102352.	0.8	2
2544	A prospective nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and aggressive prostate cancer risk. <i>Environmental Research</i> , 2023, 228, 115718.	3.7	7
2546	Prostate Problems. , 2022, , 591-605.		0
2547	Predicting prostate cancer in men with PSA levels of 4–10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
2548	An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study. <i>European Urology Oncology</i> , 2023, 6, 295-302.	2.6	5
2575	Functional Role of Non-coding RNAs in Prostate Cancer: From Biomarker to Therapeutic Targets. <i>RNA Technologies</i> , 2023, , 371-387.	0.2	0